Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof

Abstract

The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided.

Description

RELATED APPLICATIONS

[0001] The present application is a continuation-in-part of copending application Ser. No. 09/632,131 filed Aug. 3, 2000, of which the instant application claims the benefit of the filing date pursuant to 35 U.S.C. .sctn.120, and which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0002] This invention relates generally to the identification of a new superfamily of eukaryotic protein alpha kinases, and particularly to members of a subfamily selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase. The invention further relates to the use of the alpha kinases in assays to screen for specific modulators thereof. Isolated nucleic acids encoding the alpha kinases--melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase--are provided herein.

BACKGROUND OF THE INVENTION

[0003] Protein phosphorylation plays a critical role in many cellular processes (Krebs (1994) Trends Biochem. Sci. 19:439; Hanks and Hunter, (1996) FASEB J. 9:576-596; Hardie and Hanks, (1995) The Protein Kinase Facts Book (Academic, London)). There are two well-characterized superfamilies of protein kinases, with most of the protein kinases belonging to the serine/threonine/tyrosine kinase superfamily (Hanks and Hunter, (1996); Hardie and Hanks, (1995)). The characterization of several hundred members of this superfamily revealed that they all share a similar structural organization of their catalytic domains which consist of twelve conserved subdomains (Hanks and Hunter, (1996); Hardie and Hanks, (1995)). The other superfamily is referred to as the histidine kinase superfamily and is involved in the prokaryotic two-component signal transduction system, acting as sensor components (Stock et al., (1989) Microbiol. Rev. 53:450-490; Parkinson and Kofoid, (1992) Annu. Rev. Genet. 26:71-112; Swanson, et al., (1994) Trends Biochem. Sci. 19:485-490). Recently, eukaryotic members of this superfamily have also been described (Chang et al., (1993) Science 263:539-544; Ota and Varshaysky, (1993) Science 262:566-569; Maeda et al., (1994) Nature 369:242-245). Mitochondrial protein kinases have also recently been described that show structural homology to the histidine kinases, but phosphorylate their substrates on serine (Popov et al., (1992) J. Biol. Chem. 267:13127-13130; Popov et al., (1993) J. Biol. Chem. 268:26602-22606). Finally, several new protein kinases have been reported that show a lack of homology with either of the kinase superfamilies (Maru and Witte, (1991) Cell 67:459-468; Beeler et al., (1994) Mol. Cell. Biol. 14:982-988; Dikstein et al., (1996) Cell 84:781-790; Futey et al., (1995) J. Biol. Chem. 270:523-529; Eichenger et al., (1996) EMBO J. 15:5547-5556). However, these protein kinases are viewed as an exception to the general rule as they have yet to be fully characterized.

[0004] The cloning and sequencing of the extensively characterized eukaryotic elongation factor-2 kinase (eEF-2 kinase) from a variety of eukaryotic organisms has revealed the existence of a novel class of protein kinases (Ryazanov et al., (1997) Proc. Natl. Acad. Sci., USA 94:4884-4889). eEF-2 kinase, previously known as Ca.sup.2+/calmodulin-dependent protein kinase III, is highly specific for phosphorylation of elongation factor-2 (eEF-2), an abundant cytoplasmic protein that catalyzes the movement of the ribosome along mRNA during translation in eukaryotic cells (reviewed in Ryazanov and Spirin, (1993) In Translational Regulation of Gene Expression (Plenum, New York) Vol. 2, pp. 433-455; Nairn and Palfrey, (1996) In Translational Control (CSHL Press, New York) pp. 295-318). All mammalian tissues, and various invertebrate organisms, exhibit eEF-2 kinase activity (Abdelmajid et al., (1993) Int. J. Dev. Biol. 37:279-290). eEF-2 kinase catalyzes the phosphorylation of eEF-2 at two highly conserved threonine residues located within a GTP-binding domain (Ryazanov and Spirin, (1993) In Translational Regulation of Gene Expression (Plenum, New York) Vol. 2, pp. 433-455; Nairn and Palfrey, (1996) In Translational Control (CSHL Press, New York) pp. 295-318). When eEF-2 is phosphorylated, it becomes inactive with respect to protein synthesis (Ryazanov et al., (1988) Nature 334:170-173). Since eEF-2 phosphorylation is dependent on Ca.sup.2+ and calmodulin, eEF-2 kinase plays a pivotal role in modulating the protein synthesis rate in response to changes in intracellular calcium concentration. Phosphorylation of eEF-2 has also been linked to the regulation of cell cycle progression. For example, transient phosphorylation of eEF-2 occurs during the mitogenic stimulation of quiescent cells (Palfrey et al., (1987) J. Biol. Chem. 262:9785-9792) and during mitosis (Celis et al., (1990) Proc. Natl. Acad. Sci., USA 87:4231-4235). In addition, changes in the level of eEF-2 kinase activity is associated with a host of cellular processes such as cellular differentiation (End et al., (1982) J. Biol. Chem. 257:9223-9225; Koizumi et al., (1989) FEBS Lett. 253:55-58; Brady et al., (1990) J. Neurochem. 54:1034-1039), oogenesis (Severinov et al., (1990) New Biol. 2: 887-893), and malignant transformation (Bagaglio et al., (1993) Cancer Res. 53:2260-2264).

[0005] The sequence of eEF-2 kinase appears to have no homology to either the Ca.sup.2+/calmodulin-dependent protein kinases or to any members of the known protein kinase superfamilies (Ryazanov et al., (1997) Proc. Natl. Acad. Sci., USA 94:4884-4889). However, the recently described myosin heavy chain kinase A (MHCK A) from Dictyostelium (Futey et al., (1995) J. Biol. Chem. 270:523-529) shows a great deal of homology with eEF-2 kinase. These two kinases define a novel class of protein kinases that may represent a new superfamily.

[0006] Evidence for MHCK and eEF-2 kinase forming the core of a new superfamily is as follows. MHCK A from Dictyostelium, has a demonstrated role in the regulation of myosin assembly (Futey et al., (1995) J. Biol. Chem. 270:523-529; Cote et al., (1997) J. Biol. Chem. 272:6846-6849). eEF-2 kinase is a ubiquitous Ca.sup.2+/calmodulin-dependant protein kinase involved in the regulation of protein synthesis by Ca.sup.2+ (Redpath et al., (1996) J. Biol. Chem. 271:17547-17554; Ryazanov et al., (1997) Proc. Natl. Acad. Sci., USA 94:4884-4889). Both MHCK A and eEF-2 kinase display no homology to any of the known protein kinases, but are strikingly similar to each other; amino acid sequences of their catalytic domains are 40% identical. Another protein kinase homologous to MHCK A and eEF-2 kinase has recently been identified in Dictyostelium (Clancy et al., (1997) J. Biol. Chem. 272:11812-11815), and an expressed sequence tag (EST) sequence, with a high degree of similarity to the catalytic domain common to both MHCK A and eEF-2 kinase, has been deposited in GenBank (clone FC-AN09/accession #C22986). An amino acid sequence alignment of the catalytic domains of these new protein kinases is shown in FIG. 1A. These kinases have a catalytic domain of approximately 200 amino acids which can be subdivided into seven conserved subdomains. Subdomains V, VI, and VII have a predicted .beta.-sheet structure and are presumably involved in ATP-binding, while subdomains I through IV may be involved in substrate binding and catalysis. These new protein kinases have no homology to the members of the eukaryotic serine/threonine/tyrosine protein kinase superfamily with the exception of the GXGXXG motif in subdomain VI which is present in many ATP-binding proteins. Thus, MHCK A, eEF-2 kinase, and related protein kinases may represent a new superfamily. Evolutionary analysis of these new kinases (FIG. 1B) reveals that they can be subdivided into 2 families: the eEF-2 kinase family which includes eEF-2 kinases from different organisms, and the MHCK family which includes MHCK A, MHCK B and FC-AN09. These two families appear to have split more than a billion years ago.

[0007] An interesting question is why does nature employ these unusual kinases to phosphorylate eEF-2 and myosin heavy chains? Perhaps the answer is related to the secondary structure of the phosphorylation sites. As was originally reported by Small et al. (Small et al., (1977), Biochim. Biophys. Res. Comm. 79:341-346), phosphorylation sites are usually located at predicted .beta.-turns. Subsequent studies, including X-ray crystallographic data, demonstrated that phosphoacceptor sites in substrates of conventional protein kinases are often located in turns or loops and usually have flexible extended conformation (Knighton et al., (1991) Science 253:414-420; Pinna and Ruzzene (1996) Biochim. Biophys. Acta 1314:191-225). In contrast to this, the existing evidence suggests that the peptides around phosphorylation sites for eEF-2 kinases and MHCK A have an .alpha.-helical conformation. The two major phosphorylation sites for WICK A are located in a region which has a coiled-coil .alpha.-helical structure (Vaillancourt et al., (1988) J. Biol. Chem. 253:10082-10087). The major phosphorylation site in eEF-2, threonine 56, is located within a sequence which is homologous among all translational elongation factors. In the crystal structure of the prokaryotic elongation factor EF-Tu, this sequence has an .alpha.-helical conformation (Polekhina et al., (1996) Structure 4:1141-1151; Abel et al., (1996) Structure 4:1153-1159). These facts suggest that eEF-2 kinase and MHCK A differ from conventional protein kinases in that they phosphorylate amino acids located within .alpha.-helices. Thus, in addition to the two well-characterized superfamily of eukaryotic protein kinases, which phosphorylate amino acids located in loops and turns, there appears to be a third superfamily of .alpha.-helix-directed kinases.

[0008] The existence of several protein kinases which have very little or no homology to either the serine/threonine/tyrosine kinase superfamily or the histidine kinase superfamily, provides a new superfamily, the .alpha.-kinases. The isolation and analysis of additional members of this family of kinases will further our understanding of .alpha.-kinases and provide insight into the physiological roles of these kinases and their applications and uses.

[0009] The citation of references herein shall not be construed as an admission that such is prior art to the present invention.

SUMMARY OF THE INVENTION

[0010] In accordance with the present invention, a new superfamily of protein kinases, novel members thereof, and corresponding methods for assaying their phosphorylation activity are disclosed. The protein kinases of this new alpha-kinase superfamily have the following characteristics: 1) No significant sequence homology to protein kinases of either the serine/threonine/tyrosine kinase or histidine kinase super families; 2) moderate to high homology (.gtoreq.40%) to eEF-2 kinases from any organism; and, 3) the ability to phosphorylate an amino acid within an a-helical domain. In addition, a new subfamily of alpha-kinases is herein provided. In particular, a subfamily of alpha-kinases is provided in which an ion channel, particularly belonging to the TRP family of ion channels is covalently linked to a protein kinase. The placement of a kinase and channel on a single molecule is particularly interesting and suggests a self-regulated molecule, whereby the phosphorylation/autophosphorylation of these unique alpha kinases controls or contributes to the open or closed state of the channel.

[0011] The present invention provides an isolated nucleic acid encoding melanoma alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the invention provides an isolated nucleic acid encoding human melanoma alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0012] a. the DNA sequence of SEQ ID NO: 26; [0013] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0014] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0015] d. degenerate variants thereof; [0016] e. alleles thereof; and [0017] f. hybridizable fragments thereof.

[0018] In particular, the invention provides an isolated nucleic acid encoding mouse melanoma alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0019] a. the DNA sequence of SEQ ID NO: 28; [0020] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0021] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0022] d. degenerate variants thereof; [0023] e. alleles thereof; and [0024] f. hybridizable fragments thereof.

[0025] In particular, the invention provides an isolated nucleic acid encoding mammalian melanoma alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0026] a. the DNA sequence of SEQ ID NO: 28; [0027] b. the DNA sequence of SEQ ID NO: 26; [0028] c. DNA sequences that hybridize to the sequence of subparts (a) or (b) under standard hybridization conditions; and [0029] d. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of subparts (a), (b) or (c).

[0030] The present invention further provides an isolated nucleic acid encoding heart alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the present invention provides an isolated nucleic acid encoding human heart alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0031] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 34; [0032] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0033] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0034] d. degenerate variants thereof; [0035] e. alleles thereof; and [0036] f. hybridizable fragments thereof.

[0037] In particular, the present invention provides an isolated nucleic acid encoding mouse heart alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0038] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 36; [0039] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0040] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0041] d. degenerate variants thereof; [0042] e. alleles thereof; and [0043] f. hybridizable fragments thereof.

[0044] In particular, the invention provides an isolated nucleic acid encoding mammalian heart alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0045] a. the DNA sequence of SEQ ID NO: 34; [0046] b. the DNA sequence of SEQ ID NO: 36; [0047] c. DNA sequences that hybridize to the sequence of subparts (a) or (b) under standard hybridization conditions; and [0048] d. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of subparts (a), (b) or (c).

[0049] The present invention still further provides an isolated nucleic acid encoding kidney alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the invention includes an isolated nucleic acid encoding human kidney alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0050] a. the DNA sequence of SEQ ID NO: 30; [0051] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0052] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0053] d. degenerate variants thereof; [0054] e. alleles thereof; and [0055] f. hybridizable fragments thereof.

[0056] In particular, the invention includes an isolated nucleic acid encoding mouse kidney alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0057] a. the DNA sequence of SEQ ID NO: 32; [0058] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0059] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0060] d. degenerate variants thereof; [0061] e. alleles thereof; and [0062] f. hybridizable fragments thereof.

[0063] In particular, the invention provides an isolated nucleic acid encoding mammalian kidney alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0064] a. the DNA sequence of SEQ ID NO: 30; [0065] b. the DNA sequence of SEQ ID NO: 32; [0066] c. DNA sequences that hybridize to the sequence of subparts (a) or (b) under standard hybridization conditions; and [0067] d. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of subparts (a), (b) or (c).

[0068] The present invention also provides an isolated nucleic acid encoding skeletal muscle alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, an isolated nucleic acid encoding skeletal muscle alpha kinase is provided, wherein the nucleic acid is selected from the group consisting of: [0069] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 38; [0070] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0071] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0072] d. degenerate variants thereof; [0073] e. alleles thereof; and [0074] f. hybridizable fragments thereof.

[0075] In particular, the invention provides an isolated nucleic acid encoding mammalian skeletal muscle alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0076] a. the DNA sequence of SEQ ID NO: 38; [0077] b. DNA sequences that hybridize to the sequence of subpart (a) under standard hybridization conditions; and [0078] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b).

[0079] The present invention also includes an isolated nucleic acid encoding lymphocyte alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the present invention provides an isolated nucleic acid encoding lymphocyte alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0080] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 40; [0081] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0082] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0083] d. degenerate variants thereof; [0084] e. alleles thereof; and [0085] f. hybridizable fragments thereof.

[0086] In particular, the invention provides an isolated nucleic acid encoding mammalian lymphocyte alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0087] a. the DNA sequence of SEQ ID NO: 40; [0088] b. DNA sequences that hybridize to the sequence of subpart (a) under standard hybridization conditions; and [0089] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b).

[0090] The invention provides an isolated nucleic acid encoding human melanoma alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 26. The invention provides an isolated nucleic acid encoding mouse melanoma alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 28.

[0091] The invention provides an isolated nucleic acid encoding human heart alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 34. The invention provides an isolated nucleic acid encoding mouse heart alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 36.

[0092] The invention provides an isolated nucleic acid encoding human kidney alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 30. The invention provides an isolated nucleic acid encoding mouse kidney alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 32.

[0093] The invention provides an isolated nucleic acid encoding human skeletal muscle alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 38.

[0094] The invention provides an isolated nucleic acid encoding human lymphocyte alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 40.

[0095] The present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes an alpha kinase selected from the group of melanoma kinase, heart kinase, kidney kinase, skeletal muscle kinase and lymphocyte kinase; preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the alpha kinase has a nucleotide sequence or is complementary to a DNA sequence as set forth in any of SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38 and 40.

[0096] The murine and/or human DNA sequences of the alpha kinase genes of the present invention or portions thereof, may be prepared as probes to screen for complementary sequences and genomic clones in the same or alternate species. The present invention extends to probes so prepared that may be provided for screening cDNA and genomic libraries for the alpha kinase genes. For example, the probes may be prepared with a variety of known vectors, such as the phage A vector. The present invention also includes the preparation of plasmids including such vectors, and the use of the DNA sequences to construct vectors expressing antisense RNA or ribozymes which would attack the mRNAs of any or all of the DNA sequences set forth in any of SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38 and 40. Correspondingly, the preparation of antisense RNA and ribozymes are included herein.

[0097] According to other preferred features of certain preferred embodiments of the present invention, a recombinant expression system is provided to produce biologically active animal or human alpha kinase selected from the group of melanoma kinase, heart kinase, kidney kinase, skeletal muscle kinase and lymphocyte kinase.

[0098] The present invention naturally contemplates several means for preparation of the alpha kinase of the present invention, including as illustrated herein known recombinant techniques, and the invention is accordingly intended to cover such synthetic preparations within its scope. The isolation of the cDNA and amino acid sequences disclosed herein facilitates the production of the alpha kinase of the present invention by such recombinant techniques, and accordingly, the invention extends to expression vectors prepared from the disclosed DNA sequences for expression in host systems by recombinant DNA techniques, and to the resulting transformed hosts.

[0099] In a further aspect, the invention provides a recombinant DNA expression vector comprising the nucleic acid encoding an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, wherein the DNA encoding the alpha kinase is operatively associated with an expression control sequence. The invention also provides a transformed host cell transfected with said DNA vector.

[0100] The invention further includes a unicellular host transformed with a recombinant DNA molecule comprising a DNA sequence or degenerate variant thereof, which encodes an alpha kinase, or a fragment thereof, selected from the group consisting of: [0101] a. the DNA sequence of (SEQ ID NO: 26); [0102] b. the DNA sequence of (SEQ ID NO: 28); [0103] c. the DNA sequence of (SEQ ID NO: 30); [0104] d. the DNA sequence of (SEQ ID NO: 32); [0105] e. the DNA sequence of (SEQ ID NO: 34); [0106] f. the DNA sequence of (SEQ ID NO: 36); [0107] g. the DNA sequence of (SEQ ID NO: 38); [0108] h. the DNA sequence of (SEQ ID NO: 40); [0109] i. DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and [0110] j. DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences; [0111] wherein said DNA sequence is operatively linked to an expression control sequence.

[0112] Such a unicellular host is particularly selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeasts, CHO, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, and BMT10 cells, plant cells, insect cells, mouse cells and human cells in tissue culture.

[0113] In a further aspect, the present invention includes an isolated protein characterized by the presence of at least two domains, one of the domains being an alpha-kinase catalytic domain and the other domain being an ion channel domain.

[0114] Thus, the present invention provides an isolated melanoma alpha kinase protein characterized by having an alpha-kinase catalytic domain and an ion channel domain. In particular, a melanoma alpha kinase protein is provided which comprises the amino acid sequence set out in SEQ ID NO: 27 and 29, and analogs, variants and fragments thereof. The invention provides a melanoma alpha kinase protein which comprises the amino acid sequence set out in SEQ ID NO: 27 or 29, and variants thereof wherein one or more amino acids is substituted with a conserved amino acid.

[0115] The invention further provides an isolated kidney alpha kinase protein characterized by having an alpha-kinase catalytic domain and an ion channel domain. In particular, the kidney alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 31 and 33, and analogs, variants and fragments thereof. The invention provides a kidney alpha kinase protein which comprises the amino acid sequence set out in SEQ ID NO: 31 or 33, and variants thereof wherein one or more amino acids is substituted with a conserved amino acid.

[0116] The present invention further provides an isolated heart alpha kinase protein. In particular, the heart alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 35 and 37, and analogs, variants and immunogenic fragments thereof. The invention provides a heart alpha kinase protein which comprises the amino acid sequence set out in SEQ ID NO: 35 or 37, and variants thereof wherein one or more amino acids is substituted with a conserved amino acid.

[0117] The present invention still further provides an isolated skeletal muscle alpha kinase protein. In particular, the skeletal muscle alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 39, and analogs, variants and immunogenic fragments thereof. The invention provides a skeletal muscle alpha kinase protein which comprises the amino acid sequence set out in SEQ ID NO: 39, and variants thereof wherein one or more amino acids is substituted with a conserved amino acid.

[0118] The invention includes an isolated lymphocyte alpha kinase protein. In particular, the lymphocyte alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 41, and analogs, variants and immunogenic fragments thereof. The invention provides a lymphocyte alpha kinase protein which comprises the amino acid sequence set out in SEQ ID NO: 41, and variants thereof wherein one or more amino acids is substituted with a Conserved amino acid.

[0119] In a particular aspect, the present invention includes a pharmaceutical composition comprising one or more alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, and a pharmaceutically acceptable carrier.

[0120] In a further aspect, the invention provides a purified antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase.

[0121] A monoclonal antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase is still further provided. the invention includes an immortal cell line that produces a monoclonal antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase.

[0122] Any such contemplated antibody may be labeled with a detectable label. The label may be selected from the group consisting of an enzyme, a chemical which fluoresces, and a radioactive element.

[0123] The invention further includes an antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, which recognizes the phosphorylated form of the alpha kinase or a phosphorylated fragment thereof.

[0124] The present invention likewise extends to antibodies against specifically phosphorylated alpha kinase targets, including naturally raised and recombinantly prepared antibodies. These antibodies and their labeled counterparts are included within the scope or the present invention for their particular ability in detecting alpha kinase activity via detection of the phosphorylated product by ELISA or any other immunoassay known to the skilled artisan.

[0125] In the instance where a radioactive label, such as the isotopes 3H, .sup.14C, .sup.32P, .sup.33P, .sup.35S, .sup.36Cl, .sup.51Cr, .sup.57Co, .sup.58Co, 59Fe, .sup.90Y, .sup.125I, .sup.131I, and .sup.186Re are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

[0126] The present invention provides a method for treating an animal in need of increased activity of melanoma alpha kinase which comprises administration of melanoma alpha kinase to the animal.

[0127] The present invention further provides a method for treating an animal in need of increased activity of melanoma alpha kinase which comprises administration of an antibody against melanoma alpha kinase to the animal.

[0128] The present invention also provides a method for treating an animal in need of increased activity of kidney alpha kinase which comprises administration of kidney alpha kinase to the animal.

[0129] The invention also includes a method for treating an animal in need of increased activity of kidney alpha kinase which comprises administration of an antibody against kidney alpha kinase to the animal.

[0130] The invention further provides a method for treating an animal in need of increased activity of heart alpha kinase which comprises administration of heart alpha kinase to the animal.

[0131] The present invention also contemplates a method for treating an animal in need of increased activity of heart alpha kinase which comprises administration of an antibody against heart alpha kinase to the animal.

[0132] In an additional aspect, the invention provides a method for treating an animal in need of increased activity of skeletal muscle alpha kinase which comprises administration of skeletal muscle alpha kinase to the animal.

[0133] A method for treating an animal in need of increased activity of skeletal muscle alpha kinase which comprises administration of an antibody against skeletal muscle alpha kinase to the animal is further provided.

[0134] The present invention includes method for treating an animal in need of increased activity of lymphocyte alpha kinase which comprises administration of lymphocyte alpha kinase to the animal.

[0135] The present invention further provides a method for treating an animal in need of increased activity of lymphocyte alpha kinase which comprises administration of an antibody against lymphocyte alpha kinase to the animal.

[0136] The therapeutic method provided herein could include the method for the treatment of various pathologies or other cellular dysfunctions and derangements by the administration of pharmaceutical compositions that may comprise effective inhibitors of alpha kinase activity, or other equally effective drugs developed for instance by a drug screening assay prepared and used in accordance with a further aspect of the present invention.

[0137] The invention includes an assay system for screening of potential drugs effective at attenuating alpha kinase activity of target mammalian cells by interrupting or potentiating the phosphorylation of alpha kinase selected from the group of melanoma kinase, heart kinase, kidney kinase, skeletal muscle kinase and lymphocyte kinase. In one instance, the test drug could be administered to a cellular sample along with ATP carrying a detectable label on its .gamma.-phosphate that gets transferred to the kinase target, including the kinase itself, or a peptide substrate, by the particular alpha kinase. Quantification of the labeled kinase target or peptide substrate is diagnostic of the candidate drug's efficacy. A further embodiment would provide for the assay to be performed using a purely in vitro system comprised of the alpha kinase, ATP or labeled ATP, the kinase target or peptide substrate, appropriate buffer, and detection reagents and/or instrumentation to detect and quantify the extent of alpha kinase-directed phosphorylation activity.

[0138] The assay system could more importantly be adapted to identify drugs or other entities that are capable of binding to the alpha kinase and/or its cognate phosphorylation target, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating alpha kinase activity and its resultant phenotypic outcome. Such an assay would be useful in the development of drugs that would be specific against particular cellular activity, or that would potentiate such activity, in time or in level of activity. For example, such drugs might be used to treat various carcinomas or other hyperproliferative pathologies.

[0139] In an additional aspect, the present invention includes a method for detecting the presence or activity of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, wherein said alpha kinase is measured by: [0140] A. contacting a biological sample from a mammal in which the presence or activity of said alpha kinase is suspected with a binding partner of said alpha kinase under conditions that allow binding of said alpha kinase to said binding partner to occur; and [0141] B. detecting whether binding has occurred between said alpha kinase from said sample and the binding partner; [0142] wherein the detection of binding indicates that presence or activity of said alpha kinase in said sample.

[0143] The present invention further provides a method for detecting the presence of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, wherein the alpha kinase is measured by: [0144] a. contacting a sample in which the presence or activity of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase is suspected with an antibody to the said alpha kinase protein under conditions that allow binding of the alpha kinase protein to the binding partner to occur; and [0145] b. detecting whether binding has occurred between the alpha kinase protein from the sample and the antibody; wherein the detection of binding indicates the presence or activity of the alpha kinase protein in the sample.

[0146] In a still further aspect, the invention provides a method of testing the ability of a drug or other entity to modulate the kinase activity of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase which comprises: [0147] A. culturing a colony of test cells containing the alpha kinase protein; [0148] B. adding the drug or other entity under test; and [0149] C. measuring the kinase activity of said alpha kinase protein in the test cells, wherein when the amount of kinase activity in the presence of the modulator is greater than in its absence, the modulator is identified as an agonist or activator of the alpha kinase protein, whereas when the amount of kinase activity in the presence of the modulator is less than in its absence, the modulator is identified as an antagonist or inhibitor of the alpha kinase protein.

[0150] Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing description which proceeds with reference to the following illustrative drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0151] FIG. 1. A, Sequence alignment of the catalytic domains of human eEF-2 kinase, C. elegans eEF-2 kinase, MHCK A, MHCK B and clone FC-ANO9. Identical amino acids (bold) and conserved hydrophobic amino acids (.degree.) are noted. B, Phylogenetic tree of sequences shown in (A), with the addition of mouse and rat eEF-2 kinases. Tree was obtained using the J. Hein method with PAM250 residue weight table. The following accession numbers were used for the sequences: U93846-U93850, 1495779, 1170675, 1903458, C22986.

[0152] FIG. 2 depicts a sequence alignment of C. elegans, mouse, human eEF-2 kinase, and the catalytic domain of Dictyostelium discoideum MHCK A. Identical amino acids are indicated by dark blue boxed regions and chemically conserved amino acids are indicated by light blue shaded regions. Amino acids in the human sequence that are identical to the mouse sequence are represented by dots. Amino acids underlined in black correspond to the six regions that match peptides obtained from the sequencing of purified rabbit reticulocyte eEF-2 kinase. The GXGXXG nucleotide-binding motif is underlined in red. The blue dashed line over residues 625-632 in C. elegans eEF-2 kinases designates the amino acids corresponding to exon 4, which is missing in Cefk-2.

[0153] FIG. 3 depicts a schematic representation of the structure of mammalian and C. elegans eEF-2 kinases and MHCK A. The homologous regions are represented by dark shading. The regions of weak similarity are represented by light shading. The position of the GXGXXG motif is indicated by vertical arrows.

[0154] FIG. 4 depicts a sequence alignment of C. elegans, mouse, human eEF-2 kinase, and the catalytic domain of Dictyostelium discoideum MHCK A, heart kinase, melanoma kinase and ch4 kinase. Identical amino acids are indicated by dark blue boxed regions and chemically conserved amino acids are indicated by light blue shaded regions.

[0155] FIG. 5 A-C depicts the nucleic acid sequence of mouse melanoma alpha-kinase (MK).

[0156] FIG. 6 A-B depicts the predicted amino acid sequence of mouse melanoma alpha-kinase (MK).

[0157] FIGS. 7 A and B depicts the nucleic acid sequence (A) and predicted amino acid sequence (B) of human melanoma alpha-kinase (MK).

[0158] FIGS. 8 A and B depicts the nucleic acid sequence (A) and predicted amino acid sequence (B) of human heart alpha-kinase (HK).

[0159] FIGS. 9 A and B depicts the nucleic acid sequence (A) and predicted amino acid sequence (B) of human kidney alpha-kinase (KK).

[0160] FIGS. 10 A and B depicts the nucleic acid sequence (A) and predicted amino acid sequence (B) of human skeletal muscle alpha-kinase (SK).

[0161] FIGS. 11A and B depicts the nucleic acid sequence (A) and predicted amino acid sequence (B) of human lymphocyte alpha-kinase (LK).

[0162] FIG. 12 shows the alignment of the catalytic domains of the cloned alpha-kinases.

[0163] FIG. 13 depicts a phylogeneic analysis of the cloned alpha-kinases.

[0164] FIG. 14 shows the time course of .sup.32P incorporation into expressed maltose-binding protein-melanoma alpha-kinase fusion protein (MBP-MK).

[0165] FIG. 15 shows Northern Blot analysis of the tissue distribution of the alpha-kinases in human and mouse tissues. Standard Multiple Tisue Northern (MTN) blots (Clontech) were stained as described in Materials and Methods. A, B, C: Blots probed for Melanoma Kinase; A: Human MTN Blot B: Human Immune System MTN Blot II. C: Mouse MTN Blot. D: Human 12-Lane MTN Blot probed for Kidney kinase. E: Human 12-Lane MTN Blot probed for Muscle kinase. F: Mouse MTN Blot probed for Heart kinase. (abbreviations: sk. muscle--skeletal muscle, p.b. leukocyte--peripheral bood leukocyte, s. intestine--small intestine).

[0166] FIG. 16 shows a comparison of the ion channel portions of melanoma kinase (MK), kidney kinase (KK) and melastatin (ME).

[0167] FIG. 17 Sequence alignment of MK and KK with members of the LTRP channel subfamily. Roman numerals designate the six predicted transmembrane segments. Black boxes highlight identical amino acids. Gray boxes highlight conserved amino acids. The alignment was constructed using the ClustalW program and the shading was done using the Boxshade program.

[0168] FIG. 18. Schematic representation of five new .alpha.-kinases described in this paper together with eEF-2 kinase and the Dictyostelium MHCKs.

[0169] FIG. 19. A. Phylogenetic tree of the LTRP channel subfamily. This tree was generated from the full-length protein sequences using the ClustalW program. B. The proposed structural model of MK and KK.

DETAILED DESCRIPTION

[0170] Protein phosphorylation plays a pivotal role in a wide variety of cellular processes. Enzymes which assist in protein phosphorylation are referred to as "protein kinases." Two protein kinase superfamilies have been described. The vast majority of protein kinases belong to the serine/threonine/tyrosine kinase superfamily. Several hundred members of this superfamily have thus far been characterized and found to share similar structural organization of their catalytic domains consisting of 12 conserved subdomains. There is also the histidine kinase superfamily consisting primarily of sensor components of the prokaryotic two-component signal transduction systems. Eukaryotic members of this superfamily have been recently described. In addition, mitochondrial branched-chain-ketoacid dehydrogenase kinase and the mitochondrial pyruvate dehydrogenase kinase have been described which are structurally related to the histidine kinases, but phosphorylate their substrates on serine. The existence of several protein kinases have recently been reported which have very little or no homology to either superfamily. This new superfamily is termed alpha-kinase. The first two members eEF-2 kinase and MHCKA kinase differ from conventional protein kinases in that they phosphorylate amino acids located within .alpha.-helices. Thus, in addition to the two well-characterized superfamily of eukaryotic protein kinases, which phosphorylate amino acids located in loops and turns, there appears to be a third superfamily of .alpha.-helix-directed kinases.

[0171] Additional novel members of the alpha kinase superfamily have herein been cloned and sequenced. In particular, these new alpha kinases--melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte kinase--represent new members of the alpha kinase superfamily. The alpha kinases of the present invention are related to eEF-2 kinase and MHCK A and join the alpha kinase superfamily. In addition, however, the novel alpha kinases of the present invention have new and unique characteristics.

[0172] In particular, the melanoma alpha kinase and kidney kinase of the present invention have a unique structure. These proteins have two domains, one domain is the alpha-kinase catalytic domain and the other is an ion channel. This is the first recognized example of an ion channel being covalently linked to a protein kinase. It is likely that these novel protein kinases can be regulated by ion flow through the membrane. Expression of the melanoma kinase was detected in all mouse tissues studied, including heart, skeletal muscle, brain, liver and lung. This kinase is the most abundant in the heart. In contrast, the kidney kinase is present almost exclusively in kidney tissue. The ion channel portion is very similar to (70% identical) to a previously identified protein called melastatin that is selectively downregulated in metastatic tumors, and therefore is believed to be a metastasis suppressor gene. Melanoma alpha-kinase, kidney alpha-kinase, as well as melastatin, belong to the TRP family of ion channels. All TRP proteins function as tetramers, and various TRP proteins can form tetramers in different combinations that result in ion channels with different properties. Considering the high degree of similarity between melanoma kinase, kidney kinase, and melastatin, it is likely that melanoma kinase and kidney kinase can form tetrameric complexes with melastatin.

[0173] In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al, "Molecular Cloning: A Laboratory Manual" (1989); "Current Protocols in Molecular Biology" Volumes I-III [Ausubel, R. M., ed. (1994)]; "Cell Biology: A Laboratory Handbook" Volumes I-III [J. E. Celis, ed. (1994))]; "Current Protocols in Immunology" Volumes I-III [Coligan, J. E., ed. (1994)]; "Oligonucleotide Synthesis" (M. J. Gait ed. 1984); "Nucleic Acid Hybridization" [B. D. Hames & S. J. Higgins eds. (1985)]; "Transcription And Translation" [B. D. Hames & S. J. Higgins, eds. (1984)]; "Animal Cell Culture" [R. I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

[0174] Therefore, if appearing herein, the following terms shall have the definitions set out below.

[0175] The terms "elongation factor-2 kinase", "eEF-2 kinase", "EF-2 kinase", "Cefk", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIGS. 1 and 5 (SEQ ID NOS: 1, 2, 6, 8 and 14), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms elongation factor-2 kinase", "eEF-2 kinase", "EF-2 kinase", and "Cefk" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations. as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "melanoma .alpha. kinase", "melanoma alpha kinase", "melanoma kinase" and "MK" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.

[0176] The terms "heart .alpha. kinase", "heart alpha kinase", "heart kinase", "HK", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIG. 8 (SEQ ID NOS: 35 and 37), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "heart .alpha. kinase", "heart alpha kinase", "heart kinase", "HK" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.

[0177] The terms "kidney .alpha. kinase", "kidney alpha kinase", "kidney kinase", "KK", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIG. 9 (SEQ ID NOS: 31 and 33), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "kidney .alpha. kinase", "kidney alpha kinase", "kidney

[0178] The terms "kidney .alpha. kinase", "kidney alpha kinase", "kidney kinase", "KK", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIG. 9 (SEQ ID NOS: 31 and 33), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "kidney .alpha. kinase", "kidney alpha kinase", "kidney kinase", "KK" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.

[0179] The terms "skeletal muscle .alpha. kinase", "skeletal muscle alpha kinase", "skeletal muscle kinase", "SK", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIG. 10 (SEQ ID NO: 39), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "skeletal muscle .alpha. kinase", "skeletal muscle alpha kinase", "skeletal muscle kinase", "SK" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.

[0180] The terms "lymphocyte .alpha. kinase", "lymphocyte alpha kinase", "lymphocyte kinase", "LK", "Ch4" and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIG. 11 (SEQ ID NO: 41), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "lymphocyte .alpha. kinase", "lymphocyte alpha kinase", "lymphocyte kinase", "LK", "Ch4" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.

[0181] The amino acid residues described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired fractional property of immunoglobulin-binding is retained by the polypeptide. NH.sub.2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, J. Biol. Chem., 243:3552-59 (1969), abbreviations for amino acid residues are shown in the following Table of Correspondence:

TABLE-US-00001 TABLE OF CORRESPONDENCE SYMBOL 1-Letter 3-Letter AMINO ACID Y Tyr tyrosine G Gly glycine F Phe phenylalanine M Met methionine A Ala alanine S Ser serine I Ile isoleucine L Leu leucine T Thr threonine V Val valine P Pro proline K Lys lysine H His histidine Q Gln glutamine E Glu glutamic acid W Trp tryptophan R Arg arginine D Asp aspartic acid N Asn asparagine C Cys cysteine

[0182] It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues. The above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.

Nucleic Acids

[0183] The present invention provides an isolated nucleic acid encoding melanoma alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the invention provides an isolated nucleic acid encoding human melanoma alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0184] a. the DNA sequence of SEQ ID NO: 26; [0185] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0186] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0187] d. degenerate variants thereof; [0188] e. alleles thereof; and [0189] f. hybridizable fragments thereof. In particular, the invention provides an isolated nucleic acid encoding mouse melanoma alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0190] a. the DNA sequence of SEQ ID NO: 28; [0191] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0192] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0193] d. degenerate variants thereof; [0194] e. alleles thereof; and [0195] f. hybridizable fragments thereof.

[0196] The present invention further provides an isolated nucleic acid encoding heart alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the present invention provides an isolated nucleic acid encoding human heart alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0197] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 34; [0198] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0199] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0200] d. degenerate variants thereof; [0201] e. alleles thereof; and [0202] f. hybridizable fragments thereof.

[0203] In particular, the present invention provides an isolated nucleic acid encoding mouse heart alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0204] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 36; [0205] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0206] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0207] d. degenerate variants thereof; [0208] e. alleles thereof; and [0209] f. hybridizable fragments thereof.

[0210] The present invention still further provides an isolated nucleic acid encoding kidney alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the invention includes an isolated nucleic acid encoding human kidney alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0211] a. the DNA sequence of SEQ ID NO: 30; [0212] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0213] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0214] d. degenerate variants thereof; [0215] e. alleles thereof; and [0216] f. hybridizable fragments thereof.

[0217] In particular, the invention includes an isolated nucleic acid encoding mouse kidney alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0218] a. the DNA sequence of SEQ ID NO: 32; [0219] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0220] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0221] d. degenerate variants thereof; [0222] e. alleles thereof; and [0223] f. hybridizable fragments thereof.

[0224] The present invention also provides an isolated nucleic acid encoding skeletal muscle alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, an isolated nucleic acid encoding skeletal muscle alpha kinase is provided, wherein the nucleic acid is selected from the group consisting of: [0225] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 38; [0226] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0227] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0228] d. degenerate variants thereof; [0229] e. alleles thereof; and [0230] f. hybridizable fragments thereof.

[0231] The present invention also includes an isolated nucleic acid encoding lymphocyte alpha kinase, or a fragment thereof having at least 15 nucleotides. In particular, the present invention provides an isolated nucleic acid encoding lymphocyte alpha kinase, wherein the nucleic acid is selected from the group consisting of: [0232] a. nucleic acid comprising the DNA sequence of SEQ ID NO: 40; [0233] b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions; [0234] c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b); [0235] d. degenerate variants thereof; [0236] e. alleles thereof; and [0237] f. hybridizable fragments thereof.

[0238] The present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes an alpha kinase selected from the group of melanoma kinase, heart kinase, kidney kinase, skeletal muscle kinase and lymphocyte kinase; preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the alpha kinase has a nucleotide sequence or is complementary to a DNA sequence as set forth in any of SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38 and 40.

[0239] The murine and/or human DNA sequences of the alpha kinase genes of the present invention or portions thereof, may be prepared as probes to screen for complementary sequences and genomic clones in the same or alternate species. The present invention extends to probes so prepared that may be provided for screening cDNA and genomic libraries for the alpha kinase genes. For example, the probes may be prepared with a variety of known vectors, such as the phage A vector. The present invention also includes the preparation of plasmids including such vectors, and the use of the DNA sequences to construct vectors expressing antisense RNA or ribozymes which would attack the mRNAs of any or all of the DNA sequences set forth in any of SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38 and 40. Correspondingly, the preparation of antisense RNA and ribozymes are included herein.

[0240] According to other preferred features of certain preferred embodiments of the present invention, a recombinant expression system is provided to produce biologically active animal or human alpha kinase selected from the group of melanoma kinase, heart kinase, kidney kinase, skeletal muscle kinase and lymphocyte kinase.

[0241] The present invention naturally contemplates several means for preparation of the alpha kinase of the present invention, including as illustrated herein known recombinant techniques, and the invention is accordingly intended to cover such synthetic preparations within its scope. The isolation of the cDNA and amino acid sequences disclosed herein facilitates the production of the alpha kinase of the present invention by such recombinant techniques, and accordingly, the invention extends to expression vectors prepared from the disclosed DNA sequences for expression in host systems by recombinant DNA techniques, and to the resulting transformed hosts.

[0242] In a further aspect, the invention provides a recombinant DNA expression vector comprising the nucleic acid encoding an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, wherein the DNA encoding the alpha kinase is operatively associated with an expression control sequence. The invention also provides a transformed host cell transfected with said DNA vector.

[0243] The invention further includes a unicellular host transformed with a recombinant DNA molecule comprising a DNA sequence or degenerate variant thereof, which encodes an alpha kinase, or a fragment thereof, selected from the group consisting of: [0244] a. the DNA sequence of (SEQ ID NO: 26); [0245] b. the DNA sequence of (SEQ ID NO: 28); [0246] c. the DNA sequence of (SEQ ID NO: 30); [0247] d. the DNA sequence of (SEQ ID NO: 32); [0248] e. the DNA sequence of (SEQ ID NO: 34); [0249] f. the DNA sequence of (SEQ ID NO: 36); [0250] g. the DNA sequence of (SEQ ID NO: 38); [0251] h. the DNA sequence of (SEQ ID NO: 40); [0252] i. DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and [0253] j. DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences; [0254] wherein said DNA sequence is operatively linked to an expression control sequence.

[0255] Such a unicellular host is particularly selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeasts, CHO, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, and BMT10 cells, plant cells, insect cells, mouse cells and human cells in tissue culture.

[0256] A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.

[0257] A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

[0258] A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

[0259] An "origin of replication" refers to those DNA sequences that participate in DNA synthesis.

[0260] A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

[0261] Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

[0262] A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters contain Shine-Dalgamo sequences in addition to the -10 and -35 consensus sequences.

[0263] An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

[0264] A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.

[0265] The term "standard hybridization conditions" refers to salt and temperature conditions substantially equivalent to 5.times.SSC and 65.degree. C. for both hybridization and wash. However, one skilled in the art will appreciate that such "standard hybridization conditions" are dependent on particular conditions including the concentration of sodium and magnesium in the buffer, nucleotide sequence length and concentration, percent mismatch, percent formamide, and the like. Also important in the determination of "standard hybridization conditions" is whether the two sequences hybridizing are RNA-RNA, DNA-DNA or RNA-DNA. Such standard hybridization conditions are easily determined by one skilled in the art according to well known formulae, wherein hybridization is typically 10-20.degree. C. below the predicted or determined T.sub.m with washes of higher stringency, if desired.

[0266] In one aspect, the present invention relates to the identification of a new superfamily of protein kinases, denoted alpha kinases. Accordingly, it includes the DNA sequences coding for these family members. In addition, the invention also contemplates that each member of this new protein kinase superfamily has its own cognate phosphorylation target.

[0267] A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

[0268] The term "oligonucleotide," as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.

[0269] The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.

[0270] The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand.

[0271] Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.

[0272] A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

[0273] As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

[0274] A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.

[0275] Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra.

[0276] It should be appreciated that also within the scope of the present invention are DNA sequences encoding alpha kinase, selected from the group of melanoma kinase, kidney kinase, heart kinase, skeletal muscle kinase and lymphocyte kinase, which code for a protein having the same amino acid sequence as any of SEQ ID NOS:, but which are degenerate to any of SEQ ID NOS:. By "degenerate to" is meant that a different three-letter codon is used to specify a particular amino acid. It is well known in the art that the following codons can be used interchangeably to code for each specific amino acid:

TABLE-US-00002 Phenylalanine UUU or UUC (Phe or F) Leucine (Leu or L) UUA or UUG or CUU or CUC or CUA or CUG Isoleucine (Ile or I) AUU or AUC or AUA Methionine (Met or M) AUG Valine (Val or V) GUU or GUC of GUA or GUG Serine (Ser or S) UCU or UCC or UCA or UCG or AGU or AGC Proline (Pro or P) CCU or CCC or CCA or CCG Threonine (Thr or T) ACU or ACC or ACA or ACG Alanine (Ala or A) GCU or GCG or GCA or GCG Tyrosine (Tyr or Y) UAU or UAC Histidine (His or H) CAU or CAC Glutamine (Gln or Q) CAA or CAG Asparagine (Asn or N) AAU or AAC Lysine (Lys or K) AAA or AAG Aspartic Acid (Asp or D) GAU or GAC Glutamic Acid (Glu or E) GAA or GAG Cysteine (Cys or C) UGU or UGC Arginine (Arg or R) CGU or CGC or CGA or CGG or AGA or AGG Glycine (Gly or G) GGU or GGC or GGA or GGG Tryptophan (Trp or W) UGG Termination codon UAA (ochre) or UAG (amber) or UGA (opal)

[0277] It should be understood that the codons specified above are for RNA sequences. The corresponding codons for DNA have a T substituted for U.

[0278] Mutations can be made in any of SEQ ID NOS: such that a particular codon is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible. A substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. A non-conservative change is more likely to alter the structure, activity or function of the resulting protein. The present invention should be considered to include sequences containing conservative changes which do not significantly alter the activity or binding characteristics of the resulting protein.

[0279] The following is one example of various groupings of amino acids: (I) Amino acids with nonpolar R groups: Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tryptophan, Methionine; (H) Amino acids with uncharged polar R groups: Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamine; (III) Amino acids with charged polar R groups (negatively charged at pH 6.0): Aspartic acid, Glutamic acid; (IV) Basic amino acids (positively charged at pH 6.0): Lysine, Arginine, Histidine (at pH 6.0).

[0280] Another grouping may be those amino acids with phenyl groups:

Phenylalanine, Tryptophan, Tyrosine

[0281] Another grouping may be according to molecular weight (i.e., size of R groups):

TABLE-US-00003 Glycine 75 Alanine 89 Serine 105 Proline 115 Valine 117 Threonine 119 Cysteine 121 Leucine 131 Isoleucine 131 Asparagine 132 Aspartic acid 133 Glutamine 146 Lysine 146 Glutamic acid 147 Methionine 149 Histidine (at pH 6.0) 155 Phenylalanine 165 Arginine 174 Tyrosine 181 Tryptophan 204

[0282] Particularly preferred substitutions are: [0283] Lys for Arg and vice versa such that a positive charge may be maintained; [0284] Glu for Asp and vice versa such that a negative charge may be maintained; [0285] Ser for Thr such that a free --OH can be maintained; and [0286] Gln for Asn such that a free NH.sub.2 can be maintained.

[0287] Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced a potential site for disulfide bridges with another Cys. A His may be introduced as a particularly "catalytic" site (i.e., His can act as an acid or base and is the most common amino acid in biochemical catalysis). Pro may be introduced because of its particularly planar structure, which induces n-turns in the protein's structure.

[0288] Another feature of this invention is the expression of the DNA sequences disclosed herein. As is well known in the art, DNA sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host.

[0289] Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence.

[0290] A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., E. coli plasmids col El, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAS, e.g., the numerous derivatives of phage A, e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2.mu. plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

[0291] Any of a wide variety of expression control sequences--sequences that control the expression of a DNA sequence operatively linked to it--may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example; the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the LTR system, the major operator and promoter regions of phage .lamda., the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the promoters of the yeast .alpha.-mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

[0292] A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of E. coli, Pseudomonas, Bacillus, Streptomyces, fungi such as yeasts, and animal cells, such as CHO, R1.1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture.

[0293] It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

[0294] In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.

[0295] Considering these and other factors, a person skilled in the art will be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture.

[0296] The present invention extends to the preparation of antisense oligonucleotides and ribozymes that may be used to interfere with the expression of the eEF-2 kinase gene at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

[0297] Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule. (See Weintraub, 1990; Marcus-Sekura, 1988.) In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into eEF-2 kinase-producing cells. Antisense methods have been used to inhibit the expression of many genes in vitro (Marcus-Sekura, 1988; Hambor et al., 1988).

[0298] Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, 1988.). Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

[0299] Investigators have identified two types of ribozymes, Tetrahymena-type and "hammerhead"-type. (Hasselhoff and Gerlach, 1988) Tetrahymena-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to Tetrahymena-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

Polypeptides

[0300] In a further aspect, the present invention includes an isolated protein characterized by the presence of at least two domains, one of the domains being an alpha-kinase catalytic domain and the other domain being an ion channel domain.

[0301] Thus, the present invention provides an isolated melanoma alpha kinase protein characterized by having an alpha-kinase catalytic domain and an ion channel domain. In particular, a melanoma alpha kinase protein is provided which comprises the amino acid sequence set out in SEQ ID NO: 27 and 29, and analogs, variants and fragments thereof.

[0302] The invention further provides an isolated kidney alpha kinase protein characterized by having an alpha-kinase catalytic domain and an ion channel domain. In particular, the kidney alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 31 and 33, and analogs, variants and fragments thereof.

[0303] The present invention further provides an isolated heart alpha kinase protein. In particular, the heart alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 35 and 37, and analogs, variants and immunogenic fragments thereof.

[0304] The present invention still further provides an isolated skeletal muscle alpha kinase protein. In particular, the skeletal muscle alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 39, and analogs, variants and immunogenic fragments thereof.

[0305] The invention includes an isolated lymphocyte alpha kinase protein. In particular, the lymphocyte alpha kinase protein comprises the amino acid sequence set out in SEQ ID NO: 41, and analogs, variants and immunogenic fragments thereof.

[0306] Two amino acid sequences are "substantially homologous" when at least about 70% of the amino acid residues (preferably at least about 80%, and most preferably at least about 90 or 95%) are identical, or represent conservative substitutions.

Antibodies

[0307] In a further aspect, the invention provides a purified antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase.

[0308] A monoclonal antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase is still further provided. the invention includes an immortal cell line that produces a monoclonal antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase.

[0309] Any such contemplated antibody may be labeled with a detectable label. The label may be selected from the group consisting of an enzyme, a chemical which fluoresces, and a radioactive element.

[0310] The invention further includes an antibody to an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, which recognizes the phosphorylated form of the alpha kinase or a phosphorylated fragment thereof.

[0311] The present invention likewise extends to antibodies against specifically phosphorylated alpha kinase targets, including naturally raised and recombinantly prepared antibodies. These antibodies and their labeled counterparts are included within the scope of the present invention for their particular ability in detecting alpha kinase activity via detection of the phosphorylated product by ELISA or any other immunoassay known to the skilled artisan.

[0312] In the instance where a radioactive label, such as the isotopes 3H, .sup.14C, .sup.32P, .sup.33P, .sup.35S, .sup.36Cl, .sup.51Cr, .sup.57Co, .sup.58Co, .sup.59Fe, .sup.90Y, .sup.125I, .sup.131I, and .sup.186Re are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

[0313] An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Pat. Nos. 4,816,397 and 4,816,567.

[0314] An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

[0315] The phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule.

[0316] Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab').sub.2 and F(v), which portions are preferred for use in the therapeutic methods described herein.

[0317] Fab and F(ab').sub.2 portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Pat. No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-known and are produced from F(ab').sub.2 portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact antibody molecules is preferred herein.

[0318] The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.

[0319] In a particular embodiment, the present invention relates to phosphorylation target analogs, which are short peptide sequences derived from phosphorylation targets of this new superfamily of protein alpha kinases centered around the alpha kinases selected from the group of melanoma kinase, kidney kinase, heart kinase, skeletal muscle kinase and lymphocyte kinase. Specifically, it is contemplated that these peptide analogs will be instrumental in the development of high throughput screening assays to identify inhibitors of members of this new superfamily.

[0320] Also, antibodies including both polyclonal and monoclonal antibodies, and drugs that modulate the production or activity of alpha kinase may possess certain diagnostic applications and may, for example, be utilized for the purpose of detecting and/or measuring levels of alpha kinase. It is anticipated that further experimentation will reveal a prognostic correlation between alpha kinase levels and the prediction and or progression of certain malignancies associated with carcinoma. For example, alpha kinase may be used to produce both polyclonal and monoclonal antibodies to themselves in a variety of cellular media, by known techniques such as the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells.

[0321] Likewise, small molecules that mimic or antagonize the activity of alpha kinase of the invention may be discovered or synthesized, and may be used in diagnostic and/or therapeutic protocols.

[0322] The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., "Hybridoma Techniques" (1980); Hammerling et al., "Monoclonal Antibodies And T-cell Hybridomas" (1981); Kennett et al., "Monoclonal Antibodies" (1980); see also U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890.

[0323] Panels of monoclonal antibodies produced against alpha kinase peptides can be screened for various properties; i.e., isotype, epitope, affinity, etc. Of particular interest are monoclonal antibodies that neutralize the activity of alpha kinase. Such monoclonals can be readily identified in alpha kinase activity assays. High affinity antibodies are also useful when immunoaffinity purification of native or recombinant alpha kinase is desired.

[0324] Preferably, the anti-alpha kinase antibody used in the diagnostic methods of this invention is an affinity purified polyclonal antibody. More preferably, the antibody is a monoclonal antibody (mAb). In addition, it is preferable for the anti-alpha kinase antibody molecules used herein be in the form of Fab, Fab', F(ab').sub.2 or F(v) portions of whole antibody molecules.

[0325] As suggested earlier, the diagnostic method of the present invention comprises examining a cellular sample or medium by means of an assay including an effective amount of an antagonist to alpha kinase, such as an anti-alpha kinase antibody, preferably an affinity-purified polyclonal antibody, and more preferably a mAb. In addition, it is preferable for the anti-alpha kinase antibody molecules used herein be in the form of Fab, Fab', F(ab').sub.2 or F(v) portions or whole antibody molecules. As previously discussed, patients capable of benefitting from this method include those suffering from cancer, a pre-cancerous lesion, a viral infection or other like pathological derangement. Methods for isolating the alpha kinase and inducing anti-alpha kinase antibodies and for determining and optimizing the ability of anti-alpha kinase antibodies to assist in the examination of the target cells are all well-known in the art.

[0326] Methods for producing polyclonal anti-polypeptide antibodies are well-known in the art. See U.S. Pat. No. 4,493,795 to Nestor et al. A monoclonal antibody, typically containing Fab and/or F(ab').sub.2 portions of useful antibody molecules, can be prepared using the hybridoma technology described in Antibodies--A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor Laboratory, New York (1988), which is incorporated herein by reference.

[0327] Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 6000. Fused hybrids are selected by their sensitivity to HAT. Hybridomas producing a monoclonal antibody useful in practicing this invention are identified by their ability to immunoreact with a particular kinase and of the present invention and their ability to inhibit specified alpha kinase activity in target cells.

[0328] A monoclonal antibody useful in practicing the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate antigen specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well-known techniques.

[0329] Media useful for the preparation of these compositions are both well-known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virol. 8:396 (1959)) supplemented with 4.5 gm/l glucose, 20 mM glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

[0330] Methods for producing monoclonal anti-alpha kinase antibodies are also well-known in the art. See Niman et al., Proc. Natl. Acad. Sci. USA, 80:4949-4953 (1983). Typically, the present alpha kinase or a peptide analog is used either alone or conjugated to an immunogenic carrier, as the immunogen in the before described procedure for producing anti-alpha kinase monoclonal antibodies. The hybridomas are screened for the ability to produce an antibody that immunoreacts with the eEF-2 kinase peptide analog and the present alpha kinase.

Therapeutic Compositions and Methods

[0331] Therapeutic possibilities are raised by the knowledge of the alpha kinase sequences, melanoma kinase, kidney kinase, heart kinase, skeletal muscle kinase and lymphocyte kinase. Accordingly, it is contemplated that sequences that are derived from the complement to the alpha kinase mRNA sequence, and various modifications thereof, can act as potent antisense drugs that either inhibit expression in a competitive fashion, or, more effectively, by nuclease activity associated with the antisense drug that cleaves the alpha kinase mRNA sequence, thus rendering it irreversibly inactive. Alternative therapeutics are also contemplated that concern the use of peptides and peptide analogs representing portions of phosphorylation target amino acid sequences. It is envisioned that such peptide-based drugs would inhibit alpha kinase activity on its native target, thus bypassing the cascade of events that would lead to malignant transformation.

[0332] In a particular aspect, the present invention includes a pharmaceutical composition comprising one or more alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, and a pharmaceutically acceptable carrier.

[0333] The present invention provides a method for treating an animal in need of increased activity of melanoma alpha kinase which comprises administration of melanoma alpha kinase to the animal.

[0334] The present invention further provides a method for treating an animal in need of increased activity of melanoma alpha kinase which comprises administration of an antibody against melanoma alpha kinase to the animal.

[0335] The present invention also provides a method for treating an animal in need of increased activity of kidney alpha kinase which comprises administration of kidney alpha kinase to the animal.

[0336] The invention also includes a method for treating an animal in need of increased activity of kidney alpha kinase which comprises administration of an antibody against kidney alpha kinase to the animal.

[0337] The invention further provides a method for treating an animal in need of increased activity of heart alpha kinase which comprises administration of heart alpha kinase to the animal.

[0338] The present invention also contemplates a method for treating an animal in need of increased activity of heart alpha kinase which comprises administration of an antibody against heart alpha kinase to the animal.

[0339] In an additional aspect, the invention provides a method for treating an animal in need of increased activity of skeletal muscle alpha kinase which comprises administration of skeletal muscle alpha kinase to the animal.

[0340] A method for treating an animal in need of increased activity of skeletal muscle alpha kinase which comprises administration of an antibody against skeletal muscle alpha kinase to the animal is further provided.

[0341] The present invention includes method for treating an animal in need of increased activity of lymphocyte alpha kinase which comprises administration of lymphocyte alpha kinase to the animal.

[0342] The present invention further provides a method for treating an animal in need of increased activity of lymphocyte alpha kinase which comprises administration of an antibody against lymphocyte alpha kinase to the animal.

[0343] The therapeutic method provided herein could include the method for the treatment of various pathologies or other cellular dysfunctions and derangements by the administration of pharmaceutical compositions that may comprise effective inhibitors of alpha kinase activity, or other equally effective drugs developed for instance by a drug screening assay prepared and used in accordance with a further aspect of the present invention.

[0344] It is a still further object of the present invention to provide a method for the treatment of mammals to control the amount or activity of alpha kinase, so as to alter the adverse consequences of such presence or activity, or where beneficial, to enhance such activity.

[0345] It is a still further object of the present invention to provide a method for the treatment of mammals to control the amount or activity of alpha kinase, so as to treat or avert the adverse consequences of invasive, spontaneous or idiopathic pathological states.

[0346] The present invention further contemplates therapeutic compositions useful in practicing the therapeutic methods of this invention. A subject therapeutic composition includes, in admixture, a pharmaceutically acceptable excipient (carrier) and one or more of an anti-alpha kinase antibody, peptide analog capable of competing for phosphorylation of target by alpha kinase, antisense drug against alpha kinase mRNA, or any other compound that is found to inhibit alpha kinase activity. In a preferred embodiment, the composition comprises an antigen capable of modulating the activity of alpha kinase within a target cell.

[0347] The preparation of therapeutic compositions which contain polypeptides, analogs or active fragments as active ingredients is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.

[0348] A polypeptide, analog or active fragment can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

[0349] The therapeutic polypeptide-, analog- or active fragment-containing compositions are conventionally administered intravenously, as by injection of a unit dose, for example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

[0350] The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to be administered depends on the subject to be treated, capacity of the subject's immune system to utilize the active ingredient, and degree of inhibition or neutralization of eEF-2 kinase activity desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.

Formulations

Intravenous Formulation I

TABLE-US-00004 [0351] Ingredient mg/ml cefotaxime 250.0 antibody, peptide, antisense drug, or other compound 10.0 dextrose USP 45.0 sodium bisulfite USP 3.2 edetate disodium USP 0.1 water for injection q.s.a.d. 1.0 ml

Intravenous Formulation II

TABLE-US-00005 [0352] Ingredient mg/ml ampicillin 250.0 antibody, peptide, antisense drug, or other compound 10.0 sodium bisulfite USP 3.2 disodium edetate USP 0.1 water for injection q.s.a.d. 1.0 ml

Intravenous Formulation III

TABLE-US-00006 [0353] Ingredient mg/ml gentamicin (charged as sulfate) 40.0 antibody, peptide, antisense drug, or other compound 10.0 sodium bisulfite USP 3.2 disodium edetate USP 0.1 water for injection q.s.a.d. 1.0 ml

Intravenous Formulation IV

TABLE-US-00007 [0354] Ingredient mg/ml antibody, peptide, antisense drug, or other compound 10.0 dextrose USP 45.0 sodium bisulfite USP 3.2 edetate disodium USP 0.1 water for injection q.s.a.d. 1.0 ml

[0355] As used herein, "pg" means picogram, "ng" means nanogram, "ug" or ".mu.g" mean microgram, "mg" means milligram, "ul" or ".mu.l" mean microliter, "ml" means milliliter, "1" means liter.

[0356] The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.

[0357] The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant change in the S phase activity of a target cellular mass, or other feature of pathology such as for example, elevated blood pressure, fever or white cell count as may attend its presence and activity.

Assays and Methods

[0358] The present invention also relates to a variety of diagnostic applications, including methods for detecting and quantifying the levels of alpha kinase. As mentioned earlier, alpha kinase can be used to produce antibodies to itself by a variety of known techniques, and such antibodies could then be isolated and utilized as in tests for the presence and levels of alpha kinase activity in suspect target cells.

[0359] The invention includes an assay system for screening of potential drugs effective at attenuating alpha kinase activity of target mammalian cells by interrupting or potentiating the phosphorylation of alpha kinase selected from the group of melanoma kinase, heart kinase, kidney kinase, skeletal muscle kinase and lymphocyte kinase. In one instance, the test drug could be administered to a cellular sample along with ATP carrying a detectable label on its .gamma.-phosphate that gets transferred to the kinase target, including the kinase itself, or a peptide substrate, by the particular alpha kinase. Quantification of the labeled kinase target or peptide substrate is diagnostic of the candidate drug's efficacy. A further embodiment would provide for the assay to be performed using a purely in vitro system comprised of the alpha kinase, ATP or labeled ATP, the kinase target or peptide substrate, appropriate buffer, and detection reagents and/or instrumentation to detect and quantify the extent of alpha kinase-directed phosphorylation activity.

[0360] The assay system could more importantly be adapted to identify drugs or other entities that are capable of binding to the alpha kinase and/or its cognate phosphorylation target, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating alpha kinase activity and its resultant phenotypic outcome. Such an assay would be useful in the development of drugs that would be specific against particular cellular activity, or that would potentiate such activity, in time or in level of activity. For example, such drugs might be used to treat various carcinomas or other hyperproliferative pathologies.

[0361] In an additional aspect, the present invention includes a method for detecting the presence or activity of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, wherein said alpha kinase is measured by: [0362] A. contacting a biological sample from a mammal in which the presence or activity of said alpha kinase is suspected with a binding partner of said alpha kinase under conditions that allow binding of said alpha kinase to said binding partner to occur; and [0363] B. detecting whether binding has occurred between said alpha kinase from said sample and the binding partner; [0364] wherein the detection of binding indicates that presence or activity of said alpha kinase in said sample.

[0365] The present invention further provides a method for detecting the presence of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase, wherein the alpha kinase is measured by: [0366] a. contacting a sample in which the presence or activity of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase is suspected with an antibody to the said alpha kinase protein under conditions that allow binding of the alpha kinase protein to the binding partner to occur; and [0367] b. detecting whether binding has occurred between the alpha kinase protein from the sample and the antibody; wherein the detection of binding indicates the presence or activity of the alpha kinase protein in the sample.

[0368] In a still further aspect, the invention provides a method of testing the ability of a drug or other entity to modulate the kinase activity of an alpha kinase protein selected from the group of melanoma alpha kinase, kidney alpha kinase, heart alpha kinase, skeletal muscle alpha kinase and lymphocyte alpha kinase which comprises: [0369] A. culturing a colony of test cells containing the alpha kinase protein; [0370] B. adding the drug or other entity under test; and [0371] C. measuring the kinase activity of said alpha kinase protein in the test cells, wherein when the amount of kinase activity in the presence of the modulator is greater than in its absence, the modulator is identified as an agonist or activator of the alpha kinase protein, whereas when the amount of kinase activity in the presence of the modulator is less than in its absence, the modulator is identified as an antagonist or inhibitor of the alpha kinase protein.

[0372] It is a further object of the present invention to provide a method for detecting alpha kinase activity in mammals in which invasive, spontaneous, or idiopathic pathological states are suspected to be present.

[0373] As described in detail above, antibody(ies) to alpha kinase can be produced and isolated by standard methods including the well known hybridoma techniques. For convenience, the antibody(ies) to alpha kinase will be referred to herein as Ab.sub.1 and antibody(ies) raised in another species as Ab.sub.2.

[0374] The presence and levels of alpha kinase in cells can be ascertained by the usual immunological procedures applicable to such determinations. A number of useful procedures are known. Three such procedures which are especially useful, utilize either alpha kinase labeled with a detectable label, antibody Ab.sub.1 labeled with a detectable label, or antibody Ab.sub.2 labeled with a detectable label. The procedures may be summarized by the following equations wherein the asterisk indicates that the particle is labeled, and ".about." stands for alpha kinase:

.about.*+Ab.sub.1=.about.*Ab.sub.1 A.

.about.+Ab*=.about.Ab.sub.1* B.

.about.+Ab.sub.1+Ab.sub.2*=.about.Ab.sub.1Ab.sub.2* C.

[0375] The procedures and their application are all familiar to those skilled in the art and accordingly may be utilized within the scope of the present invention. The "competitive" procedure, Procedure A, is described in U.S. Pat. Nos. 3,654,090 and 3,850,752. Procedure C, the "sandwich" procedure, is described in U.S. Pat. Nos. RE 31,006 and 4,016,043. Still other procedures are known such as the "double antibody," or "DASP" procedure.

[0376] In each instance, alpha kinase forms complexes with one or more antibody(ies) or binding partners and one member of the complex is labeled with a detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

[0377] It will be seen from the above, that a characteristic property of Ab.sub.2 is that it will react with Ab.sub.1. This is because Ab.sub.1 raised in one mammalian species has been used in another species as an antigen to raise the antibody Ab.sub.2. For example, Ab.sub.2 may be raised in goats using rabbit antibodies as antigens. Ab.sub.2 therefore would be anti-rabbit antibody raised in goats. For purposes of this description and claims, Ab.sub.1 will be referred to as a primary or anti-alpha kinase antibody, and Ab.sub.2 will be referred to as a secondary or anti-Ab.sub.1 antibody.

[0378] The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others.

[0379] A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.

[0380] eEF-2 kinase can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from .sup.3H, .sup.14C, .sup.32P, .sup.33P, .sup.35S, .sup.36Cl, .sup.51Cr, .sup.57Co, .sup.58Co, .sup.59Fe, .sup.90Y, .sup.125I, .sup.131I, and .sup.186Re.

[0381] Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase, .beta.-glucuronidase, .beta.-D-glucosidase, .beta.-D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Pat. Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

[0382] A particular assay system developed and utilized in accordance with the present invention, is known as a receptor assay. In a receptor assay, the material to be assayed is appropriately labeled and then certain cellular test colonies are inoculated with a quantity of both the labeled and unlabeled material after which binding studies are conducted to determine the extent to which the labeled material binds to the cell receptors. In this way, differences in affinity between materials can be ascertained.

[0383] Accordingly, a purified quantity of the alpha kinase may be radiolabeled and combined, for example, with antibodies or other inhibitors thereto, after which binding studies would be carried out. Solutions would then be prepared that contain various quantities of labeled and unlabeled uncombined alpha kinase, and cell samples would then be inoculated and thereafter incubated. The resulting cell monolayers are then washed, solubilized and then counted in a gamma counter for a length of time sufficient to yield a standard error of <5%. These data are then subjected to Scatchard analysis after which observations and conclusions regarding material activity can be drawn. While the foregoing is exemplary, it illustrates the manner in which a receptor assay may be performed and utilized, in the instance where the cellular binding ability of the assayed material may serve as a distinguishing characteristic.

[0384] In accordance with the above, an assay system for screening potential drugs effective to modulate the activity of alpha kinase may be prepared. The alpha kinase may be introduced into a test system, and the prospective drug may also be introduced into the resulting cell culture, and the culture thereafter examined to observe any changes in the alpha kinase activity of the cells, due either to the addition of the prospective drug alone, or due to the effect of added quantities of the known alpha kinase. Alternatively, these assays can be carried out in a purely in vitro fashion as discussed below.

[0385] The invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the preferred embodiments of the invention and should in no way be construed, however, as limiting the broad scope of the invention.

Example 1

Molecular Cloning of cDNAs Encoding C. elegans, Mouse, Rat, and Human eEF-2 Kinases

[0386] eEF-2 kinase from rabbit reticulocyte lysate was purified as described (Hait et al., (1996) FEBS Lett. 397:55-60). Peptides were generated from the nitrocellulose-bound 103-kDa eEF-2 kinase protein by in situ tryptic digestion (Erdjument-Bromage et al., (1994) Protein Sci. 3:2435-2446) and fractionated by reverse-phase HPLC (Elicone et al., (1994) J. Chromatogr. 676:121-137) using a 1.0 mm Reliasil C18 column. Selected peak fraction were then analyzed by a combination of automated Edman sequencing and matrix-assisted laser-desorption time-of-flight mass spectrometry (Erdjument-Bromage et al., (1994)). The peptide sequences provided an essential lead into the cloning of eEF-2 kinase from human, mouse, rat, and Caenorhabditis elegans.

[0387] To clone the cDNA for C. elegans eEF-2 kinase, oligonucleotide primers were designed based on the amino and carboxy termini of the predicted gene product from F42A10.4. Reverse transcriptase-PCR (RT-PCR) was performed using these primers and total RNA from C. elegans. A single PCR product of -2.3 kb was obtained and gel-purified using a gel extraction kit (Qiagen, Chatsworth, Calif.). The fragment was ligated into vector pCR2.1 using the TA cloning kit (Invitrogen, Sorrento Valley, Calif.), and then transformed into Escherichia coli. Plasmid DNA was purified, and restriction analysis used to verify the orientation of the coding sequence with respect to the T7 promoter. Two clones (Cefk-1 and Cefk-2, C. elegans eEF-2 kinase isoforms 1 and 2) were chosen and sequenced using a Li-Cor (Lincoln, Nebr.) Long Read IR model 400L Automated DNA Sequencer. Analysis revealed that the two clones were identical except for a deletion of 24 bp in Cefk-2 which corresponds to exon 4 and probably represents an alternatively spliced form.

[0388] To clone the mouse eEF-2 kinase, degenerate primers were designed based on the amino acid sequence of two peptides from rabbit eEF-2 kinase (LTPQAFSHFTFER (SEQ ID NO: 15) and LANXYYEKAE (SEQ ID NO: 16)): primer A, CA(G/A)GC(C/G/T/A)TT(C/T)(T/A)(C/G)(T/CCA(C/T)TT(C/T)AC(C/G/T/A)TT(C/T)GA- (G/A(C/A)G (SEQ ID NO: 17); and primer B, TC(C/G/T/A)GC(C/T)TT(C/T)TC(G/A)TA(G/A)TA(C/T)TT(G/A)TT(C/G/A/T)GC (SEQ ID NO: 18). RT-PCR was performed using primers A and B and poly(A).sup.+ RNA from mouse spleen (CLONTECH). A single PCR product (.about.1.6 kb) was cloned into pCR2.1 (Invitrogen) and sequenced. Using sequence information form these mouse eEF-2 kinase cDNA fragments, new primers were designed for 5' rapid amplification of cDNA ends (RACE) and 3' RACE to obtain full-length mouse eEF-2 kinase cDNA. 5' RACE and 3' RACE were performed using Marathon-Ready mouse spleen cDNA (CLONTECH). This was carried out according to the manufacturer's instructions using the primers AP1 and C (TACAATCAGCTGATGACCAGAACGCTC) (SEQ ID NO: 19) 5' antisense, or D (GGATTTGGACTGGACAAGAACCCCC) (SEQ ID NO: 20) 3' sense.

[0389] To clone rat eEF-2 kinases, PCR was performed on a rat PC12 cDNA library cloned in .lamda.GT10 (CLONTECH) using primer B and vector primers. A 700-bp fragment was specifically amplified. The fragment was cloned into pCR2.1 (Invitrogen) and sequenced. This 700-bp fragments was radiolabeled and used to probe the same PC12 cDNA library (600,000 plaques). Fourteen positives were obtained in the initial screening. Five plaques were chosen for further analysis and sequencing based on insert sizes that ranged from 1.4 to 2.0 kb.

[0390] Recently, eEF-2 kinase from rabbit reticulocyte lysate was purified to near homogeneity (Hait et al., (1996)). This enabled determination of its partial amino acid sequence as noted above. Two peptide sequences (LTPQAFSHFTFER (SEQ ID NO: 15) and LANXYYEKAE (SEQ ID NO: 16)) were compared with entries in a nonredundant database using the National Center for Biotechnology Information BLAST program (Altschul et al., (1990) J. Mol. Biol. 215:403-410). Matches were found with a C. elegans hypothetical protein (F42A10.4; GenBank accession number U10414). This sequence was obtained from the C. elegans genome sequencing project and is located on chromosome 111 (Wilson et al., (1994) Nature 368:32-38). The 100% identity between the sequenced peptides and the C. elegans protein, as well as the fact that the predicted molecular weight of the C. elegans protein is similar to that of eEF-2 kinase, suggested that this gene encoded eEF-2 kinase. We cloned the full-length cDNA by RT-PCR using C. elegans total RNA. Several clones were isolated and sequenced. Cefk-1 has six of the predicted exons and encodes 768 amino acids. Cefk-2 represents an alternatively spliced form that has five exons; it is missing amino acids 625-632 that correspond to exon four. Cefk-1 and Cefk-2 were found to have eEF-2 kinase activity when expressed in cell-free system using a wheat germ extract coupled transcription/translation system.

[0391] To determine the amino acid sequence of mammalian eEF-2 kinase, we cloned and sequenced the cDNA of mouse eEF-2 kinase. We reasoned that since the sequenced peptides from rabbit eEF-2 were 100% identical to C. elegans eEF-2 kinase, then the two peptides should also match the sequence of mouse eEF-2 kinase. Degenerate primers were designed based on the amino acid sequence of the peptides and were used to perform RT-PCR on mouse spleen poly(A).sup.+ mRNA. A single PCR product of -1.6 kb was obtained and sequenced. To obtain the full-length cDNA, 5' RACE and 3' RACE were performed using mouse spleen cDNA. The full-length cDNA, which encodes 724 amino acids, was expressed in a cell-free coupled transcription/translation system. A single translation product with an apparent molecular weight of 100 kDa was obtained.

[0392] A cDNA for rat eEF-2 kinase was cloned and sequenced using a fragment of mouse eEF-2 kinase cDNA to probe a PC 12 cDNA library. However, after this work was completed, a paper describing the cloning of eEF-2 from rat skeletal muscle was published (Redpath et al., (1996) J. Biol. Chem. 271:17547-17554) and the reported sequence appears to be identical to the eEF-2 kinase sequence from PC12 cells. Like the mouse eEF-2 kinase, the rat eEF-2 kinase cDNA encodes a 724-amino acid protein.

[0393] The human eEF-2 kinase cDNA was cloned. RT-PCR was performed on poly(A).sup.+ mRNA from the human glioma cell line T98G using 20' mer primers corresponding to the 5' and 3' ends of the mouse eEF-2 kinase coding region. The human eEF-2 kinase cDNA encodes a 725 amino acid protein.

Example 2

Lack of Homology of eEF-2 Kinase to Members of Eukaryotic Protein Kinase Superfamily

[0394] The alignment of the amino acid sequences of C. elegans and mammalian eEF-2 kinases is shown in FIG. 2. Rat and mouse eEF-2 kinase are very similar being 97% identical and differing by only 23 amino acids. Human eEF-2 kinase is 90% identical to mouse and rat eEF-2 kinase. In contrast, C. elegans eEF-2 kinase is found to be only 40% identical to mammalian eEF-2 kinase.

[0395] According to the current classification, eEF-2 kinase belongs to the family of closely related calmodulin-dependent protein kinases. Surprisingly, upon analyzing eEF-2 kinase sequences, we did not find any homology to the other calmodulin-dependent kinases or to any other members of the protein kinase super-family. The only motif which it shares with all other protein kinases is the GXGXXG (SEQ ID NO: 21) motif (279-284 in C. elegans eEF-2 kinases; 295-300 in mouse eEF-2 kinase) which forms a glycine-rich loop and is part of the ATP-binding site. Comparison of mammalian and C. elegans eEF-2 kinase revealed only one extended region of homology that spans .about.200 amino acids upstream of the GXGXXG motif. The high degree of similarity and the proximity to the nucleotide-binding site suggests that these 200 amino acids represent the catalytic domain. This region has a high degree of similarity and a portion of this region (amino acids 251-300 in mouse eEF-2 kinase) displays 75% identity to the catalytic domain of MHCKA (see below), which also suggests that this is the catalytic domain. In the recently published rat eEF-2 kinase sequence [Redpath et al., J. Biol. Chem. 271: 17547-17554 (1996)], the catalytic domain was predicted to reside between amino acids 288 and 554 based on the homology with the catalytic domain of cAMP-dependant protein kinase (PKA). Our results demonstrate that their prediction cannot be correct for several reasons. First, we find that the homology of this region with PKA is not statistically significant. Second, this region is the least conserved between mammalian and C. elegans eEF-2 kinase. Finally, according to secondary structure predictions [made by Alexei V. Finkelstein, Institute of Protein Research, Russia using the ALB-GLOBULE program [Ptitsyn and Finkelstein, Biopolymers 22:15-25 (1983)]], this region most likely has a distorted structure and contains almost no .alpha.-helices or .beta.-strands, which are characteristic of a catalytic domain.

[0396] Because eEF-2 kinase is CA.sup.2+/calmodulin-dependant, it should contain a calmodulin-binding domain, which is usually represented by an amphipathic .alpha.-helix. There are several regions that could possibly assume an amphipathic .alpha.-helical conformation. Further biochemical analysis is required to determine which of these is the calmodulin-binding domain.

[0397] In the C-terminal region, there is a short stretch of 22 amino acids which is 86% identical between mammalian and C. elegans eEF-2 kinase and is preceded by a longer region of weak homology. We do not know the function of this conserved region at present. One of the possibilities is that it is that it is involved in oligomerization of the kinase. It was thought previously that eEF-2 kinase was an elongated monomer because it migrated during gel filtration as an .about.150-kDa protein and migrated on SDS gels as a 105-kDa polypeptide [Ryazanov and Spirin, Translational Regulation of Gene Expression, Pienum, N.Y., Vol 2, pp 433-455 (1993); Abdelnajid et al., Int. J. Dev. Biol., 37:279-290 (1993)]. However, the molecular weight of a monomer of mammalian eEF-2 kinase based on the predicted sequence is just 82 kDa. Thus, it is possible that eEF-2 kinase is not a monomer but a responsible for dimerization. Interestingly, according to computer prediction using the COIL program, this conserved region can form a coiled-coil. Formation of coiled-coil is often responsible for dimerization [Lupas, Trends Biochem. Sci., 21:375-382 (1996)].

[0398] We found that eEF-2 kinases is homologous to the central portion of the recently described MHCKA from Dictyostelium [Futey et al., J. Biol. Chem. 270:523-529 (1995) see FIG. 2]. The kinase was biochemically identified as a 130-kDa protein and has a demonstrated role in myosin assembly, both in vitro and in vivo [Futey et al., 1995, supra]. As with eEF-2 kinase, MHCKA displays no region with detectable similarity to the conserved catalytic domains found in known eukaryotic protein kinases. Primary structure analysis of MHCKA revealed an amino-terminal domain with a probable coiled-coil structure, a central nonrepetitive domain, and a C-terminal domain consisting of seven WD repeats [Futey et al., 1995, supra]. A fragment of the central nonrepetitive domain of MHCKA containing amino acids 552-841 was recently shown to represent the catalytic domain [Cote et al., J. Biol. Chem. 272:6846-6849 (1997)].

[0399] Because the catalytic domain of MHCKA and eEF-2 kinase have a high degree of similarity, the substrate specificity of these two kinases was assayed. It was demonstrated that MHCK A cannot phosphorylate eEF-2, and likewise, rabbit eEF-2 kinase cannot use myosin heavy chains as a substrate. This demonstrated that each of these kinases is specific for their respective substrates.

Example 3

eEF-2 Kinase and MHCKA Define a New Class of Protein Kinases

[0400] Members of the eukaryotic protein kinase superfamily are characterized by a conserved catalytic domain containing approximately 260 amino acids and is divided into twelve subdomains [Hanks and Hunter, FASEB J., 9:576-596 (1996); Hardie and Hanks, The Protein Kinase Facts Book Academic, London (1995), Taylor et al., Annu. Rev. Cell Biol. 8:429-462 (1992) Johnson et al., Cell. 85: 149-158 (1996)]. The three-dimensional structure of several protein kinases revealed that the catalytic domain consists of two lobes. The smaller N-terminal lobe, which has a twisted .beta.-sheet structure, represents the ATP-binding domain. The larger C-terminal lobe, which is predominantly .alpha.-helical is involved in substrate binding. At the primary structure level, the only motif similar between eEF-2 kinase, MHCK A, and other protein kinases is the GXGXXG motif which forms the loop interacting directly with the phosphates of ATP [Hanks and Hunter, 1996, supra; Hardie and Hanks 1995, supra; Taylor et al., supra]. In eukaryotic protein kinases, this motif is located at the very N terminus of the ATP-binding lobe of the catalytic domain. In contrast, in a eEF-2 kinase and MHCK A, this motif is close to the C terminus of the catalytic domain (see FIG. 3). However, the overall topology of the ATP-binding subdomain of eEF-2 kinase and MHCK A can be similar to other protein kinases because the region upstream of the GXGXXG (SEQ ID NO: 21) motif is strongly predicted to contain four or five .beta.-strands and thus can form a twisted .beta.-sheet.

[0401] However, the mechanism of ATP-binding to eEF-2 kinase is probably quite different in comparison to other conventional members of the eukaryotic protein kinase superfamily. In protein kinases, there is a conserved lysine residue, corresponding to Lys-72 in cAMP-dependant protein kinases which binds to the .beta.- and .gamma.-phosphates of ATP and is located at about 20 amino acids downstream of the GXGXXG motif. Analysis of eEF-2 kinase and MHCK A sequences revealed that there are no conserved lysine residues in the vicinity of the GXGXXG motif. There is another atypical protein kinase, BCR-ABLE, which does not contain this conserved lysine and it is proposed that it interacts with ATP via two cysteine residues [Maro and Witte, Cell, 67:459-468 (1991)]. Interestingly, eEF-2 kinase and MHCK-A contain two conserved cysteine residues (Cys-313 and Cys-317 in mouse eEF-2 kinase) which are located near the GXGXXG motif and therefore might be involved in ATP binding. Thus the mechanism of ATP-binding of eEF-2 kinase and MHCK A is different from other members of the protein kinase superfamily, but may be similar to that of the BCR-ABLE protein kinase.

[0402] The overall catalytic mechanism of eEF-2 kinase and MHCKA is probably also very different from other eukaryotic protein kinases. All members of the eukaryotic protein kinase superfamily contain a DXXXN (SEQ ID NO: 22) motif in the catalytic loop and a DFG motif in the activation segment [Hanks and Hunter, 1996; supra, Hardie and Hanks 1995, supra; Taylor et al., supra: Johnson et al., 1996, supra]. These two motifs, which are directly involved in the catalysis of the protein phosphorylation reaction, are absent from the eEF-2 kinase and WICK A catalytic domain.

[0403] We would predict that there are other protein kinases which are structurally similar to eEF-2 kinase and MHCK A. An extensive search of the entire nonrestricted database of the National Center for Biotechnology Information using the BLAST program did not reveal any protein with a significant homology to the catalytic domain of eEF-2 kinase and MHCKA. A search of the Expressed Sequence Tag (EST) database revealed several ESTs from C. elegans, mouse and human which are essentially identical to portions of eEF-2 kinase cDNA sequences reported here. Interestingly, a search of the recently completed genome database of Saccharomyces cerevisiae did not reveal any protein with homology to eEF-2 kinase despite the fact that eEF-2 phosphorylation was reported in yeast (41).

Conclusion

[0404] Since the catalytic domains of eEF-2 kinase and MHCK A do not share homology with other known protein kinases, these two protein kinases establish the presence of a novel and widespread superfamily of eukaryotic protein kinases. Although the existence of several unusual protein kinases have been reported, to our knowledge, we demonstrate for the first time the existence of a biochemically well-characterized and ubiquitous protein kinase that is structurally unrelated to other serine/threonine/tyrosine kinases. Contrary to the widely accepted belief that all eukaryotic protein kinases evolved from a single ancestor, our results suggest that eukaryotic protein kinases appeared at least twice during the course of evolution. This also suggests that, in addition to the relatively well-characterized catalytic mechanism employed by members of eukaryotic serine/threonine/tyrosine protein kinase superfamily, there exists another mechanism of protein kinase superfamily, there exists another mechanism of protein phosphorylation. Further studies will reveal the molecular details of this mechanism and whether there are other protein kinases that phosphorylate their substrates using this mechanism.

Example 4

Cloning and Analysis of Melanoma Alpha Kinase CDNA

[0405] Here, we describe cloning and sequencing of a novel protein entitled "melanoma alpha-kinase". This protein has two domains, one domain is the alpha-kinase catalytic domain and the other is an ion channel. This is the first example of an ion channel being covalently linked to a protein kinase. It is likely that this novel protein kinase can be regulated by ion flow through the membrane. Expression of this kinase was detected in all mouse tissues studied, including heart, skeletal muscle, brain, liver and lung. This kinase is the most abundant in the heart. The ion channel portion is very similar to (70% identical) to a previously identified protein called melastatin that is selectively downregulated in metastatic tumors, and therefore is believed to be a metastasis suppressor gene. Melanoma alpha-kinase, as well as melastatin, belongs to the TRP family of ion channels. All TRP proteins function as tetramers, and various trp proteins can form tetramers in different combinations that results in ion channel with different properties. Considering the high degree of similarity between melanoma kinase and melastatin, it is likely that melanoma kinase can form tetrameric complexes with melastatin. In humans, melanoma kinase is located on chromosome 15q21.

[0406] Human EF-2 kinase amino acid sequence (Acc. No. AAB58270) was used to search for homologous sequences in the expressed sequence tag (EST) division of Genbank using the BLAST server and the tblastn program at the National Center for Biotechnology Information. One human EST (Acc. No. AA332887) that overlapped and displayed significant homology to the catalytic domain of EF-2 kinase was found. We used the nucleotide sequence of this EST to look for overlapping EST sequences. We identified mouse melanoma EST sequence (Acc. No. AA138771) that overlapped by 45 nucleotides with the human EST sequence. We obtained the mouse melanoma EST clone from Research Genetics and sequenced the entire clone. This clone represents the 3' end of melanoma alpha-kinase mRNA and includes the 3' untranslated region plus approximately 350 amino acids of the C-terminus of the protein.

[0407] To obtain the full-length cDNA for mouse melanoma alpha-kinase, we used a Marathon-ready mouse heart cDNA library from Clontech. To obtain the remaining sequence of melanoma alpha-kinase, we performed 5' rapid amplification of cDNA ends (RACE) using the following primers: MK1-R1 (5'-TGACCAGGTACACAGCACTTTGACTGCTCT-3' (SEQ ID NO: 23)). PCR was performed under the following conditions: denaturation for 15 seconds at 95.degree. C.; annealing plus extension for 4 minutes at 68.degree. C., 30 cycles. A single PCR product of approximately 4.0 kb was obtained and gel-purified using a gel extraction kit (Qiagen). The fragment was ligated into vector pCR2.1 using the TA cloning kit (Invitrogen), and then transformed into Escherichia coli TOP10F'. Plasmid DNA was purified, and restriction analysis used to verify the orientation of the coding sequence with respect to the T7 promoter. Three clones were chosen and sequenced using an ABI 377 sequencer (Applied BioSystems).

[0408] To obtain full-length human melanoma alpha-kinase cDNA, new primers were designed for 5' and 3' RACE using sequence information from mouse melanoma alpha kinase cDNA fragments, and full-length cDNA was obtained using a human leukocyte cDNA library (provided by Dr. S. Kotenko).

[0409] Mouse melanoma alpha kinase hybridizations were performed using EST 585207 DNA as a probe. The probe was labeled with [a-32P]dCTP using the random-primed DNA labeling method. A multiple tissue northern blot (CLONTECH) was prehybridized at 42.degree. C. for 16 hours in a 50% formamide solution containing 10.times.Denhardt's solution, 5.times.SSPE, 2% SDS, and 100 .mu.g/ml salmon sperm DNA. Hybridizations were completed in the same solution containing the 32P-labeled probe (1.times.106 cpm/ml; specific activity, 1.times.108 dpm/.mu.g DNA) and 10% dextran sulfate at 42.degree. C. for 16 hours. Blots were washed twice at room temperature (15 minutes) in 2.times.SSPE, 0.05% SDS, and once at 50.degree. C. (15 minutes) in 0.5.times.SSPE, 0.5% SDS. RNA/cDNA hybrids were visualized by autoradiography.

Example 5

A Novel Type of Signaling Molecule-Protein Kinases Covalently Linked to Ion Channels

Abstract

[0410] Recently we identified a new class of protein kinases with a novel type of catalytic domain structurally and evolutionarily unrelated to the conventional eukaryotic protein kinases. This new class, which we named alpha-kinases, is represented by eukaryotic elongation factor-2 kinase and the Dictyostelium myosin heavy chain kinases. Here we cloned and sequenced five other mammalian alpha-kinases. One of these proteins, which was initially identified as an EST from a mouse melanoma cDNA library, was named melanoma alpha-kinase (MK), and according to northern analysis, has a ubiquitous tissue distribution, being present in all mouse and human tissues studied. Four other alpha kinases have a more restricted tissue distribution and were named after the tissue in which they are predominantly expressed: kidney alpha-kinase (KK), heart alpha-kinase (HK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). All these protein kinases are large proteins of more than 1000 amino acids with a typical alpha-kinase catalytic domain located at the very carboxyl-terminus. We expressed the catalytic domain of human MK in Escherichia coli, and found that it autophosphorylates on threonine residues, demonstrating that it is a genuine protein kinase.

[0411] Unexpectedly, we found that the long amino-terminal portions of melanoma and kidney .alpha.-kinases represent new members of the transient receptor potential (TRP) ion channel family, which are implicated in the mediation of capacitative Ca.sup.2+ entry in non-excitable mammalian cells. This suggests that melanoma and kidney .alpha.-kinases, which represent a novel type of signaling molecule, are involved in the regulation of Ca.sup.2+ influx into mammalian cells. It has also been implied that TRP channels may mediate the Ca2+-release-activated Ca2+ current (CRAC). The channel portions of KK and MK were highly similar to each other and highly similar to melastatin. Melastatin is a putative Ca2+ channel that was identified as a gene product specifically downregulated in metastatic melanoma. Phylogenetic analysis revealed that both KK and MK belong to the long TRP (LTRP) channel subfamily, which also includes melastatin, and several uncharacterized channel proteins from mammals, Caenorhabditis elegans and Drosophila. Among LTRP channels, only MK and KK possess an .alpha.-kinase domain.

Introduction

[0412] The vast majority of eukaryotic protein kinases have a typical catalytic domain structure consisting of twelve conserved subdomains (1). The existence of other protein kinases with a different structure was reported in eukaryotes (2-4). Recently we identified a new class of protein kinases with a novel type of catalytic domain, structurally and evolutionarily unrelated to the conventional eukaryotic protein kinases (5). This class, which we named alpha-kinases, is represented by eukaryotic elongation factor-2 (eEF-2) kinase and the Dictyostelium myosin heavy chain kinases A and B (MHCKA and B) (2, 3, 29). The catalytic domain of the alpha-kinases can be subdivided into eight domains (6). There is no significant homology between those eight domain and any of the twelve subdomains of the conventional protein kinases. We named this new class of protein kinases the alpha-kinases because the existing evidence suggests that they can phosphorylate amino acids located within a-helices (6).

[0413] In order to study how widespread the alpha-kinases are and to identify new members of the alpha-kinase family in mammals, we used a functional genomic approach. We performed an extensive expressed sequence tag (EST) database search for sequences homologous to the catalytic domain of human eEF-2 kinase. As a result of this screen, we obtained several partial sequences for putative alpha-kinases, which were subsequently used to clone the full-length cDNAs.

[0414] We cloned and sequenced and analyzed the tissue distribution of five new members of the alpha-kinase family. All these proteins contain the typical alpha-kinase catalytic domain. The expressed catalytic domain of MK was able to autophosphorylate, therefore demonstrating that it is a genuine protein kinase.

[0415] Unexpectedly, the amino-terminal portions of MK and KK appear to have a long amino-terminal portions highly homologous to a number of ion channel proteins that belong to transient receptor potential (TRP) family of Ca2+ channels. The ion channel portions of MK and KK are remarkably homologous to melastatin. Melastatin is a protein downregulated in metastatic melanoma, and is a newly discovered member of the TRP Ca2+ channel family (7, 8). TRP channels derive their name from a mutation in a Drosophila calcium channel that is involved in photoreception (30, 31). This mutation caused an inability to maintain a sustained receptor potential, and was therefore named transient receptor potential (trp), and the channel was named the TRP channel (19, 30, 31). Several homologues of TRP channels in mammals have been identified (27, 32, 33). The recent interest in the TRP channel family is related to the fact that they may represent channels responsible for store-operated calcium influx--one of the major pathways of calcium entry into non-excitable mammalian cells (9, 10, 12, 18, 24, 34).

[0416] TRP channels are Ca2+-permeable channels believed to be responsible for Ca2+ influx in response to depletion of internal Ca2+ stores (9-11). The ion channel portion of MK and KK, being highly similar to melastatin, makes MK and KK new member of the TRP family, in particular the LTRP family to which melastatin belongs.

[0417] Thus, in our work, we demonstrated a novel type of signaling molecule--an ion channel covalently linked to a protein kinase. We discuss the possibility that this hybrid ion channel/protein kinase is involved in the regulation of store-operated Ca2+ entry in non-excitable tissues.

Materials and Methods

Cloning of Melanoma Kinase

[0418] We searched the EST database, and identified several mouse and human ESTs homologous to the catalytic domain of human eEF-2 kinase. One of these EST clones was derived from a mouse melanoma cDNA library (IMAGE clone 585207; GenBank accession #AA138771). We sequenced this clone and found it encodes the C-terminus (approximately 300 amino acids) of a novel protein. We used 5' rapid amplification of cDNA ends (RACE) and a mouse heart Marathon-ready cDNA library (Clontech) to determine the full-length sequence. We used this sequence information to design primers and clone human melanoma kinase from a Hela cell cDNA library.

Cloning of Kidney Kinase

[0419] A further search in the EST database revealed an EST derived from a mouse kidney cDNA library encoding another protein homologous to the catalytic domain of eEF-2 kinase (IMAGE clone 656119; GenBank accession #AI390333). We used the sequence information to perform 5'RACE and 3'RACE using a mouse heart Marathon-ready cDNA library (Clontech). After partial sequencing of this clone, we used the new sequence information to design primers and clone human kidney kinase from a human kidney Marathon-ready cDNA library (Clontech).

Cloning of Heart Kinase

[0420] Database searches revealed another homologous EST clone approximately 2 kb in length (IMAGE clone #585879; GenBank accession #AA140393). To obtain the full length cDNA, we screened a mouse heart 5'-STRETCH PLUS cDNA lambda library (Clontech). A 32P-labeled 2 kb EST fragment was used as a probe for clone identification. Several clones gave positive signals, and were further analyzed by PCR. The largest of the clones (.about.5 kb) was sequenced. Subsequently we found a human EST in the EST database homologous to mouse heart kinase (IMAGE clone #843057; GenBank accession #AA485987). We sequenced this clone, and found it encodes a protein corresponding to the C-terminus of heart kinase. After partial sequencing of this clone, we used the new sequence information to design primers and clone human heart kinase from a human heart Marathon-ready cDNA library (Clontech).

Cloning of Skeletal Muscle Kinase

[0421] We searched the HTGS database for sequences homologous to mouse heart kinase, and found a clone containing the gene encoding a protein similar to heart kinase. We designed primers using the database sequence and performed PCR using a human placenta cDNA library to clone the catalytic domain of muscle kinase.

Cloning of Lymphocyte Kinase

[0422] By searching the non-restricted database, we found a genomic DNA clone derived from chromosome IV that encodes a protein containing the a-kinase catalytic domain. We used this sequence information to search for overlapping ESTs in order to reconstruct the full-length protein, and then to design primers for PCR to clone the full-length protein from a lymphocyte cDNA library.

Cloning of the Melanoma Kinase Catalytic Domain

[0423] The catalytic domain of melanoma kinase was cloned from a Hela cell cDNA Primers were designed based upon the sequence of melanoma kinase. The sequences of the primers are:

TABLE-US-00008 Forward: (SEQ ID NO: 24) 5'- GTTAGTACACCATCTCAGCCAAGTTGCAAA-3', Reverse: (SEQ ID NO: 25) 5'-TTATAACATCAGACGAACAGAATTAGTTGATTCTGATTCT-3'.

[0424] PCR conditions were as follows: 30 sec. at 94.degree. C., 30 sec. at 58.degree. C., 3 min. at 72.degree. C. for 30 cycles, followed by a 10 min. final extension at 72.degree. C. The PCR product was cloned into PCRII-TOPO vector (Invitrogen) as per manufacturer's instructions. The insert was then subcloned into the EcoRI site in pMAL-p2x (NEB) to tag the protein with maltose binding protein (MBP).

Expression and Purification of MBP-MK

[0425] E. coli strain DH5a carrying the pMALp2x-MK plasmid were grown to an ODI=600 0.5, then IPTG was added to a final concentration 0.3 mM. Cells were grown for additional 6 hours at 37.degree. C. All following procedures were carried out at 4.degree. C. Cells was resuspended in 20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 1 mM EDTA, 10 mM b-mercaptoethanol and sonicated. Inclusion bodies were pelleted by centrifugation at 30,000.times.g for 30 min., dissolved in 6M urea, 20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 1 mM EDTA, 10 mM b-mercaptoethanol, 20% (w/v) glycerol and centrifuged again at 30,000.times.g for 30 min. The supernatant was dialyzed overnight against the same buffer but without urea. After dialysis, the sample was centrifuged once again at 30,000.times.g for 30 min., and the supernatant was loaded onto an amylose column equilibrated with 20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 1 mM EDTA, 10 mM b-mercaptoethanol, 20% (w/v) glycerol. Elution was performed by a step gradient of the same buffer plus 10 mM maltose.

Phosphorylation of MBP-MK

[0426] Assays for MBP-MK activity were performed at 30.degree. C. in an assay buffer containing 50 mM Hepes-KOH (pH 6.6), 10 mM MgCl2, 1 mM DTT, 50 mM ATP, 20mCi [g-32P]-ATP and 3 mg MBP-MK. After incubation, Laemmli sample buffer was added, samples were boiled and 25 ml of each sample was loaded onto a 10% SDS-PAGE gel. The gel was stained with Coomassie Blue, dried and exposed to film for 16 hours.

Phosphoamino acid Analysis

[0427] Phosphorylation of MBP-MK was done as described above, but the reaction volume was increased 5-fold. The incubation time was 2 hours. Samples were separated by 10% SDS-PAGE and transferred to an Immobilon-P membrane (Millipore). The portion of membrane with phospho-MBP-MK was excised and incubated in 6M HCl at 110.degree. C. for 1 hour. After incubation, the mixture was dried, and the dried pellet was dissolved in 9 .mu.l of water, with the addition of non-radioactive phosphoserine, phosphothreonine, and phosphotyrosine. Phosphoamino acids were separated by thin-layer chromatography on cellulose (cellulose on polyester; Aldrich) using a buffer consisting of isobutyric acid and 0.5M NH.sub.4OH in a 5:3 ratio. The TLC plate was stained with 0.2% ninhydrin and exposed to film.

Northern Blot Analysis

[0428] Standard Multiple Tissue Northern (MTN) Blots (Clontech) were stained with DNA probes according to manufacturer's instructions. The probes were labeled with [.alpha.-.sup.32P]-dCTP using the Megaprime DNA labeling system (Amersham) using specific DNA fragments as templates. The DNA fragments were obtained as follows. A 430 bp DNA fragment of human melanoma kinase (corresponding to nucleotides 4331-4761) was obtained by PCR from a Hela cDNA library (Clontech). The following primers were used for PCR:

TABLE-US-00009 LMK2: (SEQ ID NO: 42) 5'CTGCGACAGAGACTACATGGGGTAGAACTC 3' LMK4: (SEQ ID NO: 43) 5'TGAGTGTCTTCGGTAGATGGCCTTCTACTG 3'

[0429] A 741 bp DNA fragment of human kidney kinase was produced by PCR from a plasmid containing kidney kinase cDNA. The region corresponding to nucleotides 3721-4462 was amplified using the following primers:

TABLE-US-00010 KK-F1: (SEQ ID NO: 44) 5'ATGGAGATTGCTGGAGAGAAG 3' and KK-R3: (SEQ ID NO: 45) 5'ATTCACTACTCTGGGCCGATC 3'

[0430] A 1.2 kb DNA fragment of human muscle kinase was obtained by EcoRI digestion of the human muscle kinase cDNA insert cloned in pCRII-TOPO (Invitrogen). The mouse melanoma kinase 2.2 kb DNA fragment was obtained from EST clone 585207. The fragment was cut out with BamHI and XhoI from pBluescript SK-vector (Stratagene). The mouse heart kinase 2 kb DNA fragment was produced by restriction with SmaI and KpnI from EST clone 585879.

Results

[0431] In our work we cloned and sequenced five new members of the alpha-kinase family. They are named according to their tissue distribution: heart alpha-kinase (HK), melanoma alpha-kinase (MK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), lymphocyte alpha-kinase (LK). The nucleic acid sequence and predicted amino acid sequence of the human heart alpha-kinase (HK) are depicted in FIGS. 8 A and B (SEQ ID NO: 34 and 35, respectively). The nucleic acid sequence and predicted amino acid sequence of the mouse heart alpha-kinase (HK) are provided in SEQ ID NO: 36 and 37, respectively. The nucleic acid sequence (SEQ ID NO: 26) and predicted amino acid sequence (SEQ ID NO: 27) of the human melanoma alpha-kinase (MK) are depicted in FIGS. 7 A and B. The nucleic acid sequence (SEQ ID NO: 28) of mouse melanoma .alpha.-kinase is shown in FIG. 5. The predicted amino acid sequence (SEQ ID NO: 29) of mouse melanoma .alpha.-kinase is shown in FIG. 6. The nucleic acid and predicted amino and sequence of the human kidney alpha-kinase (KK) are depicted in FIGS. 9 A and B (SEQ ID NO: 30 and 31, respectively). The nucleic acid and predicted amino and sequence of mouse kidney alpha-kinase (KK) are provided in SEQ ID NO: 32 and 33, respectively. FIGS. 10 A and B depicts the nucleic acid sequence (SEQ ID NO: 38) and predicted amino acid sequence (SEQ ID NO: 39) of human skeletal muscle alpha-kinase (SK). The nucleic acid sequence (SEQ ID NO: 40) and predicted amino acid sequence (SEQ ID NO: 41) of the lymphocyte alpha-kinase (LK) are shown in FIGS. 11A and B. All of these protein kinases are large proteins of more than 1000 amino acids with a typical alpha-kinase catalytic domain located at the very C-terminus. FIG. 12 shows the alignment of the catalytic domains of the cloned alpha-kinases. The catalytic domain sequence reveals 30-80% similarity between these alpha-kinases. It can be divided into several subdomains with no homology between these subdomains and any of the twelve subdomains of the conventional protein kinases. Altogether, there are sixteen positions in the alignment of the cloned proteins that are invariant among all the known alpha-kinases. All five new proteins are homologous to each other, as well as homologous to the eEF-2 kinase and MHCK B catalytic domains. A comparison of the five new .alpha.-kinases, eEF-2 kinase and WICK B reveals sixteen invariant amino acids. We reported previously (6) that the .alpha.-kinase catalytic domain can be divided into eight subdomains, each having a characteristic sequence motif. Identification of new .alpha.-kinases allowed us to characterize these subdomains more precisely. In addition, we used the ALB secondary structure prediction service (http://indy.ipr.serpukhov.su/.about.rykunov/alb/) (35) to predict a consensus secondary structure of the .alpha.-kinase catalytic domain. Subdomain I begins with a conserved Trp residue present in all .alpha.-kinases with the exception of HK, which has a Phe in this position. Subdomain I is also characterized by an invariant Gly and an invariant Arg that are part of the conserved Arg-Lys-Ala motif. Subdomain II is characterized by an invariant Lys, that is part of an Hyd-Hyd-X-Lys motif (Hyd=hydrophobic). Subdomain III contains an invariant Gln, and is predicted to form an .alpha.-helix. Subdomain IV contains a stretch of hydrophobic amino acids and is predicted to form a .beta.-sheet. Subdomain V is predicted to form an .alpha.-helix containing an invariant Glu, and is followed by a conserved Asn (an Arg in HK and SK). Subdomain VI is predicted to form a .beta.-turn-.beta.-turn structure with an invariant His in the first .beta.-strand, and the conserved sequence, Leu-Leu-Val-Val-Asp-Leu-Gln-Gly, that forms the end of the second .beta.-strand and second turn and also contains an invariant Asp and Gly. Subdomain VII is characterized by the conserved sequence, Leu-Thr-Asp-Pro-Gln-Ile, which contains an invariant Thr-Asp. Subdomain VIII begins with a Gly-rich region that is not predicted to have any regular secondary structure, followed by a sequence containing invariant Phe and His residues, an invariant Cys-Asn-X-X-Cys motif and an invariant Leu. The region containing the Cys-Asn-X-X-Cys motif is predicted to form a short .alpha.-helix.

[0432] Phylogenetic analysis (FIG. 13) of the cloned alpha-kinases suggests that all five alpha-kinases are more closely related to each other than to eEF-2 kinase or the MHCKs, and form a separate subfamily. MK is closely related to KK (78% identity). HK is similar to SK (47% identity). LK has less similarity to the others, but they all form a distinctive separate subfamily of alpha-kinases, displaying various degrees of similarity to eEF-2 kinase.

[0433] In order to analyze kinase activity, we expressed the catalytic domain of MK as maltose-binding protein (MBP) fusion protein. Affinity-purified MBP-MK was able to autophosphorylate. FIG. 14 shows the time course of 32P incorporation into MBP-MK. This phosphorylation can be reversed by incubation with lambda phosphatase. Phosphoamino acid analysis revealed that MK is phosphorylated on a threonine residue.

[0434] Using northern blot analysis, we analyzed the tissue distribution of the a-kinases in human and mouse tissues (FIG. 15). MK, KK, HK and SK are large proteins (corresponding cDNAs are 7.5 kb). LK mRNA is represented by two bands, 5.5 and 7.5 kb. An additional minor band at 9.5 kb can be seen for SK. MK is ubiquitously expressed, being detected in every tissue tested. In human tissues, it is most abundant in the liver, kidney and heart, and in mouse tissues--heart, lung, liver and kidney. There were noticeable amounts in human lymphoid, bone marrow and thymus tissues. The least amount of MK mRNA, among human tissues, was observed in brain. LK mRNA can be detected by northern analysis in various human tissues. Its tissue distribution was virtually identical to MK, although it is much less abundant than MK since three weeks of exposure were required to visualize the bands. LK can be detected by reverse transcriptase-PCR (RT-PCR) in human fetal liver and placenta tissues, and lymphocyte libraries. A full-length clone was obtained from a lymphocyte cDNA library. KK is present almost exclusively in kidney tissue, with trace amounts in human lymphocyte, brain and bone marrow tissues. HK is found almost exclusively in mouse heart tissue, with a smaller amount in skeletal muscle tissue. It was not seen in any other tissues tested. SK is very abundant in human muscle tissues, with a considerable amount in human heart tissue. Trace amounts of SK can be seen in human lung, placenta and kidney tissues.

[0435] We cloned full-length cDNA for MK and KK. The long N-terminal portion of MK and KK display high similarity to ion channels homologous to TRP channel family. The MK sequence contained 1864 amino acids and the KK sequence contained 2011 amino acids. Unexpectedly, we found that the long amino terminal portions of MK and KK are homologous to ion channels. The approximately 1200 amino acid long N-terminal portions of MK and KK were similar to each other (59% identical) and homologous to melastatin (48% and 51% identical respectively; see FIG. 17). Melastatin is a putative Ca.sup.2+ channel that belongs to the transient receptor potential (TRP) family of ion channels (8). Like melastatin, MK and KK contain all the sequence elements characteristic of the TRP channel family. These elements include six predicted transmembrane segments, a highly conserved sequence in the putative pore region between transmembrane segments 5 and 6, a highly conserved sequence at the end of transmembrane segment 6, and a Pro-Pro-Pro motif-containing sequence that immediately follows transmembrane segment 6 (FIG. 17). We found several human, mouse, Caenorhabditis elegans and Drosophila proteins in GenBank that are highly similar to the melastatin-like portions of MK and KK (FIG. 17). All these proteins belong to a subfamily of the TRP channels which were named long TRP channels (LTRPC), and are characterized by a long conserved N-terminal sequence that precedes the transmembrane segments (14). These proteins include a protein that was initially called TRPC7 (36), and was later renamed LTRPC2 (14), a protein named MTR1 or LTRPC5 (14, 37), an unnamed human putative protein we named LTRPC6 (GenBank accession #AK000048), three C. elegans proteins (F54D1.5, T01H8.5, and C05C12.3) named respectively CeLTRPC1, CeLTRPC2 and CeLTRPC3 (14), and a Drosophila putative protein that we named DmLTRPC1 (GenBank accession #AE008311) (FIG. 17). Thus, MK and KK can be classified as members of the LTRPC subfamily, and we suggest they be designated LTRPC3 and LTRPC4, respectively. As can be seen in FIG. 17, MK and KK, like other LTRPC proteins, contain a long N-terminal sequence (approximately 600-800 amino acids) that has several conserved and unique motifs. The ALB program predicted several long .alpha.-helices in this region in all LTRPC proteins.

[0436] Phylogenetic analysis revealed that MK, KK as well as other LTRPC proteins are related to the prototypic Drosophila TRP protein, but are more similar to each other than to the prototypic TRP (FIG. 19).

[0437] We also determined the full-length sequence of LK cDNA that encodes a protein containing 1242 amino acids. The TMPred program predicts four transmembrane segments located close to the N-terminus.

[0438] HK and SK cDNAs encode proteins of 1531 and 1215 amino acids, respectively. Comparison of the predicted amino acid sequences of HK and SK with other proteins in GenBank using the BLAST program revealed that there is an approximately 100 amino acid motif located just N-terminal to the catalytic domain that displays sequence similarity to immunoglobulin-like domains of titin, myosin light chain kinase, and several other proteins. The same region in both kinases is identified as an immunoglobulin-like domain using the CD-Search program. The remainder of the HK amino acid sequence did not display any strong similarity to any known proteins. The N-terminal portion of SK displayed a weak similarity to collagen, which may be attributed to the high glycine and proline content.

Discussion

[0439] In our previous work, we discussed the unique structure of eEF-2 kinase and the Dictyostelium MHCKs, and suggested that they represent a new class of protein kinases, the .alpha.-kinases (5, 6). In this work, we cloned and sequenced five new members of the .alpha.-kinase class. Thus, together with eEF-2 kinase, there are at least six distinct .alpha.-kinases in mammals. These six .alpha.-kinases encompass all sequences from vertebrate sources deposited in GenBank thus far with homology to the .alpha.-kinases. With approximately 90% of the human genome represented in GenBank to date, it is likely we cloned most, if not all, of the mammalian .alpha.-kinases. Interestingly, in the C. elegans genome there is only one .alpha.-kinase (eEF-2 kinase) while none have been identified in the Drosophila, yeast and plant genomes. However, the .alpha.-kinases appear to be widespread among the protozoa: sequences encoding proteins with a high similarity to the .alpha.-kinases are present in the genomes of Trypanosoma, Leishmania, and Amoeba.

[0440] We cloned and sequenced five new members of the alpha-kinase family. All of these kinases have a typical alpha-kinase catalytic domain located the very carboxyl-terminus. The alignment of the cloned alpha-kinase catalytic domains reveals eight subdomains characteristic of the alpha-kinases which have no significant homology to the conventional eukaryotic protein kinase catalytic domain. An alignment of the .alpha.-kinase catalytic domain revealed several characteristic motifs. These motifs are different from those that characterize the eukaryotic Ser/Thr/Tyr protein kinase superfamily, suggesting that the .alpha.-kinases and conventional eukaryotic protein kinases are structurally and evolutionarily unrelated. The expressed catalytic domain of MK is able to efficiently autophosphorylate. Tissue distribution of the new cloned proteins reveals that among the cloned alpha-kinases, MK has a wide tissue distribution, while the others (KK, HK, LK and SK) are specific for particular tissues. SK, which is specific to human skeletal muscle, is remarkably abundant. Phylogenetic analysis suggests that our cloned alpha-kinases are closely related to each other, and are distantly related to eEF-2 kinase and the MHCKs, forming a distinctive subfamily of alpha-kinases. All of the five new alpha-kinases probably evolved from a common ancestor during the evolutionary process. Therefore, the alpha-kinase family has been enlarged and now includes five new members.

[0441] Recently the structure of a novel type of protein kinase catalytic domain has been determined represented by the bacterial histidine kinases, EnvZ and CheA (38, 39). The structure of the catalytic domain of the histidine kinases appears to be completely different from that of the Ser/Thr/Tyr protein kinase superfamily but utilizes a fold similar to Hsp90, DNA gyrase B, and MutL (Bergerat fold; 40). There are protein kinases that are highly similar to the bacterial histidine kinases, but phosphorylate their substrates on serine residues [for example, plant phytochromes (41) and animal pyruvate dehydrogenase kinase (42)] or on tyrosine residues [DivL (43)], suggesting that protein kinases with the Bergerat fold can phosphorylate amino acids other than histidine. Is it possible that the .alpha.-kinases also use a similar fold? We noticed that the distribution of consensus secondary structure elements predicted for the .alpha.-kinases using the ALB program is similar to the distribution of secondary structure elements in EnvZ as determined by NMR. Moreover, the conserved asparagine and invariant aspartic acid residues located in subdomains V and VI, respectively, may correspond to the invariant asparagine and aspartic acid residues located in the N and G1 boxes, respectively, of the histidine kinases. These residues play a crucial role in ATP binding (38, 39, 40). The glycine-rich region in subdomain VIII of the .alpha.-kinases may correspond to the G2 box of histidine kinases, which is a highly mobile region that forms part of the "lid" of the ATP binding site (38, 39, 40). In addition, the histidine residues phosphorylated by histidine kinases are located within .alpha.-helices (39, 44, 45), suggesting that the catalytic domain of these protein kinases is adapted to recognize .alpha.-helices. Finally, the overall topology of some .alpha.-kinases (MK, KK and LK) with several transmembrane segments in the N-terminal region of the molecule and catalytic domain located at the C-terminal region resemble the topology of many histidine kinases (46). All these facts raise the possibility that the .alpha.-kinases and the histidine kinases may be evolutionarily related.

[0442] The expressed catalytic domain of MK is able to autophosphorylate, demonstrating that it is a genuine protein kinase. Phosphoamino acid analysis revealed that MK autophosphorylates exclusively on a threonine residue. Interestingly, the only two other .alpha.-kinases for which the substrates have been identified, eEF-2 kinase and MHCK A, both phosphorylate their substrates on threonine residues. Therefore, it is possible that the .alpha.-kinases in general are specific for phosphothreonine.

[0443] Northern analysis reveals that MK and LK have a wide tissue distribution suggesting a general function for these kinases, while KK, HK and SK are expressed primarily within specific tissues, suggesting they have tissue-specific functions. Interestingly, the tissue distribution patterns of MK and LK were virtually identical, suggesting that these two proteins are similarly regulated and may have similar functions.

[0444] Remarkably, two of the new members, MK and KK, appeared to have ion channels at the very amino-terminus that are highly homologous to the TRP channel family. TRP channels are Ca2+-permeable channels that are believe to be responsible for Ca2+ influx in response to depletion of internal Ca2+ stores (9-11). Such a depletion of intracellular Ca2+ stores followed by activation of the Ca2+ entry mechanism at the plasma membrane is called capacitative Ca2+ entry (CCE).

[0445] CCE is loosely defined as an influx of Ca2+ from the extracellular space following inositol 1,4,5-triphosphate (IP3) or other Ca2+-mobilizing agent-induced depletion of internal Ca2+ from the ER and SR. CCE plays a central role in many aspects of cell signaling, and is present in many types of cells. It is an essential component of the cellular response to many hormones and growth factors. (12, 13). The TRP gene of Drosophila (19, 20) and its homologue, TRP-like (TRPL; 21) together with recently-discovered mammalian homologues (22-25) were suggested to encode the CCE channels (26, 27). The family of known TRPS and their homologues are conserved from worms to humans. All show the same basic channel subunit structure with six putative transmembrane helices, and a range of motifs in the amino- and carboxyl-terminal regions (14).

[0446] It was recently suggested that by their functional properties and structure, the TRP channel family can be subdivided into three subfamilies: short TRP (STRP), osmoTRP (OTRP) and long TRP (LTRP) (14). MK and KK display similarity to melastatin, which, by its structure and function, can be classified as an LTRP (14). Melastatin is a putative Ca2+ channel identified recently as a gene specifically downregulated in metastatic melanoma (8). Sequence analysis of the ion channel region of MK and KK reveals a typical structure of LTRPs. The function of STRP including Drosophila TRP and many mammalian homologs is to mediate Ca2+ influx subsequent to activation of phospholipase C. The OTRP subfamily is Ca2+-permeable channels involved in pain transduction, chemo-, mechano- and osmoregulation. The function of the LTRP subfamily channels is not yet well characterized.

[0447] LTRP channels have longer coding sequences than STRP and OTRP, particularly at their amino-termini. All TRP channels share similar structure: they have six transmembrane segments and a pore-forming loop between the fifth and sixth segments (reviewed in 24, 9, 14, 47). The same conserved sequences are present in MK and KK (FIG. 4). The Pro-Pro-Pro motif that follows the sixth transmembrane segment in MK and KK is characteristic for STRP and LTRP channels. LTRPs do not have the ankyrin repeats characteristic of the STRPs and OTRPs (14). Instead, they have a long N-terminus with a unique and highly-conserved sequence. As can be seen in FIG. 17, the long N-terminal portion of MK and KK also has this highly conserved sequence. This region in MK and KK is predicted to form several long .alpha.-helices. In addition to MK and KK, we identified eight other LTRP channels among the sequences deposited in GenBank: four in mammals, three in C. elegans, and one in Drosophila. The first LTRP to be identified was melastatin, a putative Ca.sup.2+ channel whose mRNA is specifically downregulated in metastatic melanoma (7, 8). MK and KK are particularly similar to melastatin (more than 48% and 51% identity) suggesting that MK and KK may be a product of a recent evolutionary event--a fusion between the .alpha.-kinase catalytic domain and a melastatin-like ion channel. Thus, considering the striking similarity of MK and KK to LTRP channels, we suggest that MK and KK are ion channels with a unique molecular structure--ion channels covalently linked to a protein kinase. FIG. 18 and FIG. 19 show a schematic representation of the major domains of MK, KK as well as other .alpha.-kinases, a phylogenetic tree of LTRP channels, and a proposed structural model of MK and KK. Thus, MK and KK, having ion channel part with the typical structure of LTRPs, can be considered a new member of the LTRP family. To date, MK and KK are the only known channels covalently linked to a protein kinase catalytic domain.

[0448] It is possible that the other three .alpha.-kinases may also have regions homologous to ion channels. LK has four predicted transmembrane segments near its N-terminus, although this region is not similar to the TRP channels. We did not find sequences homologous to ion channels at the N-termini of HK and SK, however, it is likely that we did not obtain the very N-terminal regions of these proteins.

[0449] TRP channels are Ca2+-permeable channels believed to be responsible for Ca2+ influx in response to depletion of internal Ca2+ stores (9-12, 18, 24, 27, 32, 34). The TRP gene of Drosophila (19, 31) together with recently-discovered mammalian homologues (27, 32, 33) were suggested to encode store-operated Ca.sup.2+ channels, also known as capacitative Ca.sup.2+ entry channels (9, 10, 12, 18, 24, 27, 31, 32, 34).

[0450] The first of the Ca.sup.2+-permeable store-operated channels to be characterized in detail were those mediating Ca.sup.2+-release-activated current (I.sub.CRAC) (16, 48, 51). CRAC channels are highly Ca.sup.2+ selective, low conductance channels that mediate Ca.sup.2+ entry in response to depletion of Ca.sup.2+ from intracellular stores in various non-excitable cells, and play a central role in activation of lymphocytes, degranulation of mast cells, and possibly mitogenic stimulation of various cells (16, 48, 51, 54, 55). The molecular identity of CRAC channels has not yet been determined. It has been suggested that members of the TRP channel family may underlie I.sub.CRAC (9, 10, 12, 18, 24, 27, 32, 34, 55). However, none of the TRP channels studied to date have all the properties of CRAC channels (14). Nevertheless, TRP proteins are currently the most likely candidates for CRAC channels, and it has been suggested that the CRAC channels may be hidden in the LTRP family whose function is largely unknown (14).

[0451] It is possible that MK and KK are indeed the "hidden" members of the LTRP channel family mediating I.sub.CRAC. The tissue distribution of MK (which is ubiquitously expressed in all tissues tested, and predominant in non-excitable tissues such as liver and lymphocytes) is consistent with this idea. Moreover, the protein kinase domain can be part of the signaling mechanism that modulates channel function. There is evidence that protein phosphorylation is involved in both the activation of the store-operated Ca.sup.2+ channels as well as in the regulation of channel closure (54, 56-59).

[0452] The conserved location of the transmembrane domain and catalytic domains linked together reveals a new structure for a novel type of protein. What is the role of such an unusual protein structure? There are a number of reports indicating a role for protein phosphorylation in CCE. There are indications that protein phosphatases may regulate the responsiveness of the entry channel to hypothetical diffusible component of the entry, implying that the latter may act by promoting channel phosphorylation (34). It has been proposed that the endoplasmic reticulum might possess protein kinases or phosphatases capable of altering the phosphorylation state of the entry channel (12). Phosphatase inhibitors will enhance Ca2+ entry by serine/threonine phosphorylation (52). Tyrosine phosphorylation has been implicated in coupling store depletion of Ca2+ entry, but there are inconsistencies in overall information and a possible explanation is that separate kinases phosphorylate different components of the entry mechanism. Different kinases may be involved in the process of CCE, one of the consistent implications is that protein kinases possibly phosphorylate the IP3 receptor, but the CRAC channel is the likely target for protein phosphorylation (12). It was also shown that phosphatase inhibitors can inhibit ICRAC. The tissue distribution of MK is consistent with its being a CRAC since it is present in all tissues and is most prominent in non-excitable, while barely detectable in the brain. We suggest that we discovered a new type of molecule--a protein kinase covalently linked to an ion channel--represents a new signaling molecule which underlies CRAC channels. The placement of a kinase and channel on a single molecule is particularly interesting and suggests a self-regulated molecule, whereby the phosphorylation/autophosphorylation of these unique alpha kinases controls or contributes to the open or closed state of the channel. In addition, such an unusual molecular structure may be a part of a signal transduction mechanism that links depletion of internal Ca2+ stores to channel opening.

[0453] In summary, our discovery of five new members has broadened the class of .alpha.-kinases. Two of the new .alpha.-kinases represent a novel type of signaling molecule--a TRP-like ion channel covalently linked to a protein kinase suggesting that one of the functions of the .alpha.-kinases is to regulate Ca.sup.2+ influx in mammalian cells. It is also possible that MK and KK are CRAC channels and play a central role in the immune response.

REFERENCES

[0454] 1. Hanks, S. K, & Hunter, T., (1995) FASEB J., 9, 576-596. [0455] 2. Cote, G. P., Luo, X., Murphy, M. B., and Egelhoff, T. T. (1997) J. Biol. Chem. 272, 6846-6849. [0456] 3. Futey, L. M., Medley, Q G., Cote, G. P., and Egelhoff, T. T. (1995) J. Biol. Chem. 270, 523-529. [0457] 4. Redpath, N. T., Price, N. T., and Proud, C. G. (1996) J. Biol. Chem. 271, 17547-17554. [0458] 5. Ryazanov, A. G. et al. (1997) Proc. Natl. Acad. Sci. USA 94, 4884-4889. [0459] 6. Ryazanov, A. G., Pavur, K. S., and Dorovkov, M. V. (1999) Curr. Biol. 9, R43-R45. [0460] 7. Duncan, L. M., Deeds, J., Hunter, J., Shao, J., Holmgren, L. M., Woolf, E. A., Tepper, R. I., & Shyjan, A. W. (1998) Cancer Res. 58, 1515-1520. [0461] 8. Hunter, J. J., Shao, J., Smutko, J. S., Dussault, B. J., Nagle, D. L., Woolf, E. A., Holmgren, L. M., Moore, K. J., & Shyjan, A. W. (1998) Genomics 54, 116-123. [0462] 9. Putney, J. W., Jr., & McKay, R. R. (1999) Bioessays 21, 38-46. [0463] 10. Hardie, R. C. (1996) Curr. Biol. 6, 1371-1373. [0464] 11. Friel, D. D. (1996) Cell 85, 617-619. [0465] 12. Berridge, M. J. (1995) Biochem. J. 312, 1-11. [0466] 13. Putney, J. W., Jr. (1990) Cell Calcium 11, 611-624. [0467] 14. Harteneck, C., Plant, T. D., & Schultz, G. (2000) Trends Neurosci. 23, 159-163. [0468] 15. Putney, J. W., Jr. (2000) Calcium Signaling (CRC Press, New York, N.Y.). [0469] 16. Hoth, M., & Penner, R. (1993) J. Physiol. 465, 359-386. [0470] 17. Garcia R L, Schilling W P. Biochem Biophys Res Commun. 1997 Oct. 9; 239(1):279-83. [0471] 18. Parekh A B, Penner R. Store depletion and calcium influx. Physiol Rev. 1997 October; 77(4):901-30. [0472] 19. Montell C, Rubin G M. Molecular characterization of the Drosophila tip locus: a putative integral membrane protein required for phototransduction. Neuron. 1989 April; 2(4):1313-23. [0473] 20. Wong F, Schaefer E L, Roop B C, LaMendola J N, Johnson-Seaton D, Shao D. Proper function of the Drosophila hp gene product during pupal development is important for normal visualtransduction in the adult. Neuron. 1989 July; 3(1):81-94. [0474] 21. Phillips A M, Bull A, Kelly L E. Identification of a Drosophila gene encoding a calmodulin-binding protein with homology to the tip phototransduction gene. Neuron. 1992 April; 8(4):631-42. [0475] 22. Philipp S, Cavalie A, Freichel M, Wissenbach U, Zimmer S, Trost C, Marquart A, Murakami M, Flockerzi V. A mammalian capacitative calcium entry channel homologous to Drosophila TRP and TRPL. EMBO J. 1996 Nov. 15; 15(22):6166-71. [0476] 23. Zitt C, Zobel A, Obukhov A G, Harteneck C, Kalkbrenner F, Luckhoff A, Schultz G. Cloning and functional expression of a human Ca2+-permeable cation channel activated by calcium store depletion. Neuron. 1996 June; 16(6):1189-96. [0477] 24. Birnbaumer L, Zhu X, Jiang M, Boulay G, Peyton M, Vannier B, Brown D, Platano D, Sadeghi H, Stefani E, Birnbaumer M. On the molecular basis and regulation of cellular capacitative calcium entry: roles for Trp proteins. Proc Natl Acad Sci USA. 1996 Dec. 24; 93(26):15195-202. [0478] 25. Sinkins, W. G. & Schilling, W. P. (1997) Biophys. J. 72, A271. [0479] 26. Hardie R C, Minke B. Novel Ca2+ channels underlying transduction in Drosophila photoreceptors: implications for phosphoinositide-mediated Ca2+ mobilization. Trends Neurosci. 1993 September; 16(9):371-6. [0480] 27. Zhu X, Jiang M, Peyton M, Boulay G, Hurst R, Stefani E, Birnbaumer L. trp, a novel mammalian gene family essential for agonist-activated capacitative Ca2+ entry. Cell. 1996 May 31; 85(5):661-71. [0481] 28. Hoth M, Penner R. Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature. 1992 Jan. 23; 355(6358):353-6. [0482] 29. Clancy, C. E., Mendoza, M. G., Naismith, T. V., Kolman, M. F., and Egelhoff, T. T. Identification of a protein kinase from Dictoyostelium with homology to the novel ctalytic domain of myosin heavy chain kinase A. (1997) J. Biol. Chem. 272, 11812-11815. [0483] 30. Cosens, D. J., and Manning, A. (1969) Abnormal electroretinogram from a Drosophila mutant. Nature 224, 285-287. [0484] 31. Hardie, R. C., and Minke, B. (1992) The trp gene is essential for a light-activated Ca.sup.2+ channel in Drosophila photoreceptors. Neuron 8, 643-651. [0485] 32. Wes, P. D., Chevesich, J., Jeromin, A., Rosenberg, C., Stetten, G., and Montell, C. (1995) TRPC1, a human homolog of a Drosophila store-operated channel. Proc. Natl. Acad. Sci. USA 92, 9652-9656. [0486] 33. Zhu, X., Chu, P. B., Peyton, M., and Birnbaumer, L. (1995) Molecular cloning of a widely expressed human homologue for the Drosophila trp gene. FEBS Lett. 373, 193-198. [0487] 34. Barritt, G. J. (1999) Receptor-activated Ca.sup.2+ inflow in animal cells: a variety of pathways tailored to meet different intracellular Ca.sup.2+ signalling requirements. Biochem. J. 337, 153-169. [0488] 35. Ptitsyn, O. B., and Finkelstein, A. V. (1983) Theory of protein secondary structure and algorithm of its prediction. Biopolymers 22, 15-25. [0489] 36. Nagamine, K., Kudoh, J., Minoshima, S., Kawasaki, K., Asakawa, S., Ito, F., and Shimizu, N. (1998) Molecular cloning of a novel putative Ca.sup.2+ channel protein (TRPC7) highly expressed in brain. Genomics 54, 124-131. [0490] 37. Prawitt, D., Enklaar, T., Klemm, G., Gartner, B., Spangenberg, C., Winterpacht, A., Higgins, M., Pelletier, J., and Zabel, B. (2000) Identification and characterization of MTR1, a novel gene with homology to melastatin (MLSN1) and the trp gene family located in the BWS-WT2 critical region on chromosome 11p15.5 and showing allele-specific expression. Hum. Mol. Gen. 9, 203-216. [0491] 38. Tanaka, T., et al. (1998) NMR structure of the histidine kinase domain of the E. coli osmosensor EnvZ. Nature 396, 88-92. [0492] 39. Bilwes, A. M., Alex, L. A., Crane, B. R., and Simon, M. I. (1999) Structure of CheA, a signal-transducing histidine kinase. Cell 96, 131-141. [0493] 40. Dutta, R., and Inouye, M. (2000) GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25, 24-28. [0494] 41. Yeh, K. C., and Lagarias, J. C. (1998) Eukaryotic phytochromes: light-regulated serine/threonine protein kinases with histidine kinase ancestry. Proc. Natl. Acad. Sci. USA 95, 13976-13981. [0495] 42. Bowker-Kinley, M., and Popov, K. M. (1999) Evidence that pyruvate dehydrogenase kinase belongs to the ATPase/kinase superfamily. Biochem. J. 344, 47-53. [0496] 43. Wu, J., Ohta, N., Zhao, J. L., and Newton, A. (1999) A novel bacterial tyrosine kinase essential for cell division and differentiation. Proc. Natl. Acad. Sci. USA 96, 13068-13073. [0497] 44. Zhou, H., Lowry, D. F., Swanson, R. V., Simon, M. I., and Dahlquist, F. W. (1995) NMR studies of the phosphotransfer domain of the histidine kinase CheA from Escherichia coli: assignments, secondary structure, general fold, and backbone dynamics. Biochemistry 34, 13858-13870. [0498] 45. Tomomori, C., et al. (1999) Solution structure of the homodimeric core domain of Escherichia coli histidine kinase EnvZ. Nat. Struct. Biol. 6, 729-734. [0499] 46. Hoch, J. A., and Silhavy, T. J., eds., (1995) Two-component signal transduction (Washington, D.C.: ASM Press). [0500] 47. Philipp, S., Wissenbach, U., and Flockerzi, V. (2000) Molecular Biology of Calcium Channels. In Calcium Signaling, ed. Putney, J. W., Jr. (CRC Press, New York, N.Y.), pp. 321-342. [0501] 48. Zweifach A, Lewis R S. Mitogen-regulated Ca2+ current of T lymphocytes is activated by depletion of intracellular Ca2+ stores. Proc Natl Acad Sci USA. 1993 Jul. 1; 90(13):6295-9. [0502] 49. McDonald T V, Premack B A, Gardner P. Flash photolysis of caged inositol 1,4,5-trisphosphate activates plasma membrane calcium current in human T cells. J Biol. Chem. 1993 Feb. 25; 268(6):3889-96. [0503] 50. Fasolato C, Hoth M, Penner R. A GTP-dependent step in the activation mechanism of capacitative calcium influx. J Biol. Chem. 1993 Oct. 5; 268(28):20737-40. [0504] 51. Hoth M, Penner R. Calcium release-activated calcium current in rat mast cells. J Physiol (Lond). 1993 June; 465:359-86. [0505] 52. Medley, Q. G., Gariepy, J., Cote, G. P. Dictyostelium myosin II heavy-chain kinase A is activated by autophosphorylation: studies with Dictyostelium myosin II and synthetic peptides. (1990) Biochem. 29, 8992-8997. [0506] 53. Kolman, M. F., and Egelhoff, T. T. Dictoyostelium myosin heavy chain kinse A subdomains. Coiled-coil and wd repeat roles in oligomerization and substrate targeting. (1997) J. Biol. Chem. 272, 16904-16910. [0507] 54. Parekh, A. B., and Penner, R. (1995) Depletion-activated calcium current is inhibited by protein kinase in RBL-2H3 cells. Proc. Natl. Acad. Sci. USA 92, 7907-7911. [0508] 55. Lewis, R. S. (1999) Store-operated Calcium Channels. In Advances in Second Messenger and Phosphoprotein Research, eds. Armstrong, A. L., and Rossie, S. (Academic Press, New York, N.Y.), pp. 279-307. [0509] 56. Parekh, A. B., Terlau, H., and Stuhmer, W. (1993) Depletion of InsP3 stores activates a Ca.sup.2+ and K.sup.+ current by means of a phosphatase and a diffusible messenger. Nature 364, 814-818. [0510] 57. Koike, Y., Ozaki, Y., Qi, R., Satoh, L., Kurota, K., Yatomi, Y., and Kume, S. (1994) Phosphatase inhibitors suppress Ca.sup.2+ influx induced by receptor-mediated intracellular Ca.sup.2+ store depletion in human platelets. Cell Calcium 15, 381-390. [0511] 58. Thomas, D., and Hanley, M. R. (1995) Evaluation of calcium influx factors from stimulated Jurkat T-lymphocytes by microinjection into Xenopus oocytes. J. Biol. Chem. 270, 6429-6432. [0512] 59. Hahn, J., Jung, W., Kim, N., Uhm, D. Y., and Chung, S. (2000) Characterization and regulation of rat microglial Ca.sup.2+ release-activated Ca.sup.2+ (CRAC) channel by protein kinases. Glia 31, 118-124.

[0513] This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all aspects illustrate and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

[0514] Various references are cited throughout this Specification, each of which is incorporated herein by reference in its entirety.

Sequence CWU 1

1

451238PRTHomo sapiens 1Gly Glu Trp Leu Asp Asp Glu Val Leu Ile Lys Met Ala Ser Gln Pro1 5 10 15Phe Gly Arg Gly Ala Met Arg Glu Cys Phe Arg Thr Lys Lys Leu Ser 20 25 30Asn Phe Leu His Ala Gln Gln Trp Lys Gly Ala Ser Asn Tyr Val Ala 35 40 45Lys Arg Tyr Ile Glu Pro Val Asn Arg Asp Val Tyr Phe Glu Asp Val 50 55 60Arg Leu Gln Met Glu Ala Lys Leu Trp Gly Asp Asp Tyr Asn Arg His65 70 75 80Lys Pro Pro Lys Gln Val Asp Ile Met Gln Met Cys Ile Ile Glu Leu 85 90 95Lys Asp Arg Pro Gly Lys Pro Leu Phe His Leu Asp His Tyr Ile Asp 100 105 110Gly Lys Tyr Ile Lys Tyr Asn Ser Asn Ser Gly Phe Val Arg Asp Asp 115 120 125Asn Ile Arg Leu Thr Pro Gln Ala Phe Ser His Phe Thr Phe Glu Arg 130 135 140Ser Gly His Gln Leu Ile Val Val Asp Ile Gln Gly Val Gly Asp Leu145 150 155 160Tyr Thr Asp Pro Gln Ile His Thr Glu Thr Gly Thr Asp Phe Gly Asn 165 170 175Gly Asn Leu Gly Val Arg Gly Met Ala Leu Phe Phe Tyr Ser His Ala 180 185 190Cys Asn Arg Ile Cys Glu Ser Met Gly Leu Ala Pro Phe Asp Leu Ser 195 200 205Pro Arg Glu Arg Asp Ala Val Asn Gln Asn Thr Lys Leu Leu Gln Ser 210 215 220Ala Lys Thr Ile Leu Arg Gly Thr Asp Asp Lys Cys Gly Ser225 230 2352233PRTC. elegans 2Leu Gln Trp Thr Glu Asp Ile Val Asp Val Arg Leu His Pro Asp Ser1 5 10 15Phe Ala Arg Gly Ala Met Arg Glu Cys Tyr Arg Leu Lys Lys Cys Ser 20 25 30Lys His Gly Thr Ser Gln Asp Trp Ser Ser Asn Tyr Val Ala Lys Arg 35 40 45Tyr Ile Cys Gln Val Asp Arg Arg Val Leu Phe Asp Asp Val Arg Leu 50 55 60Gln Met Asp Ala Lys Leu Trp Ala Glu Glu Tyr Asn Arg Tyr Asn Pro65 70 75 80Pro Lys Lys Ile Asp Ile Val Gln Met Cys Val Ile Glu Met Ile Asp 85 90 95Val Lys Gly Ser Pro Leu Tyr His Leu Glu His Phe Ile Glu Gly Lys 100 105 110Tyr Ile Lys Tyr Asn Ser Asn Ser Gly Phe Val Ser Asn Ala Ala Arg 115 120 125Leu Thr Pro Gln Ala Phe Ser His Phe Thr Phe Glu Arg Ser Gly His 130 135 140Gln Met Met Val Val Asp Ile Gln Gly Val Gly Asp Leu Tyr Thr Asp145 150 155 160Pro Gln Ile His Thr Val Val Gly Thr Asp Tyr Gly Asp Gly Asn Leu 165 170 175Gly Ile Arg Gly Met Ala Leu Phe Phe His Ser His Arg Cys Asn Asp 180 185 190Ile Cys Glu Thr Met Asp Leu Ser Asn Phe Glu Leu Ser Pro Pro Glu 195 200 205Ile Glu Ala Thr Glu Val Ala Met Glu Val Ala Ala Lys Gln Lys Lys 210 215 220Ser Cys Ile Val Pro Pro Thr Val Phe225 2303259PRTDictyostelium discoideum 3Asn Lys Trp Ile Arg Leu Ser Met Lys Leu Lys Val Glu Arg Lys Pro1 5 10 15Phe Ala Glu Gly Ala Leu Arg Glu Ala Tyr His Thr Val Ser Leu Gly 20 25 30Val Gly Thr Asp Glu Asn Tyr Asp Pro Leu Gly Thr Thr Thr Lys Leu 35 40 45Phe Pro Pro Ile Glu Met Ile Ser Pro Ile Ser Lys Asn Asn Gly Ala 50 55 60Met Thr Gln Leu Lys Asn Gly Thr Lys Phe Val Leu Lys Leu Tyr Lys65 70 75 80Lys Glu Ala Glu Gln Gln Ala Ser Arg Glu Leu Tyr Phe Glu Asp Val 85 90 95Lys Met Gln Met Val Cys Arg Asp Trp Gly Asn Lys Phe Asn Gln Lys 100 105 110Lys Pro Pro Lys Lys Ile Glu Phe Leu Met Ser Trp Val Val Glu Leu 115 120 125Ile Asp Arg Ser Pro Ser Ser Asn Gly Gln Pro Ile Leu Cys Ser Ile 130 135 140Glu Pro Leu Leu Val Gly Glu Phe Lys Lys Asn Asn Ser Asn Tyr Gly145 150 155 160Ala Val Leu Thr Asn Arg Ser Thr Pro Gln Ala Phe Ser His Phe Thr 165 170 175Tyr Gly Leu Ser Asn Lys Gln Met Ile Val Val Asp Ile Gln Gly Val 180 185 190Asp Asp Leu Tyr Thr Asp Pro Gln Ile His Thr Pro Asp Gly Lys Gly 195 200 205Phe Gly Leu Gly Asn Leu Gly Lys Ala Gly Ile Asn Lys Phe Ile Thr 210 215 220Thr His Lys Cys Asn Ala Val Cys Ala Leu Leu Asp Leu Asp Val Lys225 230 235 240Leu Gly Gly Val Leu Ser Gly Asn Asn Lys Lys Gln Leu Gln Gln Gly 245 250 255Thr Met Val4212PRTDictyostelium discoideum 4Ala Gln Trp Thr Cys Thr Ala Thr Leu Val Lys Val Glu Pro Val Pro1 5 10 15Phe Ala Glu Gly Ala Phe Arg Lys Ala Tyr His Thr Leu Asp Leu Ser 20 25 30Lys Ser Gly Ala Ser Gly Arg Tyr Val Ser Lys Ile Gly Lys Lys Pro 35 40 45Thr Pro Arg Pro Ser Tyr Phe Glu Asp Val Lys Met Gln Met Ile Ala 50 55 60Lys Lys Trp Ala Asp Lys Tyr Asn Ser Phe Lys Pro Pro Lys Lys Ile65 70 75 80Glu Phe Leu Gln Ser Cys Val Leu Glu Phe Val Asp Arg Thr Ser Ser 85 90 95Asp Leu Ile Cys Gly Ala Glu Pro Tyr Val Glu Gly Gln Tyr Arg Lys 100 105 110Tyr Asn Asn Asn Ser Gly Phe Val Ser Asn Asp Glu Arg Asn Thr Pro 115 120 125Gln Ser Phe Ser His Phe Thr Tyr Glu His Ser Asn His Gln Leu Leu 130 135 140Ile Ile Asp Ile Gln Gly Val Gly Asp His Tyr Thr Asp Pro Gln Ile145 150 155 160His Thr Tyr Asp Gly Val Gly Phe Gly Ile Gly Asn Leu Gly Gln Lys 165 170 175Gly Phe Glu Lys Phe Leu Asp Thr His Lys Cys Asn Ala Ile Cys Gln 180 185 190Tyr Leu Asn Leu Gln Ser Ile Asn Pro Lys Ser Glu Lys Ser Asp Cys 195 200 205Gly Thr Val Pro 21052178DNAHomo sapiens 5atggcagacg aagacctcat cttccgcctg gaaggtgttg atggcggcca gtccccccga 60gctggccatg atggtgattc tgatggggac agcgacgatg aggaaggtta cttcatctgc 120cccatcacgg atgacccaag ctcgaaccag aatgtcaatt ccaaggttaa taagtactac 180agcaacctaa caaaaagtga gcggtatagc tccagcgggt ccccggcaaa ctccttccac 240ttcaaggaag cctggaagca cgcaatccag aaggccaagc acatgcccga cccctgggct 300gagttccacc tggaagatat tgccaccgaa cgtgctactc gacacaggta caacgccgtc 360accggggaat ggctggatga tgaagttctg atcaagatgg catctcagcc cttcggccga 420ggagcaatga gggagtgctt ccggacgaag aagctctcca acttcttgca tgcccagcag 480tggaagggcg cctccaacta cgtggcgaag cgctacatcg agcccgtaga ccgggatgtg 540tactttgagg acgtgcgtct acagatggag gccaagctct ggggggagga gtataatcgg 600cacaagcccc ccaagcaggt ggacatcatg cagatgtgca tcatcgagct gaaggacaga 660ccgggcaagc ccctcttcca cctggagcac tacatcgagg gcaagtacat caagtacaac 720tccaactctg gctttgtccg tgatgacaac atccgactga cgccgcaggc cttcagccac 780ttcacttttg agcgttccgg ccatcagctg atagtggtgg acatccaggg agttggggat 840ctctacactg acccacagat ccacacggag acgggcactg actttggaga cggcaaccta 900ggtgtccgcg ggatggcgct cttcttctac tctcatgcct gcaaccggat ttgcgagagc 960atgggccttg ctccctttga cctctcgccc cgggagaggg atgcagtgaa tcagaacacc 1020aagctgctgc aatcagccaa gaccatcttg agaggaacag aggaaaaatg tgggagcccc 1080cgagtaagga ccctctctgg gagccggcca cccctgctcc gtcccctttc agagaactct 1140ggagacgaga acatgagcga cgtgaccttc gactctctcc cttcttcccc atcttcggcc 1200acaccacaca gccagaagct agaccacctc cattggccag tgttcagtga cctcgataac 1260atggcatcca gagaccatga tcatctagac aaccaccggg agtctgagaa tagtggggac 1320agcggatacc ccagtgagaa gcggggtgag ctggatgacc ctgagccccg agaacatggc 1380cactcataca gtaatcggaa gtacgagtct gacgaagaca gcctgggcag ctctggacgg 1440gtatgtgtag agaagtggaa tctcctcaac tcctcccgcc tccacctgcc gagggcttcg 1500gccgtggccc tggaagtgca aaggcttaat gctctggacc tcgaaaagaa aatcgggaag 1560tccattttgg ggaaggtcca tctggccatg gtgcgctacc acgagggtgg gcgcttctgc 1620gagaagggcg aggagtggga ccaggagtcg gctgtcttcc acctggagca cgcagccaac 1680ctgggcgagc tggaggccat cgtgggcctg ggactcatgt actcgcagtt gcctcatcac 1740atcctagccg atgtctctct gaaggagaca gaagagaaca aaaccaaagg atttgattac 1800ttactaaagg ccgctgaagc tggcgacagg cagtccatga tcctagtggc gcgagctttt 1860gactctggcc agaacctcag cccggacagg tgccaagact ggctagaggc cctgcactgg 1920tacaacactg ccctggagat gacggactgt gatgagggcg gtgagtacga cggaatgcag 1980gacgagcccc ggtacatgat gctggccagg gaggcagaga tgctgttcac aggaggctac 2040gggctggaga aggacccgca gagatcaggg gacttgtata cccaggcagc agaggcagcg 2100atggaagcca tgaagggccg actggccaac cagtactacc aaaaggctga agaggcctgg 2160gcccagatgg aggaataa 21786724PRTHomo sapiens 6Met Ala Asp Glu Asp Leu Ile Phe Arg Leu Glu Gly Val Asp Gly Gly1 5 10 15Gln Ser Pro Arg Ala Gly His Asp Gly Asp Ser Asp Gly Asp Ser Asp 20 25 30Asp Glu Glu Gly Tyr Phe Ile Cys Pro Ile Thr Asp Asp Pro Ser Ser 35 40 45Asn Gln Asn Val Asn Ser Lys Val Asn Lys Tyr Tyr Ser Asn Leu Thr 50 55 60Lys Ser Glu Arg Tyr Ser Ser Ser Gly Ser Pro Ala Asn Ser Phe His65 70 75 80Phe Lys Glu Ala Asn Lys His Ala Ile Gln Lys Ala Lys His Met Pro 85 90 95Asp Pro Trp Ala Glu Phe His Leu Glu Asp Ile Ala Thr Glu Arg Ala 100 105 110Thr Arg His Arg Tyr Asn Ala Val Thr Gly Glu Trp Leu Asp Asp Glu 115 120 125Val Leu Ile Lys Met Ala Ser Gln Pro Phe Gly Arg Gly Ala Met Arg 130 135 140Glu Cys Phe Arg Thr Lys Lys Leu Ser Asn Phe Leu His Ala Gln Gln145 150 155 160Trp Lys Gly Ala Ser Asn Tyr Val Ala Lys Arg Tyr Ile Glu Pro Val 165 170 175Asp Arg Asp Val Tyr Phe Glu Asp Val Arg Leu Gln Met Glu Ala Lys 180 185 190Leu Trp Gly Glu Glu Tyr Asn Arg His Lys Pro Pro Lys Gln Val Asp 195 200 205Ile Met Gln Met Cys Ile Ile Glu Leu Lys Asp Arg Pro Gly Lys Pro 210 215 220Leu Phe His Leu Glu His Tyr Ile Glu Gly Lys Tyr Ile Lys Tyr Asn225 230 235 240Ser Asn Ser Gly Phe Val Arg Asp Asp Asn Ile Arg Leu Thr Pro Gln 245 250 255Ala Phe Ser His Phe Thr Phe Glu Arg Ser Gly His Gln Leu Ile Val 260 265 270Val Asp Ile Gln Gly Val Gly Asp Leu Tyr Thr Asp Pro Gln Ile His 275 280 285Thr Glu Thr Gly Thr Asp Phe Gly Asp Gly Asn Leu Gly Val Arg Gly 290 295 300Met Ala Leu Phe Phe Tyr Ser His Ala Cys Asn Arg Ile Cys Glu Ser305 310 315 320Met Gly Leu Ala Pro Phe Asp Leu Ser Pro Arg Glu Arg Asp Ala Val 325 330 335Asn Gln Asn Thr Lys Leu Leu Gln Ser Ala Lys Thr Ile Leu Arg Gly 340 345 350Thr Glu Glu Lys Cys Gly Ser Pro Arg Val Arg Thr Leu Ser Gly Ser 355 360 365Arg Pro Pro Leu Leu Arg Pro Leu Ser Glu Asn Ser Gly Asp Gly Asn 370 375 380Met Ser Asp Val Thr Pro Asp Ser Leu Pro Ser Ser Pro Ser Ser Ala385 390 395 400Thr Pro His Ser Gln Lys Leu Asp His Leu His Trp Pro Val Phe Ser 405 410 415Asp Leu Asp Asn Met Ala Ser Arg Asp His Asp His Leu Asp Asn His 420 425 430Arg Glu Ser Glu Asn Ser Gly Asp Ser Gly Tyr Pro Ser Glu Lys Arg 435 440 445Gly Glu Leu Asp Asp Pro Glu Pro Arg Glu His Gly His Ser Tyr Ser 450 455 460Asn Arg Lys Tyr Gly Ser Asp Glu Asp Ser Leu Gly Ser Ser Gly Arg465 470 475 480Val Cys Val Glu Lys Trp Asn Leu Leu Asn Ser Ser Arg Leu His Leu 485 490 495Pro Arg Ala Ser Ala Val Ala Leu Glu Val Gln Arg Leu Asn Ala Leu 500 505 510Asp Leu Glu Lys Lys Ile Gly Lys Ser Ile Leu Gly Asp Val His Leu 515 520 525Ala Met Val Arg Tyr His Glu Gly Gly Arg Phe Cys Glu Lys Gly Glu 530 535 540Glu Trp Asp Gln Glu Ser Ala Val Phe His Leu Glu His Ala Ala Asn545 550 555 560Leu Gly Glu Leu Glu Ala Ile Val Gly Leu Gly Leu Met Tyr Ser Gln 565 570 575Leu Pro His His Ile Leu Ala Asp Val Ser Leu Lys Glu Thr Glu Glu 580 585 590Asn Lys Thr Lys Gly Phe Asp Tyr Leu Leu Lys Ala Ala Glu Ala Gly 595 600 605Asp Arg Gln Ser Met Ile Leu Val Ala Arg Ala Phe Asp Ser Gly Gln 610 615 620Asn Leu Ser Pro Asp Arg Cys Gln Asp Trp Leu Glu Ala Leu His Trp625 630 635 640Tyr Asn Thr Ala Leu Glu Met Thr Asp Cys Asp Glu Gly Gly Glu Tyr 645 650 655Asp Gly Met Gln Asp Glu Arg Tyr Met Met Leu Ala Arg Glu Ala Glu 660 665 670Met Leu Phe Thr Gly Gly Tyr Gly Leu Glu Lys Asp Pro Gln Arg Ser 675 680 685Gly Asp Leu Tyr Thr Gln Ala Ala Glu Ala Ala Met Glu Ala Met Lys 690 695 700Gly Arg Leu Ala Asn Gln Tyr Tyr Gln Lys Ala Glu Glu Ala Trp Ala705 710 715 720Gln Met Glu Glu 72175DNAMus musculus 7atggcagacg aagacctcat cttctgcctg gaaggtgttg acggtggcag gtgctcccga 60gctggccaca atgcggactc tgacacagac agtgacgatg atgagggcta tttcatctgc 120cccatcactg atgaccacat gtccaatcag aatgtcagct ccaaagtcca gagctactat 180agcaacctaa caaaaacaga gtgcggctcc acagggtcac cagccagctc cttccacttc 240aaggaagcct ggaagcatgc gatcgagaaa gccaagcaca tgcctgaccc ctgggctgaa 300ttccatctcg aggacatcgc cacagaacat gctactcggc acaggtacaa cgctgtcacc 360ggggaatggc tgaaagacga ggttctgatc aagatggcgt ctcagccctt cggccgtgga 420gcaatgaggg agtgcttcag gacgaagaaa ctctccaact tcttgcacgc ccagcaatgg 480aagggggcct ccaactacgt ggccaagcgc tacatcgagc cggtggacag gagcgtgtac 540tttgaggatg tgcagctcca gatggaggcg aagctctggg gggaggatta caatcggcac 600aagcccccca agcaggtgga tatcatgcag atgtgcatca ttgagctaaa ggacagacca 660ggccagcccc tcttccactt ggagcactac attgagggca agtacatcaa gtacaattcc 720aactcaggct ttgtccgtga tgacaacatc cgactaaccc cacaggcctt cagccatttc 780acatttgagc gttctggtca tcagctgatt gtagtggaca tccagggtgt gggtgacctt 840tataccgacc cacagatcca cactgagaaa ggcactgact ttggagatgg taaccttggt 900gtccggggaa tggctctctt cttctactct catgcctgca accggatttg tcagagcatg 960ggccttacgc cctttgacct ctccccacgg gaacaggatg cggtgaatca gagcaccagg 1020ctattgcaat cagccaagac catcttgagg gggacagagg agaagtgtgg gagtccccgc 1080ataaggacac tctctagcag ccggccccct ttgctccttc gcctgtcaga gaactccggg 1140gatgagaaca tgagtgacgt gacctttgac tctctgcctt cctccccgtc ttcagctaca 1200ccacacagcc agaaactgga ccacctccat tggccagtgt ttggtgacct cgataacatg 1260ggccctagag accatgaccg tatggacaat caccgggact ctgagaatag tggggacagt 1320gggtatccaa gcgagaagcg aagtgacctg gatgatcctg agccccgaga acacggccac 1380tccaacggca accgaaggca tgaatctgac gaggatagcc tgggcagctc tggacgggtc 1440tgtgtggaga cgtggaacct gctcaatccc tcccgcctgc acctgccgag gccctcggcc 1500gtggccctag aagtgcagag gctaaatgcc ctggaccttg gaaggaaaat cgggaagtct 1560gttttgggga aagtccattt ggccatggtg cgataccacg agggcgggcg cttctgcgag 1620aaggatgagg agtgggatcg agagtcagcc atcttccatc tggagcatgc agctgacctg 1680ggagaactgg aggccatcgt gggcctaggc ctcatgtact ctcagctgcc ccaccacatc 1740ctggctgatg tctctctgaa ggagacagag gagaacaaga caaaaggctt tgattactta 1800ctgaaggcgg cagaagctgg tgacaggcat tccatgattt tagtggcccg agcttttgac 1860actggcctga acctcagccc agacaggtgt caagactggt cggaagcctt gcactggtac 1920aacacagccc tggagacaac agactgcgat gaaggcgggg agtacgatgg gatacaggac 1980gagccccagt acgcactgct ggccagggag gcggagatgc tgctcaccgg gggatttgga 2040ctggacaaga acccccaaag atcaggagat ttgtacaccc aggcagctga ggcagcaatg 2100gaagccatga agggccggct agccaaccag tactacgaga aggcggaaga ggcctgggcc 2160cagatggagg aataa 21758725PRTMus musculus 8Met Ala Asp Glu Asp Leu Ile Phe Cys Leu Glu Gly Val Asp Gly Gly1 5 10 15Arg Cys Ser Arg Ala Gly His Asn Ala Asp Ser Asp Thr Asp Ser Asp 20 25 30Asp Asp Glu Gly Tyr Phe Ile Cys Pro Ile Thr Asp Asp His Met Ser 35 40 45Asn Gln Asn Val Ser Ser Lys Val Gln Ser Tyr Tyr Ser Asn Leu Thr 50 55

60Lys Thr Glu Leu Cys Gly Ser Thr Gly Ser Pro Ala Ser Ser Phe His65 70 75 80Phe Lys Glu Ala Trp Lys His Ala Ile Glu Lys Ala Lys His Met Pro 85 90 95Asp Pro Trp Ala Glu Phe His Leu Glu Asp Ile Ala Thr Glu His Ala 100 105 110Thr Arg His Arg Tyr Asn Ala Val Thr Gly Glu Trp Leu Lys Asp Glu 115 120 125Val Leu Ile Lys Met Ala Ser Gln Pro Phe Gly Arg Gly Ala Met Arg 130 135 140Glu Cys Phe Arg Thr Lys Lys Leu Ser Asn Phe Leu His Ala Gln Gln145 150 155 160Trp Lys Gly Ala Ser Asn Tyr Val Ala Lys Arg Tyr Ile Glu Pro Val 165 170 175Asp Arg Ser Val Tyr Phe Glu Asp Val Gln Leu Gln Met Glu Ala Lys 180 185 190Leu Trp Gly Glu Asp Tyr Asn Arg His Lys Pro Pro Lys Gln Val Asp 195 200 205Ile Met Gln Met Cys Ile Ile Glu Leu Lys Asp Arg Pro Gly Gln Pro 210 215 220Leu Phe His Leu Glu His Tyr Ile Glu Gly Lys Tyr Ile Lys Tyr Asn225 230 235 240Ser Asn Ser Gly Phe Val Arg Asp Asp Asn Ile Arg Leu Thr Pro Gln 245 250 255Ala Phe Ser His Phe Thr Phe Glu Arg Ser Gly His Gln Leu Ile Val 260 265 270Val Asp Ile Gln Gly Val Gly Asp Leu Tyr Thr Asp Pro Gln Ile His 275 280 285Thr Glu Lys Gly Thr Asp Phe Gly Asp Gly Asn Leu Gly Val Arg Gly 290 295 300Met Ala Leu Phe Phe Tyr Ser His Ala Cys Asn Arg Ile Cys Gln Ser305 310 315 320Met Gly Leu Thr Pro Phe Asp Leu Ser Pro Arg Glu Gln Asp Ala Val 325 330 335Asn Gln Ser Thr Arg Leu Leu Gln Ser Ala Lys Thr Ile Leu Arg Gly 340 345 350Thr Glu Glu Lys Cys Gly Ser Pro Arg Ile Arg Thr Leu Ser Ser Ser 355 360 365Arg Pro Pro Leu Leu Leu Arg Leu Ser Glu Asn Ser Gly Asp Glu Asn 370 375 380Met Ser Asp Val Thr Phe Asp Ser Leu Pro Ser Ser Pro Ser Ser Ala385 390 395 400Thr Pro His Ser Gln Lys Leu Asp His Leu His Trp Pro Val Phe Gly 405 410 415Asp Leu Asp Asn Met Gly Pro Arg Asp His Asp Arg Met Asp Asn His 420 425 430Arg Asp Ser Glu Asn Ser Gly Asp Ser Gly Tyr Pro Ser Glu Lys Arg 435 440 445Ser Asp Leu Asp Asp Pro Glu Pro Arg Glu His Gly His Ser Asn Gly 450 455 460Asn Arg Arg His Glu Ser Asp Glu Asp Ser Leu Gly Ser Ser Gly Arg465 470 475 480Val Cys Val Glu Thr Trp Asn Leu Leu Asn Pro Ser Arg Leu His Leu 485 490 495Pro Arg Pro Ser Ala Val Ala Leu Glu Val Gln Arg Leu Asn Ala Leu 500 505 510Asp Leu Gly Arg Lys Ile Gly Lys Ser Val Leu Gly Lys Val His Leu 515 520 525Ala Met Val Arg Tyr His Glu Gly Gly Arg Phe Cys Glu Lys Asp Glu 530 535 540Glu Trp Asp Arg Glu Ser Ala Ile Phe His Leu Glu His Ala Ala Asp545 550 555 560Leu Gly Glu Leu Glu Ala Ile Val Gly Leu Gly Leu Met Tyr Ser Gln 565 570 575Leu Pro His His Ile Leu Ala Asp Val Ser Leu Lys Glu Thr Glu Glu 580 585 590Asn Lys Thr Lys Gly Phe Asp Tyr Leu Leu Lys Ala Ala Glu Ala Gly 595 600 605Asp Arg His Ser Met Ile Leu Val Ala Arg Ala Phe Asp Thr Gly Leu 610 615 620Asn Leu Ser Pro Asp Arg Cys Gln Asp Trp Ser Glu Ala Leu His Trp625 630 635 640Tyr Asn Thr Ala Leu Glu Thr Thr Asp Cys Thr Glu Gly Gly Glu Tyr 645 650 655Asp Gly Ile Gln Asp Glu Pro Gln Tyr Ala Leu Leu Ala Arg Glu Ala 660 665 670Glu Met Leu Leu Thr Gly Gly Phe Gly Leu Asp Lys Asn Pro Gln Arg 675 680 685Ser Gly Asp Leu Tyr Thr Gln Ala Ala Glu Ala Ala Met Glu Ala Met 690 695 700Lys Gly Arg Leu Ala Asn Gln Tyr Tyr Gly Lys Ala Glu Glu Ala Trp705 710 715 720Ala Gln Met Glu Glu 72593465DNADictyostelium discoideum 9atgtttaata taaaaaagag aaaagagagt ataacaggta taccaccaat aaatgttaat 60agtccacaat cagttccatt gagtggaaca ttgcaatcac cattgattac accaaattca 120ccaaattttg tttcacgtca atgtccattc aaaaagtttg gatgtagtag ttttttagtt 180tcaaaggcag agtttgataa tcacttaaag gatgacgcac aatttcattt acaattggca 240gtggagaaat ttgatcatca atttgattta cacacacaat tgatggcaca ttttactgag 300caaatggagg atcaattaga gaaaacaatg aaggtcgtac gtaatcatac agatagttta 360ggcggtaatg ttcaaaccaa attggatgaa ggcattgaaa aatgtatggc ttttgctaaa 420aaggttgaac aacaacaaca acaattggcc aaaagattaa tcactcaaca aattcaagag 480aagaaatcaa cctcttcacc tttagttaaa ggtggtatta gtggtggtgg tggtagtggt 540ggcgatgatt cttttgatgg cgcaaatata tcatcaatgt caactagtaa acaagaatta 600caacaagaat tacaatcatt atcaattaaa atgaaaaaag aattgacaga attatccgat 660gaactatcac aaaaattaga acgttcaaca ggtaatatag atattaaaat aaagagaatc 720gaaggtgaag ttaatgaaaa gattgataaa cgtcaattgg tctctacgat cgatgattca 780attggaaaga aaacagattc catcggttat acattggaga gttcaatcat taaaaaggtt 840gaagagaaag agaaaaagaa atccgaacaa aatcaacttc tctttgattc aaagattgaa 900tccttaaaag ataagattaa aatcattgaa actcaacaat tggatacttc atcagaggtt 960agaaaattga aattagaaag tacaagtagt ggaaatttaa tggcaggtct taatggtacc 1020tctggtagac cttcatcatc ttctcacttt attccatcct ctgtttctgc cgctgctaac 1080aatatcaaca agaatgaaat catggaagag gttaaaaagg tagaagagaa acttcaaaag 1140aaaattcgtg aagagattga taatacaaaa gctgaactct caaaggttga acgttccgtt 1200aaagataatc gtagtgaaat tgaaggtttg gaaaaagatt gtaagaatca attcgataaa 1260caagacaata agatcaaaca agttgaggat gatttgaaaa agagtgattc attacttttg 1320ttaatgcaaa ataacctcaa gaaatataat gaatttgttg atagagaacg tgatcgtgaa 1380agtgaacgtt tgaaacttca agattctatc aaacgtttag aacaaaatca aaagaaaatc 1440gaagctgaaa ttcaagaagg taatgaacaa gttgaacgtg ttttacgtga ggaagcttca 1500atctcaccaa ttagttcagt tccaaaatca ccaatcacaa ccaaacgttc atcgattatt 1560ttaaattcac caccaatgac ttcacaacaa tcatcaccaa agattcaaga tcttctctca 1620agtagtggta gtagtagtgt tagtggtata aatatttcct ctgaaaccgg tgaaatgggt 1680attctttggg aatttgatcc aatcattaac aaatggatta gattatcaat gaagctaaag 1740gtagaaagaa aaccatttgc agagggtgct cttagagagg cttatcatac cgtttcattg 1800ggtgttggaa ccgatgaaaa ttatccatta ggtacaacca ccaaattatt cccaccaatt 1860gaaatgattt caccaatttc aaagaataat gaggcaatga ctcaattgaa gaatggtaca 1920aaatttgttt tgaaactcta caaaaaggaa gctgaacaac aagctagcag agaattatac 1980tttgaagatg ttaaaatgca aatggtctgt agagattggg gtaataaatt caatcaaaag 2040aaaccaccaa agaaaattga attccttatg tcttgggttg tagagttaat cgatagatct 2100ccttcttcca atggtcaacc aatactttgt tccattgaac cattattggt tggtgaattc 2160aaaaagaata attcaaatta tggtgcagtt ttaaccaatc gttcaactcc acaagcattc 2220tctcatttca cctatgaact ctcaaataaa caaatgatcg ttgtcgatat tcaaggtgtt 2280gatgatcttt acactgatcc tcaaattcat acacccgatg gtaaaggatt tggtcttggt 2340aatcttggta aagcaggtat caataaattc atcaccactc acaaatgtaa tgctgtttgt 2400gctcttttag atttagatgt taaattgggt ggtgtactat ctggaaataa taagaaacaa 2460cttcaacaag gtactatggt tatgccagat attctcccag aacttatgcc atctgataac 2520accattaaag tgggtgcaaa acaacttcca aaagctgaat tctcaaagaa agatctcaaa 2580tgtgttagca ccattcaaag tttccgtgaa cgtgttaact cgatcgcatt ctttgataat 2640caaaagttat tatgcgctgg ttatggtgat ggtacctata gagttttcga tgtcaatgac 2700aattggaaat gtttatacac tgtcaatggt catagaaaat caattgaaag tatcgcttgt 2760aatagtaatt acattttcac ttcatcacct gataacacca tcaaagttca tatcattcgt 2820agtggtaaca ccaaatgtat agagacattg gttggtcaca ctggtgaagt taattgtgtc 2880gtggccaatg aaaaatatct tttcagttgt agttatgata aaactatcaa ggtttgggat 2940ttgtcaacct ttaaagaaat taaatcattt gagggtgttc atacaaagta cattaaaaca 3000ttggctttga gtggacgtta tctttttagt ggtggtaacg atcaaatcat ttacgtttgg 3060gatactgaaa cacttagtat gcttttcaat atgcaaggtc atgaagattg ggtactctct 3120cttcattgta ccgctagtta tcttttctca acctcaaaag ataatgtcat caagatttgg 3180gatctctcaa atttcagttg tatcgatact ctaaaaggtc attggaattc tgtctcaagt 3240tgtgtcgtaa aagatcgtta tctatacagt ggttctgaag ataattcaat caaagtttgg 3300gatctcgata cacttgaatg tgtttacacc attccaaaat ctcattcttt gggtgtaaaa 3360tgtttaatgg ttttcaataa tcaaatcatt tctgctgctt tcgatggttc aattaaagtt 3420tgggaatggc aatcgaaata atctttgtaa atttttgtta aaaaa 3465101146PRTDictyostelium discoideum 10Met Phe Asn Ile Lys Lys Arg Lys Glu Ser Ile Thr Gly Ile Pro Pro1 5 10 15Ile Asn Val Asn Ser Pro Gln Ser Val Pro Leu Ser Gly Thr Leu Gln 20 25 30Ser Pro Leu Ile Thr Pro Asn Ser Pro Asn Phe Val Ser Arg Gln Cys 35 40 45Pro Phe Lys Lys Phe Gly Cys Ser Ser Phe Leu Val Ser Lys Ala Glu 50 55 60Phe Asp Asn His Leu Lys Asp Asp Ala Gln Phe His Leu Gln Leu Ala65 70 75 80Val Glu Lys Phe Asp His Gln Phe Asp Leu His Thr Gln Leu Met Ala 85 90 95His Phe Thr Glu Gln Met Glu Asp Gln Leu Glu Lys Thr Met Lys Val 100 105 110Val Arg Asn His Thr Asp Ser Leu Gly Gly Asn Val Gln Thr Lys Leu 115 120 125Asp Glu Gly Ile Glu Lys Cys Met Ala Phe Ala Lys Lys Val Glu Gln 130 135 140Gln Gln Gln Gln Leu Ala Lys Arg Leu Ile Thr Gln Gln Ile Gln Glu145 150 155 160Lys Lys Ser Thr Ser Ser Pro Leu Val Lys Gly Gly Ile Ser Gly Gly 165 170 175Gly Gly Ser Gly Gly Asp Asp Ser Phe Asp Gly Ala Asn Ile Ser Ser 180 185 190Met Ser Thr Ser Lys Gln Glu Leu Gln Gln Glu Leu Gln Ser Leu Ser 195 200 205Ile Lys Met Lys Lys Glu Leu Thr Glu Leu Ser Asp Glu Leu Ser Gln 210 215 220Lys Leu Glu Arg Ser Thr Gly Asn Ile Asp Ile Lys Ile Lys Arg Ile225 230 235 240Glu Gly Glu Val Asn Glu Lys Ile Asp Lys Arg Gln Leu Val Ser Thr 245 250 255Ile Asp Asp Ser Ile Gly Lys Lys Thr Asp Ser Ile Gly Tyr Thr Leu 260 265 270Glu Ser Ser Ile Ile Lys Lys Val Glu Glu Lys Glu Lys Lys Lys Ser 275 280 285Glu Gln Asn Gln Leu Leu Phe Asp Ser Lys Ile Glu Ser Leu Lys Asp 290 295 300Lys Ile Lys Ile Ile Glu Thr Gln Gln Leu Asp Thr Ser Ser Glu Val305 310 315 320Arg Lys Leu Lys Leu Glu Ser Thr Ser Ser Glu Asn Leu Met Ala Gly 325 330 335Leu Asn Gly Thr Ser Gly Arg Pro Ser Ser Ser Ser His Phe Ile Pro 340 345 350Ser Ser Val Ser Ala Ala Ala Asn Asn Ile Asn Lys Asn Glu Ile Met 355 360 365Glu Glu Val Lys Lys Val Glu Glu Lys Leu Gln Lys Lys Ile Arg Glu 370 375 380Glu Ile Asp Asn Thr Lys Ala Glu Leu Ser Lys Val Glu Arg Ser Val385 390 395 400Lys Asp Asn Arg Ser Glu Leu Glu Gly Leu Glu Lys Asp Cys Lys Asn 405 410 415Gln Phe Asp Lys Gln Asp Asn Lys Ile Lys Gln Val Glu Asp Asp Leu 420 425 430Lys Lys Ser Asp Ser Leu Leu Leu Leu Met Gln Asn Asn Leu Lys Lys 435 440 445Tyr Asn Glu Phe Val Asp Arg Glu Arg Asp Arg Glu Ser Glu Arg Leu 450 455 460Lys Leu Gln Asp Ser Ile Lys Arg Leu Glu Gln Asn Gln Lys Lys Ile465 470 475 480Glu Ala Glu Ile Gln Glu Gly Asn Glu Gln Val Glu Arg Val Leu Arg 485 490 495Glu Glu Ala Ser Ile Ser Pro Ile Ser Ser Val Pro Lys Ser Pro Ile 500 505 510Thr Thr Lys Arg Ser Ser Ile Ile Leu Asn Ser Pro Pro Met Thr Ser 515 520 525Gln Gln Ser Ser Pro Lys Ile Gln Asp Leu Leu Ser Ser Ser Gly Ser 530 535 540Ser Ser Val Ser Gly Ile Asn Ile Ser Ser Glu Thr Gly Glu Met Gly545 550 555 560Ile Leu Trp Glu Phe Asp Pro Ile Ile Asn Lys Trp Ile Arg Leu Ser 565 570 575Met Lys Leu Lys Val Glu Arg Lys Pro Phe Ala Glu Gly Ala Leu Arg 580 585 590Glu Ala Tyr His Thr Val Ser Leu Gly Val Gly Thr Asp Glu Asn Tyr 595 600 605Pro Leu Gly Thr Thr Thr Lys Leu Phe Pro Pro Ile Glu Met Ile Ser 610 615 620Pro Ile Ser Lys Asn Asn Glu Ala Met Thr Gln Leu Lys Asn Gly Thr625 630 635 640Lys Phe Val Leu Lys Leu Tyr Lys Lys Glu Ala Glu Gln Gln Ala Ser 645 650 655Arg Glu Leu Tyr Phe Glu Asp Val Lys Met Gln Met Val Cys Arg Asp 660 665 670Trp Gly Asn Lys Phe Asn Gln Lys Lys Pro Pro Lys Lys Ile Glu Phe 675 680 685Leu Met Ser Trp Val Val Glu Leu Ile Asp Arg Ser Pro Ser Ser Asn 690 695 700Gly Gln Pro Ile Leu Cys Ser Ile Glu Pro Leu Leu Val Gly Glu Phe705 710 715 720Lys Lys Asn Asn Ser Asn Tyr Gly Ala Val Leu Thr Asn Arg Ser Thr 725 730 735Pro Gln Ala Phe Ser His Phe Thr Tyr Glu Leu Ser Asn Lys Gln Met 740 745 750Ile Val Val Asp Ile Gln Gly Val Asp Asp Leu Tyr Thr Asp Pro Gln 755 760 765Ile His Thr Pro Asp Gly Lys Gly Phe Gly Leu Gly Asn Leu Gly Lys 770 775 780Ala Gly Ile Asn Lys Phe Ile Thr Thr His Lys Cys Asn Ala Val Cys785 790 795 800Ala Leu Leu Asp Leu Asp Val Lys Leu Gly Gly Val Leu Ser Gly Asn 805 810 815Asn Lys Lys Gln Leu Gln Gln Gly Thr Met Val Met Pro Asp Ile Leu 820 825 830Pro Glu Leu Met Pro Ser Asp Asn Thr Ile Lys Val Gly Ala Lys Gln 835 840 845Leu Pro Lys Ala Glu Phe Ser Lys Lys Asp Leu Lys Cys Val Ser Thr 850 855 860Ile Gln Ser Phe Arg Glu Arg Val Asn Ser Ile Ala Phe Phe Asp Asn865 870 875 880Gln Lys Leu Leu Cys Ala Gly Tyr Gly Asp Gly Thr Tyr Arg Val Phe 885 890 895Asp Val Asn Asp Asn Trp Lys Cys Leu Tyr Thr Val Asn Gly His Arg 900 905 910Lys Ser Ile Glu Ser Ile Ala Cys Asn Ser Asn Tyr Ile Phe Thr Ser 915 920 925Ser Pro Asp Asn Thr Ile Lys Val His Ile Ile Arg Ser Gly Asn Thr 930 935 940Lys Cys Ile Glu Thr Leu Val Gly His Thr Gly Glu Val Asn Cys Val945 950 955 960Val Ala Asn Glu Lys Tyr Leu Phe Ser Cys Ser Tyr Asp Lys Thr Ile 965 970 975Lys Val Trp Asp Leu Ser Thr Phe Lys Glu Ile Lys Ser Phe Glu Gly 980 985 990Val His Thr Lys Tyr Ile Lys Thr Leu Ala Leu Ser Gly Arg Tyr Leu 995 1000 1005Phe Ser Gly Gly Asn Asp Gln Ile Ile Tyr Val Trp Asp Thr Glu 1010 1015 1020Thr Leu Ser Met Leu Phe Asn Met Gln Gly His Glu Asp Trp Val 1025 1030 1035Leu Ser Leu His Cys Thr Ala Ser Tyr Leu Phe Ser Thr Ser Lys 1040 1045 1050Asp Asn Val Ile Lys Ile Trp Asp Leu Ser Asn Phe Ser Cys Ile 1055 1060 1065Asp Thr Leu Lys Gly His Trp Asn Ser Val Ser Ser Cys Val Val 1070 1075 1080Lys Asp Arg Tyr Leu Tyr Ser Gly Ser Glu Asp Asn Ser Ile Lys 1085 1090 1095Val Trp Asp Leu Asp Thr Leu Glu Cys Val Tyr Thr Ile Pro Lys 1100 1105 1110Ser His Ser Leu Gly Val Lys Cys Leu Met Val Phe Asn Asn Gln 1115 1120 1125Ile Ile Ser Ala Ala Phe Asp Gly Ser Ile Lys Val Trp Glu Trp 1130 1135 1140Gln Ser Lys 1145112237DNADictyostelium discoideum 11ataagaagat agaagatgat atttaaagtt tggttttcat atgaagatga ggaagtggaa 60ctatcagaat taacaaatga tacaacagtg tcagcaatta gaaagatctt acatgaaggt 120aaaatattta gatttccata tggtacatct caaacagact tgcaaattgg aaagatgtta 180ccatctggta gtggtggagg tgcaactgca gacagcaaat ttgagaagtt taaagcacgt 240aatacattag cagatattca atataaagtt ggtgatacat tatatgttag agttaaaaaa 300agtaaaccaa caaatgattc attattacca acattaaata tagcattttt agatggatca 360gaacgtgcaa ttaaatggga atatgaccca tatactacaa ctgctcaatg gacctgtaca 420gcaacattag tcaaagttga accagtacca

tttgctgaag gtgcatttag gaaagcttat 480catacattgg atttaagtaa atctggtgca agtggaagat atgtatcaaa gattggtaaa 540aaaccaacac caagaccatc atattttgaa gatgtaaaga tgcaaatgat agcaaagaaa 600tgggcagata aatataattc atttaaacct ccaaaaaaga ttgaattttt acaatcatgc 660gttttagagt ttgtagatag aacatcatca gatttaattt gtggagcaga accatatgta 720gaaggacaat atagaaagta taataataat agtggattcg ttagtaatga tgaaagaaat 780acaccacaat cattctctca tttcacatat gaacattcaa atcatcaatt attgattata 840gatattcaag gtgttggtga tcactataca gacccacaaa ttcataccta tgatggtgtt 900ggttttggta ttggtaattt gggtcaaaaa ggttttgaaa agtttttaga tactcataaa 960tgtaatgcaa tttgccaata tttaaattta caatcaatta atccaaaatc tgaaaaaagt 1020gattgtggta ctgtaccaag accagattta attttccctg atacatctga aagagataat 1080aataataata ataataataa taataataat aataataata ataataataa taatagtaat 1140aataataata ataacaatag tagtatttca aaatcattag ttgaaatttc aagtggtagt 1200aaagaaagaa atgatagaga ttcgccaagt agacaattat ttgtttcaaa tgatggtaat 1260acattaaata caaataaaga gagatcaaaa tcaaaatcaa tagatttaga aaaaccagaa 1320attttaataa ataataagaa aaaagagagt ataaatttgg aaacgataaa attaattgaa 1380actattaaag gatatcatgt tacaagtcat ttatgtattt gtgataattt attatttaca 1440ggatgttcag ataattcaat tagagtgtat gattataaga gtcaaaatat ggaatgtgtt 1500caaaccttga aaggtcatga aggtccagtt gaatcaattt gttataatga tcaatatttg 1560tttagtggtt catcagatca ttcaattaaa gtttgggatt taaagaaatt aagatgtatt 1620tttactttgg agggtcatga taaacctgtc catacggttc tattgaatga taaatatttg 1680tttagtggtt cctctgacaa aactatcaaa gtttgggatt tgaaaacttt ggaatgtaaa 1740tatacccttg aaagtcatgc cagagccgtc aaaacacttt gtatatctgg tcaatattta 1800tttagtggtt caaatgataa aactatcaag gtttgggatt tgaaaacttt tcgttgtaac 1860tacactctaa aaggtcatac taaatgggtc accactatct gtatattagg taccaatctc 1920tacagtggct cctatgataa aactataaga gtttggaatt taaagagttt agaatgttcc 1980gctactttaa gaggccatga tagatgggtt gaacatatgg taatttgtga taaattatta 2040tttactgcta gtgacgataa tacaattaaa atttgggatt tagaaacatt aagatgtaat 2100acaactttgg aaggacataa tgcaaccgtt caatgtttag cagtttggga agataaaaaa 2160tgtgttatta gttgtagtca tgatcaaagt attagagttt ggggttggaa ttaatttaaa 2220ataaaaaaaa aaaacat 223712732PRTDictyostelium discoideum 12Met Ile Phe Lys Val Trp Phe Ser Tyr Glu Asp Glu Glu Val Glu Leu1 5 10 15Ser Glu Leu Thr Asn Asp Thr Thr Val Ser Ala Ile Arg Lys Ile Leu 20 25 30His Glu Gly Lys Ile Phe Arg Phe Pro Tyr Gly Thr Ser Gln Thr Asp 35 40 45Leu Gln Ile Gly Lys Met Leu Pro Ser Gly Ser Gly Gly Gly Ala Thr 50 55 60Ala Asp Ser Lys Phe Glu Lys Phe Lys Ala Arg Asn Thr Leu Ala Asp65 70 75 80Ile Gln Tyr Lys Val Gly Asp Thr Leu Tyr Val Arg Val Lys Lys Ser 85 90 95Lys Pro Thr Asn Asp Ser Leu Leu Pro Thr Leu Asn Ile Ala Phe Leu 100 105 110Asp Gly Ser Glu Arg Ala Ile Lys Trp Glu Tyr Asp Pro Tyr Thr Thr 115 120 125Thr Ala Gln Trp Thr Cys Thr Ala Thr Leu Val Lys Val Glu Pro Val 130 135 140Pro Phe Ala Glu Gln Ala Phe Arg Lys Ala Tyr His Thr Leu Asp Leu145 150 155 160Ser Lys Ser Gly Ala Ser Gly Arg Tyr Val Ser Lys Ile Gly Lys Lys 165 170 175Pro Thr Pro Arg Pro Ser Tyr Phe Glu Asp Val Lys Met Gln Met Ile 180 185 190Ala Lys Lys Trp Ala Asp Lys Tyr Asn Ser Phe Lys Pro Pro Lys Lys 195 200 205Ile Glu Phe Leu Gln Ser Cys Val Leu Glu Phe Val Asp Arg Thr Ser 210 215 220Ser Asp Leu Ile Cys Gly Ala Glu Pro Tyr Val Glu Gly Gln Tyr Arg225 230 235 240Lys Tyr Asn Asn Asn Ser Gly Phe Val Ser Asn Asp Glu Arg Asn Thr 245 250 255Pro Gln Ser Phe Ser His Phe Thr Tyr Glu His Ser Asn His Gln Leu 260 265 270Leu Ile Ile Asp Ile Gln Gly Val Gly Asp His Tyr Thr Asp Pro Gln 275 280 285Ile His Thr Tyr Asp Gly Val Gly Phe Gly Ile Gly Asn Leu Gly Gln 290 295 300Lys Gly Phe Glu Lys Phe Leu Asp Thr His Lys Cys Asn Ala Ile Cys305 310 315 320Gln Tyr Leu Asn Leu Gln Ser Ile Asn Pro Lys Ser Glu Lys Ser Asp 325 330 335Cys Gly Thr Val Pro Arg Pro Asp Leu Ile Phe Pro Asp Thr Ser Glu 340 345 350Arg Asp Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn 355 360 365Asn Asn Asn Asn Asn Ser Asn Asn Asn Asn Asn Asn Asn Ser Ser Ile 370 375 380Ser Lys Ser Leu Val Glu Ile Ser Ser Gly Ser Lys Glu Arg Asn Asp385 390 395 400Arg Asp Ser Pro Ser Arg Gln Leu Phe Val Ser Asn Asp Gly Asn Thr 405 410 415Leu Asn Thr Asn Lys Glu Arg Ser Lys Ser Lys Ser Ile Asp Leu Glu 420 425 430Lys Pro Glu Ile Leu Ile Asn Asn Lys Lys Lys Glu Ser Ile Asn Leu 435 440 445Glu Thr Ile Lys Leu Ile Glu Thr Ile Lys Gly Tyr His Val Thr Ser 450 455 460His Leu Cys Ile Cys Asp Asn Leu Leu Phe Thr Gly Cys Ser Asp Asn465 470 475 480Ser Ile Arg Val Tyr Asp Tyr Lys Ser Gln Asn Met Glu Cys Val Gln 485 490 495Thr Leu Lys Gly His Glu Gly Pro Val Glu Ser Ile Cys Tyr Asn Asp 500 505 510Gln Tyr Leu Phe Ser Gly Ser Ser Asp His Ser Ile Lys Val Trp Asp 515 520 525Leu Lys Lys Leu Arg Cys Ile Phe Thr Leu Glu Gly His Asp Lys Pro 530 535 540Val Thr His Val Leu Leu Asn Asp Lys Tyr Leu Phe Ser Gly Ser Ser545 550 555 560Asp Lys Thr Ile Lys Val Trp Asp Leu Lys Thr Leu Glu Cys Lys Tyr 565 570 575Thr Leu Glu Ser His Ala Arg Ala Val Lys Thr Leu Cys Ile Ser Gly 580 585 590Gln Tyr Leu Phe Ser Gly Ser Asn Asp Lys Ile Thr Lys Val Trp Asp 595 600 605Leu Lys Thr Phe Arg Cys Asn Tyr Thr Leu Lys Gly His Thr Lys Trp 610 615 620Val Thr Thr Ile Cys Ile Leu Gly Thr Asn Leu Tyr Ser Gly Ser Tyr625 630 635 640Asp Lys Thr Ile Arg Val Trp Asn Leu Lys Ser Leu Glu Cys Ser Ala 645 650 655Thr Leu Arg Gly His Asp Arg Trp Val Glu His Met Val Ile Cys Asp 660 665 670Lys Leu Leu Phe Thr Ala Ser Asp Asp Asn Thr Ile Lys Ile Trp Asp 675 680 685Leu Glu Thr Leu Arg Cys Asn Thr Thr Leu Glu Gly His Asn Ala Thr 690 695 700Val Gln Cys Leu Ala Val Trp Glu Asp Lys Lys Cys Val Ile Ser Cys705 710 715 720Ser His Asp Gln Ser Ile Arg Val Trp Gly Trp Asn 725 730132307DNAC. elegans 13atgacgatcg acacaacaaa tgagagcgac aatagtccaa ctaactcacc aggattggag 60gcctcggctc ggacattctc gctcaatgcg tcaaaaatgg ttcggataac cgacgactac 120gcagatgaag tgttcattga acagaatgat gtcgttatcg agaagcctcg tatggatcct 180ctccacgtta gaaaacttat ggagacatgg cgcaaggctg ctcgccgagc aagaacaaac 240tatatagatc catgggatga gttcaacatc cacgagtatc cagtacaacg agctaaacga 300tataggtatt ctgcaatcag aaagcaatgg acagaggata tagtcgatgt gagacttcat 360ccggacagtt ttgcacgtgg agccatgcga gaatgctacc gactcaaaaa gtgctccaag 420cacggaacaa gtcaagattg gagcagcaac tatgtcgcaa aaagatacat ttgtcaagtc 480gatcgtagag ttcttttcga tgatgtcaga cttcagatgg atgccaaatt atgggctgaa 540gaatataatc ggtataatcc accgaagaaa attgatattg ttcaaatgtg tgtcattgag 600atgattgatg taaaaggttc tccactctat catttggagc atttcatcga gggaaaatat 660ataaaataca attcaaactc aggatttgta tcaaatgcag ctcgtcttac accacaagca 720ttttctcact tcaccttcga acgttctggt catcaaatga tggttgtcga tattcaagga 780gttggtgatc tttacacaga tcctcagatt catacagttg tgggaactga ttatggagat 840ggaaacctcg gaactcgtgg aatggctctt ttcttccatt cacacagatg taacgatatt 900tgtgagacaa tggatctatc aaatttcgaa ctttcgccac ctgaaatcga ggctaccgaa 960gttgcgatgg aagtagctgc aaagcagaaa aagtcatgca tagttcctcc aactgtgttc 1020gaagcaagaa gaaatcgaat ttcaagtgaa tgtgtacatg tcgagcatgg tatttcgatg 1080gatcaattga gaaaaaggaa gacgttgaat caatcgtcaa ccgatttgtc agcaaagagt 1140cacaacgaag actgtgtatg tcctgagtgt attccagttg ttgagcaact ctgtgagcct 1200tgctccgaag atgaagagga cgaagaagaa gactatccaa gaagtgaaaa aagtggaaat 1260agtcagaaaa gtcgacgtag tagaatgagc atttcaacga gatcttctgg cgatgaatca 1320gcatctcgtc ctagaaaatg cggatttgta gatttaaact cacttcgtca gagacatgat 1380agcttcagaa gttctgttgg gacatattct atgaatagtt ctagacaaac cagagacact 1440gaaaaggatg aattctggaa ggttcttcga aaacaatcag ttccagcaaa cattctatca 1500cttcaacttc aacaaatggc tgctaacctg gaaaatgatg aagacgtacc acaagtcacc 1560gggcatcagt tctctgtcct cggtcagatt catattgatc tctcacgata tcatgagctc 1620gggcggttcg tagaagttga ttcagaacat aaggaaatgc ttgagggaag tgaaaatgac 1680gctcgtgtac caatcaaata cgacaagcag tctgcaattt tccatttgga tatcgctcgg 1740aagtgtggaa tccttgaggc tgtgctaaca tcggctcata ttgttctcgg attaccacat 1800gaattgttga aagaagtcac cgttgatgat ctgtttccta atgggtttgg agaacaggaa 1860aatggaattc gagctgataa aggacaaaaa ccttgtgacc tagaagagtt cggctccgat 1920ctgatggaaa ttgctgcaga gatgggtgat aagggtgcaa tgctgtacat ggcacacgct 1980tatgaaactg gtcagcatct cggaccgaat cgaagaacgg attataagaa atcgattgat 2040tggtatcaac gcgtcgttgg attccaagaa gaagaagaac ttgactctga ttgtggaaaa 2100acgacattct cctcatttgc tccactgact cgtcacgaga ttctagccaa aatggctgaa 2160atgtacaaag agggaggtta tggcctgaat caagacttcg aacgagcata tggtctattc 2220aatgaagctg ctgaagcagc aatggaagca atgaatggaa agctcgcaaa taaatactat 2280gaaaaagcgg aaatgtgtgg agaatga 230714767PRTC. elegans 14Met Thr Ile Asp Thr Thr Asn Glu Ser Asp Asn Ser Pro Thr Asn Ser1 5 10 15Pro Gly Leu Glu Ala Ser Ala Arg Thr Phe Ser Leu Asn Ala Ser Lys 20 25 30Met Val Arg Ile Thr Asp Asp Tyr Ala Asp Glu Val Phe Ile Glu Gln 35 40 45Asn Asp Val Val Ile Glu Lys Pro Arg Met Asp Pro Leu His Val Arg 50 55 60Lys Leu Met Glu Thr Trp Arg Lys Ala Ala Arg Arg Ala Arg Thr Asn65 70 75 80Tyr Ile Asp Pro Trp Lys Glu Phe Asn Ile His Glu Tyr Pro Val Gln 85 90 95Arg Ala Lys Arg Tyr Arg Tyr Ser Ala Ile Arg Lys Gln Trp Thr Glu 100 105 110Asp Ile Val Asp Val Arg Leu His Pro Asp Ser Phe Ala Arg Gly Ala 115 120 125Met Arg Glu Cys Tyr Arg Leu Lys Lys Cys Ser Lys His Gly Thr Ser 130 135 140Gln Asp Trp Ser Ser Asn Tyr Val Ala Lys Arg Tyr Ile Cys Gln Val145 150 155 160Asp Arg Arg Val Leu Phe Asp Asp Val Arg Leu Gln Met Asp Ala Lys 165 170 175Leu Trp Ala Glu Glu Tyr Asn Arg Tyr Asn Pro Pro Lys Lys Ile Asp 180 185 190Ile Val Gln Met Cys Val Ile Glu Met Ile Asp Val Lys Gly Ser Pro 195 200 205Leu Tyr His Leu Glu His Phe Ile Glu Gly Lys Tyr Ile Lys Tyr Asn 210 215 220Ser Asn Ser Gly Phe Val Ser Asn Ala Ala Arg Leu Thr Pro Gly Ala225 230 235 240Phe Ser His Phe Thr Phe Glu Arg Ser Gly His Gln Met Met Val Val 245 250 255Asp Ile Gln Gly Val Gly Asp Leu Tyr Thr Asp Pro Gln Ile His Thr 260 265 270Val Val Gly Thr Asp Tyr Gly Asp Gly Asn Leu Gly Thr Arg Gly Met 275 280 285Ala Leu Phe Phe His Ser His Arg Cys Asn Asp Ile Cys Glu Thr Met 290 295 300Asp Leu Ser Asn Phe Glu Leu Ser Pro Pro Glu Ile Glu Ala Thr Glu305 310 315 320Val Ala Met Glu Val Ala Ala Lys Gln Lys Lys Ser Cys Ile Val Pro 325 330 335Pro Thr Val Phe Glu Ala Arg Arg Asn Arg Ile Ser Ser Glu Cys Val 340 345 350His Val Glu His Gly Ile Ser Met Asp Gln Leu Arg Lys Arg Lys Thr 355 360 365Leu Asn Gln Ser Ser Thr Asp Leu Ser Ala Lys Ser His Asn Glu Asp 370 375 380Cys Val Cys Pro Glu Cys Ile Pro Val Val Glu Gln Leu Cys Glu Pro385 390 395 400Cys Ser Glu Asp Glu Glu Asp Glu Glu Glu Asp Tyr Pro Arg Ser Glu 405 410 415Lys Ser Gly Asn Ser Gln Lys Ser Arg Arg Ser Arg Met Ser Ile Ser 420 425 430Thr Arg Ser Ser Gly Asp Glu Ser Ala Ser Arg Pro Arg Lys Cys Gly 435 440 445Phe Val Asp Leu Asn Ser Leu Arg Gln Arg His Asp Ser Phe Arg Ser 450 455 460Ser Val Gly Thr Tyr Ser Met Asn Ser Ser Arg Gln Thr Arg Asp Thr465 470 475 480Glu Lys Asp Glu Phe Trp Lys Val Leu Arg Lys Gln Ser Val Pro Ala 485 490 495Asn Ile Leu Ser Leu Gln Leu Gln Gln Met Ala Ala Asn Leu Glu Asn 500 505 510Asp Glu Asp Val Pro Gln Val Thr Gly His Gln Phe Ser Val Leu Gly 515 520 525Gln Ile His Ile Asp Leu Ser Arg Tyr His Glu Leu Gly Arg Phe Val 530 535 540Glu Val Asp Ser Glu His Lys Glu Met Leu Glu Gly Ser Glu Asn Asp545 550 555 560Ala Arg Val Pro Ile Lys Tyr Asp Lys Gln Ser Ala Ile Phe His Leu 565 570 575Asp Ile Ala Arg Lys Cys Gly Ile Leu Glu Ala Val Leu Thr Ser Ala 580 585 590His Ile Val Leu Gly Leu Pro His Glu Leu Leu Lys Glu Val Thr Val 595 600 605Asp Asp Leu Phe Pro Asn Gly Phe Gly Glu Gln Glu Asn Gly Ile Arg 610 615 620Ala Asp Lys Gly Gln Lys Pro Cys Asp Leu Glu Glu Phe Gly Ser Asp625 630 635 640Leu Met Glu Ile Ala Ala Glu Met Gly Asp Lys Gly Ala Met Leu Tyr 645 650 655Met Ala His Ala Tyr Glu Thr Gly Gln His Leu Gly Pro Asn Arg Arg 660 665 670Thr Asp Tyr Lys Lys Ser Ile Asp Trp Tyr Gln Arg Val Val Gly Phe 675 680 685Gln Glu Glu Glu Leu Asp Ser Asp Cys Gly Lys Thr Thr Phe Ser Ser 690 695 700Phe Ala Pro Leu Thr Arg His Glu Ile Leu Ala Lys Met Ala Glu Met705 710 715 720Tyr Lys Glu Gly Gly Tyr Gly Leu Asn Gln Asp Phe Glu Arg Ala Tyr 725 730 735Gly Leu Phe Asn Glu Ala Ala Glu Ala Ala Met Glu Ala Met Asn Gly 740 745 750Lys Leu Ala Asn Lys Tyr Tyr Glu Lys Ala Glu Met Cys Gly Glu 755 760 7651513PRTrabbit 15Leu Thr Pro Gln Ala Phe Ser His Phe Thr Phe Glu Arg1 5 101610PRTrabbitMISC_FEATURE(4)..(4)X can be any amino acid 16Leu Ala Asn Xaa Tyr Tyr Glu Lys Ala Glu1 5 101729DNAUnknownprimer 17cangcnttnn nncanttnac nttnganng 291826DNAUnknownprimer 18tcngcnttnt cntantantt nttngc 261927DNAUnknownprimer 19tacaatcagc tgatgaccag aacgctc 272025DNAUnknownprimer 20ggatttggac tggacaagaa ccccc 25216PRTArtificial sequenceconsensus sequence 21Gly Xaa Gly Xaa Xaa Gly1 5225PRTUnknownconsensus sequence 22Asp Xaa Xaa Xaa Asn1 52330DNAArtificial Sequenceprimer 23tgaccaggta cacagcactt tgactgctct 302430DNAArtificial Sequenceprimer 24gttagtacac catctcagcc aagttgcaaa 302540DNAArtificial Sequenceprimer 25ttataacatc agacgaacag aattagttga ttctgattct 40266405DNAHomo sapiens 26cgggcgcggg cgcgtccctg tggccagtca cccggaggag ttggtcgcac aattatgaaa 60gactcggctt ctgctgctag cgccggagct gagttagttc tgagaaggtt tccctgggcg 120ttccttgtcc ggcggcctct gctgccgcct ccggagacgc ttcccgatag atggctacag 180gccgcggagg aggaggaggt ggagttgctg cccttccgga gtccgccccg tgaggagaat 240gtcccagaaa tcctggatag aaagcacttt gaccaagagg gaatgtgtat atattatacc 300aagttccaag gaccctcaca gatgccttcc aggatgtcaa atttgtcagc aactcgtcag 360gtgtttttgt ggtcgcttgg tcaagcaaca tgcttgtttt actgcaagtc ttgccatgaa 420atactcagat gtgaaattgg gtgaccattt taatcaggca atagaagaat ggtctgtgga 480aaagcataca gaacagagcc caacggatgc ttatggagtc ataaattttc aagggggttc 540tcattcctac agagctaagt atgtgaggct atcatatgac accaaacctg aagtcattct 600gcaacttctg cttaaagaat ggcaaatgga gttacccaaa cttgttatct ctgtacatgg 660gggcatgcag aaatttgagc ttcacccacg aatcaagcag ttgcttggaa aaggtcttat 720taaagctgca gttacaactg gagcctggat tttaactgga

ggagtaaaca caggtgtggc 780aaaacatgtt ggagatgccc tcaaagaaca tgcttccaga tcatctcgaa agatttgcac 840tatcggaata gctccatggg gagtgattga aaacagaaat gatcttgttg ggagagatgt 900ggttgctcct tatcaaacct tattgaaccc cctgagcaaa ttgaatgttt tgaataatct 960gcattcccat ttcatattgg tggatgatgg cactgttgga aagtatgggg cggaagtcag 1020actgagaaga gaacttgaaa aaactattaa tcagcaaaga attcatgcta ggattggcca 1080gggtgtccct gtggtggcac ttatatttga gggtgggcca aatgttatcc tcacagttct 1140tgaatacctt caggaaagcc cccctgttcc agtagttgtg tgtgaaggaa caggcagagc 1200tgcagatctg ctagcgtata ttcataaaca aacagaagaa ggagggaatc ttcctgatgc 1260agcagagccc gatattattt ccactatcaa aaaaacattt aactttggcc agaatgaagc 1320acttcattta tttcaaacac tgatggagtg catgaaaaga aaggagctta tcactgtttt 1380ccatattggg tcagatgaac atcaagatat agatgtagca atacttactg cactgctaaa 1440aggtactaat gcatctgcat ttgaccagct tatccttaca ttggcatggg atagagttga 1500cattgccaaa aatcatgtat ttgtttatgg acagcagtgg ctggttggat ccttggaaca 1560agctatgctt gatgctcttg taatggatag agttgcattt gtaaaacttc ttattgaaaa 1620tggagtaagc atgcataaat tccttaccat tccgagactg gaagaacttt acaacactaa 1680acaaggtcca actaatccaa tgctgtttca tcttgttcga gacgtcaaac agggaaatct 1740tcctccagga tataagatca ctctgattga tataggactt gttattgaat atctcatggg 1800aggaacctac agatgcacct atactaggaa acgttttcga ttaatatata atagtcttgg 1860tggaaataat cggaggtctg gccgaaatac ctccagcagc actcctcagt tgcgaaagag 1920tcatgaatct tttggcaata gggcagataa aaaggaaaaa atgaggcata accatttcat 1980taagacagca cagccctacc gaccaaagat tgatacagtt atggaagaag gaaagaagaa 2040aagaaccaaa gatgaaattg tagacattga tgaatggatt gttattgctt atatttttac 2100ttatgccatt gagaaagtcc gtgagatctt tatgtctgaa gctgggaaag taaaccagaa 2160gattaaagta tggtttagtg attacttcaa catcagtgat acaattgcca taatttcttt 2220cttcattgga tttggactaa gatttggagc aaaatggaac tttgcaaatg catatgataa 2280tcatgttttt gtggctggaa gattaattta ctgtcttaac ataatatttt ggtatgtgcg 2340tttgctagat tttctagctg taaatcaaca ggcaggacct tatgtaatga tgattggaaa 2400aatggtggcc aatatgttct acattgtagt gattatggct cttgtattac ttagttttgg 2460tgttcccaga aaggcaatac tttatcctca tgaagcacca tcttggactc ttgctaaaga 2520tatagttttt cacccatact ggatgatttt tggtgaagtt tatgcatacg aaattgatgt 2580gtgtgcaaat gattctgtta tccctcaaat ctgtggtcct gggacgtggt tgactccatt 2640tcttcaagca gtctacctct ttgtacagta tatcattatg gttaatcttc ttattgcatt 2700tttcaacaat gtgtatttac aagtgaaggc aatttccaat attgtatgga agtaccagcg 2760ttatcatttt attatggctt atcatgagaa accagttctg cctcctccac ttatcattct 2820tagccatata gtttctctgt tttgctgcat atgtaagaga agaaagaaag ataagacttc 2880cgatggacca aaacttttct taacagaaga agatcaaaag aaacttcatg attttgaaga 2940gcagtgtgtt gaaatgtatt tcaatgaaaa agatgacaaa tttcattctg ggagtgaaga 3000gagaattcgt gtcacttttg aaagagtgga acagatgtgc attcagatta aagaagttgg 3060agatcgtgtc aactacataa aaagatcatt acaatcatta gattctcaaa ttggccattt 3120gcaagatctt tcagccctga cggtagatac attaaaaaca ctcactgccc agaaagcgtc 3180ggaagctagc aaagttcata atgaaatcac acgagaactg agcatttcca aacacttggc 3240tcaaaacctt attgatgatg gtcctgtaag accttctgta tggaaaaagc atggtgttgt 3300aaatacactt agctcctctc ttcctcaagg tgatcttgaa agtaataatc cttttcattg 3360taatatttta atgaaagatg acaaagatcc ccagtgtaat atatttggtc aagacttacc 3420tgcagtaccc cagagaaaag aatttaattt tccagaggct ggttcctctt ctggtgcctt 3480attcccaagt gctgtttccc ctccagaact gcgacagaga ctacatgggg tagaactctt 3540aaaaatattt aataaaaatc aaaaattagg cagttcatct actagcatac cacatctgtc 3600atccccacca accaaatttt ttgttagtac accatctcag ccaagttgca aaagccactt 3660ggaaactgga accaaagatc aagaaactgt ttgctctaaa gctacagaag gagataatac 3720agaatttgga gcatttgtag gacacagaga tagcatggat ttacagaggt ttaaagaaac 3780atcaaacaag ataaaaatac tatccaataa caatacttct gaaaacactt tgaaacgagt 3840gagttctctt gctggattta ctgactgtca cagaacttcc attcctgttc attcaaaaca 3900agaaaaaatc agtagaaggc catctaccga agacactcat gaagtagatt ccaaagcagc 3960tttaataccg gtttggttac aagatagacc atcaaacaga gaaatgccat ctgaagaagg 4020aacattaaat ggtctcactt ctccatttaa gccagctatg gatacaaatt actattattc 4080agctgtggaa agaaataact tgatgaggtt atcacagagc attccattta cacctgtgcc 4140tccaagaggg gagcctgtca cagtgtatcg tttggaagag agttcaccca acatactaaa 4200taacagcatg tcttcttggt cacaactagg cctctgtgcc aaaatagagt ttttaagcaa 4260agaggagatg ggaggaggtt tacgaagagc tgtcaaagta cagtgtacct ggtcagaaca 4320tgatatcctc aaatcagggc atctttatat tatcaaatct tttcttccag aggtggttaa 4380tacatggtca agtatttaca aagaagatac agttctgcat ctctgtctga gagaaattca 4440acaacagaga gcagcacaaa agcttacgtt tgcctttaat caaatgaaac ccaaatccat 4500accatattct ccaaggttcc ttgaagtttt cctgctgtat tgccattcag caggacagtg 4560gtttgctgtg gaagaatgta tgactggaga atttagaaaa tacaacaata ataatggaga 4620tgagattatt ccaactaata ctctggaaga gatcatgcta gcctttagcc actggactta 4680cgaatataca agaggggagt tactggtact tgatttgcaa ggtgttggtg aaaatttgac 4740tgacccatct gtgataaaag cagaagaaaa gagatcctgt gatatggttt ttggcccagc 4800aaatctagga gaagatgcaa ttaaaaactt cagagcaaaa catcactgta attcttgctg 4860tagaaagctt aaacttccag atcgtaagag gaatgattat acgcctgata aaattatatt 4920tcctcaggat gagccttcag atttgaatct tcagcctgga aattccacca aagaatcaga 4980atcaactaat tctgttcgtc tgatgttata atattaatat tactgaatca ttggttttgc 5040ctgcacctca cagaaatgtt actgtgtcac ttttccctcg ggaggaaatt gtttggtaat 5100atagaaaggt gtatgcaagt tgaatttgct gactccagca cagttaaaag gtcaatattc 5160ttttgacctg attaatcagt cagaaagtcc ctataggata gagctggcag ctgagaaatt 5220ttaaaggtaa ttgataatta gtatttataa ctttttaaag ggctctttgt atagcagagg 5280atctcatttg actttgtttt gatgagggtg atgctctctc ttatgtggta caataccatt 5340aaccaaaggt aggtgtccat gcagatttta ttggcagctg ttttattgcc attcaactag 5400ggaaatgaag aaatcacgca gccttttggt taaatggcag tcaaaatttt cctcagtgta 5460tttagtgtgt tcagtgatga tatcactggt tcccaactag atgcttgttg gccacgggaa 5520gggaaatgac ttgttctaat tctaggttca cagaggtatg agaagcctga actgaagacc 5580attttcaaga gggacggtat ttatgaatca gggttaggct ccatatttaa agatagagcc 5640agtttttttt tttaaataga acccaaattg tgtaaaaatg ttaattgggt tttttaaaca 5700ttgttttatc aagtcactgt taagtagaag aaagccatgg taaactgata cataacctaa 5760attataaaag cagaaaccta actcactcgt caagggaagt taccttttga ggaaagttaa 5820agtacttttt tccctatctg tatctatagc aacaacccag aacttacaaa cttctccaaa 5880gattttattg attgttatat caaatcagaa tgtaaacatg aactcttgca tatatttaaa 5940attgtgttgg aacatttgaa catgaatgct gtttgtggta cttaagaaat taattcagtt 6000ggattatcat tatgtgatac tggcagattg cagtgcaacc ttatgccaat aaaatgtaat 6060ttaacagccc cagatattgt tgaatattca acaataacaa gaaaagcttt tcatctaagt 6120tttatgcttt aatttttttt cttttttttt ctttttcttt tgtttccttg gtactaattt 6180taatttttat ttggaaggga gcagtataaa gcttatttgt atttagtagt gtatctccat 6240agatacagac aaggcaagag atgataagct gtttaaatag tgtttaatat tgattggggg 6300tggggagaaa gaaaaagtgt attacttaaa gatactatat acgttttgta tatcattaaa 6360tctttaaaag aaatgaaata aatttattgt ttacagataa aaaaa 6405271864PRTHomo sapiens 27Met Ser Gln Lys Ser Trp Ile Glu Ser Thr Leu Thr Lys Arg Glu Cys1 5 10 15Val Tyr Ile Ile Pro Ser Ser Lys Asp Pro His Arg Cys Leu Pro Gly 20 25 30Cys Gln Ile Cys Gln Gln Leu Val Arg Cys Phe Cys Gly Arg Leu Val 35 40 45Lys Gln His Ala Cys Phe Thr Ala Ser Leu Ala Met Lys Tyr Ser Asp 50 55 60Val Lys Leu Gly Asp His Phe Asn Gln Ala Ile Glu Glu Trp Ser Val65 70 75 80Glu Lys His Thr Glu Gln Ser Pro Thr Asp Ala Tyr Gly Val Ile Asn 85 90 95Phe Gln Gly Gly Ser His Ser Tyr Arg Ala Lys Tyr Val Arg Leu Ser 100 105 110Tyr Asp Thr Lys Pro Glu Val Ile Leu Gln Leu Leu Leu Lys Glu Trp 115 120 125Gln Met Glu Leu Pro Lys Leu Val Ile Ser Val His Gly Gly Met Gln 130 135 140Lys Phe Glu Leu His Pro Arg Ile Lys Gln Leu Leu Gly Lys Gly Leu145 150 155 160Ile Lys Ala Ala Val Thr Thr Gly Ala Trp Ile Leu Thr Gly Gly Val 165 170 175Asn Thr Gly Val Ala Lys His Val Gly Asp Ala Leu Lys Glu His Ala 180 185 190Ser Arg Ser Ser Arg Lys Ile Cys Thr Ile Gly Ile Ala Pro Trp Gly 195 200 205Val Ile Glu Asn Arg Asn Asp Leu Val Gly Arg Asp Val Val Ala Pro 210 215 220Tyr Gln Thr Leu Leu Asn Pro Leu Ser Lys Leu Asn Val Leu Asn Asn225 230 235 240Leu His Ser His Phe Ile Leu Val Asp Asp Gly Thr Val Gly Lys Tyr 245 250 255Gly Ala Glu Val Arg Leu Arg Arg Glu Leu Glu Lys Thr Ile Asn Gln 260 265 270Gln Arg Ile His Ala Arg Ile Gly Gln Gly Val Pro Val Val Ala Leu 275 280 285Ile Phe Glu Gly Gly Pro Asn Val Ile Leu Thr Val Leu Glu Tyr Leu 290 295 300Gln Glu Ser Pro Pro Val Pro Val Val Val Cys Glu Gly Thr Gly Arg305 310 315 320Ala Ala Asp Leu Leu Ala Tyr Ile His Lys Gln Thr Glu Glu Gly Gly 325 330 335Asn Leu Pro Asp Ala Ala Glu Pro Asp Ile Ile Ser Thr Ile Lys Lys 340 345 350Thr Phe Asn Phe Gly Gln Asn Glu Ala Leu His Leu Phe Gln Thr Leu 355 360 365Met Glu Cys Met Lys Arg Lys Glu Leu Ile Thr Val Phe His Ile Gly 370 375 380Ser Asp Glu His Gln Asp Ile Asp Val Ala Ile Leu Thr Ala Leu Leu385 390 395 400Lys Gly Thr Asn Ala Ser Ala Phe Asp Gln Leu Ile Leu Thr Leu Ala 405 410 415Trp Asp Arg Val Asp Ile Ala Lys Asn His Val Phe Val Tyr Gly Gln 420 425 430Gln Trp Leu Val Gly Ser Leu Glu Gln Ala Met Leu Asp Ala Leu Val 435 440 445Met Asp Arg Val Ala Phe Val Lys Leu Leu Ile Glu Asn Gly Val Ser 450 455 460Met His Lys Phe Leu Thr Ile Pro Arg Leu Glu Glu Leu Tyr Asn Thr465 470 475 480Lys Gln Gly Pro Thr Asn Pro Met Leu Phe His Leu Val Arg Asp Val 485 490 495Lys Gln Gly Asn Leu Pro Pro Gly Tyr Lys Ile Thr Leu Ile Asp Ile 500 505 510Gly Leu Val Ile Glu Tyr Leu Met Gly Gly Thr Tyr Arg Cys Thr Tyr 515 520 525Thr Arg Lys Arg Phe Arg Leu Ile Tyr Asn Ser Leu Gly Gly Asn Asn 530 535 540Arg Arg Ser Gly Arg Asn Thr Ser Ser Ser Thr Pro Gln Leu Arg Lys545 550 555 560Ser His Glu Ser Phe Gly Asn Arg Ala Asp Lys Lys Glu Lys Met Arg 565 570 575His Asn His Phe Ile Lys Thr Ala Gln Pro Tyr Arg Pro Lys Ile Asp 580 585 590Thr Val Met Glu Glu Gly Lys Lys Lys Arg Thr Lys Asp Glu Ile Val 595 600 605Asp Ile Asp Asp Pro Glu Thr Lys Arg Phe Pro Tyr Pro Leu Asn Glu 610 615 620Leu Leu Ile Trp Ala Cys Leu Met Lys Arg Gln Val Met Ala Arg Phe625 630 635 640Leu Trp Gln His Gly Glu Glu Ser Met Ala Lys Ala Leu Val Ala Cys 645 650 655Lys Ile Tyr Arg Ser Met Ala Tyr Glu Ala Lys Gln Ser Asp Leu Val 660 665 670Asp Asp Thr Ser Glu Glu Leu Lys Gln Tyr Ser Asn Asp Phe Gly Gln 675 680 685Leu Ala Val Glu Leu Leu Glu Gln Ser Phe Arg Gln Asp Glu Thr Met 690 695 700Ala Met Lys Leu Leu Thr Tyr Glu Leu Lys Asn Trp Ser Asn Ser Thr705 710 715 720Cys Leu Lys Leu Ala Val Ala Ala Lys His Arg Asp Phe Ile Ala His 725 730 735Thr Cys Ser Gln Met Leu Leu Thr Asp Met Trp Met Gly Arg Leu Arg 740 745 750Met Arg Lys Asn Pro Gly Leu Lys Val Ile Leu Ser Ile Leu Val Pro 755 760 765Pro Ala Ile Leu Leu Leu Glu Tyr Lys Thr Lys Ala Glu Met Ser His 770 775 780Ile Pro Gln Ser Gln Asp Ala His Gln Met Thr Met Asp Asp Ser Glu785 790 795 800Asn Asn Phe Gln Asn Ile Thr Glu Glu Ile Pro Met Glu Val Phe Lys 805 810 815Glu Val Arg Ile Leu Asp Ser Asn Glu Gly Lys Asn Glu Met Glu Ile 820 825 830Gln Met Lys Ser Lys Lys Leu Pro Ile Thr Arg Lys Phe Tyr Ala Phe 835 840 845Tyr His Ala Pro Ile Val Lys Phe Trp Phe Asn Thr Leu Ala Tyr Leu 850 855 860Gly Phe Leu Met Leu Tyr Thr Phe Val Val Leu Val Gln Met Glu Gln865 870 875 880Leu Pro Ser Val Gln Glu Trp Ile Val Ile Ala Tyr Ile Phe Thr Tyr 885 890 895Ala Ile Glu Lys Val Arg Glu Ile Phe Met Ser Glu Ala Gly Lys Val 900 905 910Asn Gln Lys Ile Lys Val Trp Phe Ser Asp Tyr Phe Asn Ile Ser Asp 915 920 925Thr Ile Ala Ile Ile Ser Phe Phe Ile Gly Phe Gly Leu Arg Phe Gly 930 935 940Ala Lys Trp Asn Phe Ala Asn Ala Tyr Asp Asn His Val Phe Val Ala945 950 955 960Gly Arg Leu Ile Tyr Cys Leu Asn Ile Ile Phe Trp Tyr Val Arg Leu 965 970 975Leu Asp Phe Leu Ala Val Asn Gln Gln Ala Gly Pro Tyr Val Met Met 980 985 990Ile Gly Lys Met Val Ala Asn Met Phe Tyr Ile Val Val Ile Met Ala 995 1000 1005Leu Val Leu Leu Ser Phe Gly Val Pro Arg Lys Ala Ile Leu Tyr 1010 1015 1020Pro His Glu Ala Pro Ser Trp Thr Leu Ala Lys Asp Ile Val Phe 1025 1030 1035His Pro Tyr Trp Met Ile Phe Gly Glu Val Tyr Ala Tyr Glu Ile 1040 1045 1050Asp Val Cys Ala Asn Asp Ser Val Ile Pro Gln Ile Cys Gly Pro 1055 1060 1065Gly Thr Trp Leu Thr Pro Phe Leu Gln Ala Val Tyr Leu Phe Val 1070 1075 1080Gln Tyr Ile Ile Met Val Asn Leu Leu Ile Ala Phe Phe Asn Asn 1085 1090 1095Val Tyr Leu Gln Val Lys Ala Ile Ser Asn Ile Val Trp Lys Tyr 1100 1105 1110Gln Arg Tyr His Phe Ile Met Ala Tyr His Glu Lys Pro Val Leu 1115 1120 1125Pro Pro Pro Leu Ile Ile Leu Ser His Ile Val Ser Leu Phe Cys 1130 1135 1140Cys Ile Cys Lys Arg Arg Lys Lys Asp Lys Thr Ser Asp Gly Pro 1145 1150 1155Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys Lys Leu His Asp Phe 1160 1165 1170Glu Glu Gln Cys Val Glu Met Tyr Phe Asn Glu Lys Asp Asp Lys 1175 1180 1185Phe His Ser Gly Ser Glu Glu Arg Ile Arg Val Thr Phe Glu Arg 1190 1195 1200Val Glu Gln Met Cys Ile Gln Ile Lys Glu Val Gly Asp Arg Val 1205 1210 1215Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser Gln Ile Gly 1220 1225 1230His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu Lys Thr 1235 1240 1245Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn Glu 1250 1255 1260Ile Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu 1265 1270 1275Ile Asp Asp Gly Pro Val Arg Pro Ser Val Trp Lys Lys His Gly 1280 1285 1290Val Val Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu 1295 1300 1305Ser Asn Asn Pro Phe His Cys Asn Ile Leu Met Lys Asp Asp Lys 1310 1315 1320Asp Pro Gln Cys Asn Ile Phe Gly Gln Asp Leu Pro Ala Val Pro 1325 1330 1335Gln Arg Lys Glu Phe Asn Phe Pro Glu Ala Gly Ser Ser Ser Gly 1340 1345 1350Ala Leu Phe Pro Ser Ala Val Ser Pro Pro Glu Leu Arg Gln Arg 1355 1360 1365Leu His Gly Val Glu Leu Leu Lys Ile Phe Asn Lys Asn Gln Lys 1370 1375 1380Leu Gly Ser Ser Ser Thr Ser Ile Pro His Leu Ser Ser Pro Pro 1385 1390 1395Thr Lys Phe Phe Val Ser Thr Pro Ser Gln Pro Ser Cys Lys Ser 1400 1405 1410His Leu Glu Thr Gly Thr Lys Asp Gln Glu Thr Val Cys Ser Lys 1415 1420 1425Ala Thr Glu Gly Asp Asn Thr Glu Phe Gly Ala Phe Val Gly His 1430 1435 1440Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser Asn Lys 1445 1450 1455Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu Lys 1460 1465 1470Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser 1475 1480 1485Ile Pro Val His Ser Lys Gln Glu Lys Ile Ser Arg Arg Pro Ser 1490 1495 1500Thr Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro 1505 1510 1515Val Trp Leu Gln Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu 1520 1525

1530Glu Gly Thr Leu Asn Gly Leu Thr Ser Pro Phe Lys Pro Ala Met 1535 1540 1545Asp Thr Asn Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met 1550 1555 1560Arg Leu Ser Gln Ser Ile Pro Phe Thr Pro Val Pro Pro Arg Gly 1565 1570 1575Glu Pro Val Thr Val Tyr Arg Leu Glu Glu Ser Ser Pro Asn Ile 1580 1585 1590Leu Asn Asn Ser Met Ser Ser Trp Ser Gln Leu Gly Leu Cys Ala 1595 1600 1605Lys Ile Glu Phe Leu Ser Lys Glu Glu Met Gly Gly Gly Leu Arg 1610 1615 1620Arg Ala Val Lys Val Gln Cys Thr Trp Ser Glu His Asp Ile Leu 1625 1630 1635Lys Ser Gly His Leu Tyr Ile Ile Lys Ser Phe Leu Pro Glu Val 1640 1645 1650Val Asn Thr Trp Ser Ser Ile Tyr Lys Glu Asp Thr Val Leu His 1655 1660 1665Leu Cys Leu Arg Glu Ile Gln Gln Gln Arg Ala Ala Gln Lys Leu 1670 1675 1680Thr Phe Ala Phe Asn Gln Met Lys Pro Lys Ser Ile Pro Tyr Ser 1685 1690 1695Pro Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser Ala Gly 1700 1705 1710Gln Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg Lys 1715 1720 1725Tyr Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu 1730 1735 1740Glu Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr 1745 1750 1755Arg Gly Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn 1760 1765 1770Leu Thr Asp Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys 1775 1780 1785Asp Met Val Phe Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys 1790 1795 1800Asn Phe Arg Ala Lys His His Cys Asn Ser Cys Cys Arg Lys Leu 1805 1810 1815Lys Leu Pro Asp Leu Lys Arg Asn Asp Tyr Thr Pro Asp Lys Ile 1820 1825 1830Ile Phe Pro Gln Asp Glu Pro Ser Asp Leu Asn Leu Gln Pro Gly 1835 1840 1845Asn Ser Thr Lys Glu Ser Glu Ser Thr Asn Ser Val Arg Leu Met 1850 1855 1860Leu287090DNAMus musculus 28cgggcgcggg cgcgtccctc tggccagtca cccggcggag ctggtcgcac aattatgaaa 60gactcgactt ctgctgctag cgctggagct gagttagttc tgagaaggtt tcccggggct 120gtccttgttc ggtggcccgt gccaccgcct ccggagacgc tttccgatag gtggctgcag 180gccgcggagg tggaggagga gccgctgccc ttccggagtc cgccccgtga ggagaatgtc 240ccagaaatcc tggatagaga gcactttgac caagagggag tgtgtatata ttataccaag 300ctccaaagac cctcacagat gtcttccagg atgtcagatt tgtcagcaac ttgtcagatg 360tttctgtggt cgtttggtca agcaacatgc atgctttact gcaagtcttg ccatgaaata 420ctcagatgtg agattgggtg aacactttaa ccaggcaata gaagaatggt ctgtggaaaa 480gcacacggag cagagcccaa cagatgctta tggagtcatc aattttcaag ggggttctca 540ttcctacaga gctaagtatg tgagactatc atatgatacc aaacctgaaa tcattctgca 600acttctgctt aaagaatggc aaatggagtt acccaaactt gttatttctg tacatggagg 660catgcagaag tttgaacttc atccaagaat caagcagttg cttggaaagg gtcttattaa 720agctgcagtt acaaccggag cttggatttt aactggagga gtcaatacag gtgtggcaaa 780acatgttggt gatgccctca aagaacatgc ttccagatca tctcgaaaaa tttgcactat 840tggaatagct ccatggggag tgatagaaaa cagaaatgat cttgttggga gagatgtggt 900tgctccttat caaaccctat tgaatccctt gagcaaattg aatgttctga ataatctaca 960ctcccatttc atcttggtgg atgatggcac tgttggaaag tatggggcag aagtcagact 1020gagaagagaa cttgaaaaaa ccattaatca gcaaagaatt catgctagaa ttgggcaagg 1080agttcctgtg gtggctttga tatttgaagg cgggccaaat gtcatcctta cagtactgga 1140gtaccttcag gaaagccccc cagttccagt tgttgtgtgt gaagggacag gcagagctgc 1200agatttacta gcctatatcc acaaacagac agaggaagga ggaaatcttc ctgatgcagc 1260agagcctgat attatatcaa ctatcaagaa aacatttaac tttggccaga gtgaagcagt 1320tcatttattt caaacaatga tggagtgtat gaaaaaaaaa gagcttatca ctgtttttca 1380cattggatca gaggatcatc aagatataga tgtggccata ctcactgcac tgctgaaagg 1440tactaatgca tctgcatttg accagcttat ccttacactg gcatgggaca gagttgatat 1500tgccaaaaat catgtatttg tttatggaca acagtggctg gttggatcct tggaacaggc 1560tatgcttgat gctcttgtaa tggacagagt ttcatttgta aaacttctta ttgaaaacgg 1620agtaagcatg cataaattcc ttaccattcc cagactggaa gaactttata acactaaaca 1680aggtccaacc aatccaatgt tgttccatct cattcgggat gtcaagcagg gtaatctccc 1740cccggggtac aagatcactt taattgatat aggacttgtg attgagtatc tcatgggagg 1800aacctacaga tgcacataca cacgaaaacg ttttcgattg atatataata gtcttggtgg 1860aaataaccgg aggtcaggtc gaaatacctc cagcagcacc cctcagttgc gaaagagtca 1920tgaaactttt ggcaatagag ctgataaaaa ggaaaaaatg agacacaatc atttcattaa 1980aacagcccaa ccctacagac caaagatgga tgcatctatg gaagaaggaa agaagaaaag 2040aaccaaagat gaaattgtag atatagatga tccagagacc aagcgctttc cttatcctct 2100taatgaatta ttaatttggg cttgccttat gaagaggcag gtcatggccc gctttttatg 2160gcagcatggt gaagaatcaa tggctaaagc attagttgcc tgtaaaatct atcgttcaat 2220ggcttatgag gcaaagcaga gtgacctggt agatgatact tcagaggaac tgaagcagta 2280ttccaatgat tttggccaac tggcagttga attactggaa cagtccttca gacaggatga 2340aacgatggct atgaaattac tcacttatga actcaaaaac tggagtaatt caacctgcct 2400caagttagca gtttcttcaa gacttagacc ttttgtagct cacacttgta cacagatgtt 2460gttatctgat atgtggatgg gacggctgaa tatgagaaaa aattcctggt ataaggtcat 2520attaagcatt ttagttccac ctgccatatt aatgctagag tataaaacca aggctgaaat 2580gtcccatatc ccacaatctc aagatgctca tcaaatgacg atggaggata gtgaaaacaa 2640ttttcacaac ataacagaag agatacccat ggaagtattt aaagaagtaa agattttgga 2700cagcagtgat ggaaagaatg aaatggagat acatattaaa tcaaaaaagc ttccaatcac 2760acgaaaattt tatgcctttt atcatgcacc aattgtaaag ttctggttta acacattggc 2820atatttagga tttctgatgc tttatacatt tgtagttctt gtaaaaatgg aacagttacc 2880ttcagttcaa gaatggattg ttatcgctta tatttttacc tatgctattg aaaaagtccg 2940tgaggtcttc atgtctgaag ctgggaaaat cagccagaag attaaagtat ggtttagtga 3000ctacttcaat gtcagtgaca caattgccat catttctttc tttgttggat ttggactaag 3060atttggagca aaatggaact atattaatgc atatgataat catgtttttg tggctggaag 3120attaatttac tgtcttaata taatattttg gtatgtgcgt ttgctagact ttctagccgt 3180aaatcaacag gcaggacctt atgtaatgat gattggaaaa atggtggcca atatgttcta 3240cattgtagtg ataatggctc ttgtattgct tagttttggt gttcccagaa aagcaatact 3300ttatccacat gaagaaccat cttggtctct tgctaaagat atagtttttc atccatactg 3360gatgattttt ggtgaagttt atgcatatga aattgatgtg tgtgcaaatg actccactct 3420cccgacaatc tgtggtcctg gaacttggtt gactccattt cttcaagcag tctacctctt 3480tgtacagtat atcattatgg ttaatctcct tatcgcattt ttcaataatg tatatttaca 3540agtgaaggca atttccaata ttgtatggaa gtatcagcgg tatcatttta ttatggctta 3600tcatgaaaaa ccagtcctgc ctcctcctct tatcatcctc agccatatag tttcactgtt 3660ttgctgtgta tgcaaaagaa gaaagaaaga taagacttcc gatgggccaa aacttttctt 3720aacagaagaa gatcaaaaga aactccatga ttttgaagag cagtgtgttg agatgtactt 3780tgatgagaaa gatgacaaat tcaattctgg gagtgaagag agaatccggg tcacttttga 3840aagagtggag cagatgagca ttcagattaa agaagttgga gatcgtgtca actacataaa 3900aagatcatta cagtctttag attctcaaat tggtcatctg caagatctct cagccctaac 3960agtagataca ttgaaaacac ttacagccca gaaagcttca gaagctagta aagtgcacaa 4020tgagatcaca cgagaattga gtatttccaa acacttggct cagaatctta ttgatgatgt 4080tcctgtaaga cctttgtgga agaaacctag tgctgtaaac acactgagtt cctctcttcc 4140tcaaggtgat cgggaaagta ataatccttt tctttgtaat atttttatga aagatgaaaa 4200agacccccaa tataatctgt ttggacaaga tttgcccgtg ataccccaga gaaaagaatt 4260caacattcca gaggctggtt cctcctgtgg tgccttattc ccaagtgctg tttctccccc 4320agaattacga cagagacgac atggggtaga aatgttaaaa atatttaata aaaatcaaaa 4380attaggcagt tcacctaata gttcaccaca tatgtcctcc ccaccaacca aattttctgt 4440gagtacccca tcccagccaa gttgcaaaag ccacttggaa tccacaacca aagatcaaga 4500acccattttc tataaagctg cagaagggga taacatagaa tttggagcat ttgtgggaca 4560cagagatagt atggacttac agaggtttaa agaaacatca aacaaaataa gagaactgtt 4620atctaatgat actcctgaaa acactctgaa acatgtgggt gctgctggat atagtgaatg 4680ttgtaagact tctacttctc ttcactcagt gcaagcagaa agctgtagta gaagagcgtc 4740gacggaagac tctccagaag tcgattctaa agcagctttg ttaccggatt ggttacgaga 4800tagaccatca aacagagaaa tgccatctga aggaggaaca ttaaatggtc ttgcttctcc 4860atttaagccc gttttggata caaattacta ttattcagct gtggaaagaa ataacctgat 4920gaggttgtca cagagtattc ccttcgttcc tgtacctcca cgaggcgagc ctgtcacagt 4980gtaccgtctg gaggagagtt ctcccagtat actgaataac agcatgtctt catggtctca 5040gctaggcctc tgtgccaaaa ttgagttttt aagtaaagag gaaatgggag gtggtttacg 5100aagagcagtc aaagtgctgt gtacctggtc agagcacgat atcctgaagt cagggcatct 5160ctatatcatt aagtcatttc ttcctgaggt gataaacaca tggtcaagca tttataaaga 5220agatacggtt ctacatctct gtctcagaga aatacaacaa cagagagcag cacaaaagct 5280cacatttgcc tttaatcaga tgaaacccaa atccatacca tattctccaa ggttccttga 5340agttttcctg ttgtactgcc attcagcagg gcagtggttt gctgtagaag agtgcatgac 5400tggtgaattt agaaaataca acaacaataa tggtgatgaa atcattccta caaatactct 5460agaagagatc atgctagcct ttagccactg gacctatgaa tataccagag gggagttact 5520ggtacttgac ttacaaggag tgggagaaaa cttgactgac ccatctgtaa taaaagctga 5580agaaaaaaga tcctgtgaca tggtttttgg ccctgccaat ctaggagaag atgcaataaa 5640aaacttcaga gccaaacatc actgtaattc ttgctgtcga aagcttaaac ttccagattt 5700gaagaggaat gactacacgc ctgataaaat tatatttcct caggatgagt catcagattt 5760gaatcttcaa tctggaaatt ccaccaaaga atcagaagca acaaattctg ttcgtctgat 5820gttatagtgc tgagtcattg gtttttgcct acacttcaca aaagtgtaac tgtcagtttt 5880cctttcgggg gaattgatga tataggaaga tgtgtgcaaa atgagcttgc tggccccaca 5940catagtctag aggtaatgtt ctcattgaaa aacgcctgga ggctgcagat gacagctgga 6000aagtgctagc tggcagagag tcagtgctct cggctggtga agggcgggaa ccttgctgct 6060gagagtggtg gttctctcac ctggtgcagg accattaacc aaagtcaagt cttcagattt 6120gattggctgc tcagtcacag ccattcagct aaggaaacta aattgcgcag ctttttaaat 6180ggctgaagtc ttcctcagtt tgtgctctat gataatgatg ttagctctca actaggtgtt 6240tgtggccacg ggagaactac tccttacaat tttgcttcac aggcatgtta caaagcctgc 6300actgaaaacc gtttgtcttc cctctctccc tccctctttt ccctgtagta ttgaggatca 6360aacccagggc ctcatgaaga ccattttcta agagacattt tatttaagaa tcaactatag 6420agtctatgtt tatggataca gccagttttt gttaaacaaa acctgaattg tgcaaaaggg 6480ttttttaaca tttatcaatg ttaagtaaaa gaaagccatg ataaataaga attaactcac 6540tgttcaatgg gtgtttcctg tgaggaaggt tacagttgta acagcctgca gttgcataca 6600tctccaaaga tttacagact tagtgtatca aatcagagtg tcatgtgagc tctcacattg 6660aaaattctat aggaatgtgt caatgtgaat tctatttctg gtacttaaga aatcagttgt 6720tggattatcc ttatacagta tagggagatc acaatacaac tttatgccaa taaaatctaa 6780cttaattgcc cagatatttt tgcatattta gcaacaagaa aagcttatca tttgactcaa 6840gttttatgct ttctctttct tttcatttcc taggtactaa ttttaatttt tatttggaag 6900gagcagtgta aagcttactt gtattcaata gtgtatctca tagatacaga caaggccgca 6960gagataagct gttaaatagt gtttaatgtt gatgtggaga gaaaggtgta ttacttaaaa 7020atactatacc atatacgttt tgtatatcat taaatcttta aaagaaatta aatttattct 7080tgtttacaaa 7090291863PRTMus musculus 29Met Ser Gln Lys Ser Trp Ile Glu Ser Thr Leu Thr Lys Arg Glu Cys1 5 10 15Val Tyr Ile Ile Pro Ser Ser Lys Asp Pro His Arg Cys Leu Pro Gly 20 25 30Cys Gln Ile Cys Gln Gln Leu Val Arg Cys Phe Cys Gly Arg Leu Val 35 40 45Lys Gln His Ala Cys Phe Thr Ala Ser Leu Ala Met Lys Tyr Ser Asp 50 55 60Val Arg Leu Gly Glu His Phe Asn Gln Ala Ile Glu Glu Trp Ser Val65 70 75 80Glu Lys His Thr Glu Gln Ser Pro Thr Asp Ala Tyr Gly Val Ile Asn 85 90 95Phe Gln Gly Gly Ser His Ser Tyr Arg Ala Lys Tyr Val Arg Leu Ser 100 105 110Tyr Asp Thr Lys Pro Glu Ile Ile Leu Gln Leu Leu Leu Lys Glu Trp 115 120 125Gln Met Glu Leu Pro Lys Leu Val Ile Ser Val His Gly Gly Met Gln 130 135 140Lys Phe Glu Leu His Pro Arg Ile Lys Gln Leu Leu Gly Lys Gly Leu145 150 155 160Ile Lys Ala Ala Val Thr Thr Gly Ala Trp Ile Leu Thr Gly Gly Val 165 170 175Asn Thr Gly Val Ala Lys His Val Gly Asp Ala Leu Lys Glu His Ala 180 185 190Ser Arg Ser Ser Arg Lys Ile Cys Thr Ile Gly Ile Ala Pro Trp Gly 195 200 205Val Ile Glu Asn Arg Asn Asp Leu Val Gly Arg Asp Val Val Ala Pro 210 215 220Tyr Gln Thr Leu Leu Asn Pro Leu Ser Lys Leu Asn Val Leu Asn Asn225 230 235 240Leu His Ser His Phe Ile Leu Val Asp Asp Gly Thr Val Gly Lys Tyr 245 250 255Gly Ala Glu Val Arg Leu Arg Arg Glu Leu Glu Lys Thr Ile Asn Gln 260 265 270Gln Arg Ile His Ala Arg Ile Gly Gln Gly Val Pro Val Val Ala Leu 275 280 285Ile Phe Glu Gly Gly Pro Asn Val Ile Leu Thr Val Leu Glu Tyr Leu 290 295 300Gln Glu Ser Pro Pro Val Pro Val Val Val Cys Glu Gly Thr Gly Arg305 310 315 320Ala Ala Asp Leu Leu Ala Tyr Ile His Lys Gln Thr Glu Glu Gly Gly 325 330 335Asn Leu Pro Asp Ala Ala Glu Pro Asp Ile Ile Ser Thr Ile Lys Lys 340 345 350Thr Phe Asn Phe Gly Gln Ser Glu Ala Val His Leu Phe Gln Thr Met 355 360 365Met Glu Cys Met Lys Lys Lys Glu Leu Ile Thr Val Phe His Ile Gly 370 375 380Ser Glu Asp His Gln Asp Ile Asp Val Ala Ile Leu Thr Ala Leu Leu385 390 395 400Lys Gly Thr Asn Ala Ser Ala Phe Asp Gln Leu Ile Leu Thr Leu Ala 405 410 415Trp Asp Arg Val Asp Ile Ala Lys Asn His Val Phe Val Tyr Gly Gln 420 425 430Gln Trp Leu Val Gly Ser Leu Glu Gln Ala Met Leu Asp Ala Leu Val 435 440 445Met Asp Arg Val Ser Phe Val Lys Leu Leu Ile Glu Asn Gly Val Ser 450 455 460Met His Lys Phe Leu Thr Ile Pro Arg Leu Glu Glu Leu Tyr Asn Thr465 470 475 480Lys Gln Gly Pro Thr Asn Pro Met Leu Phe His Leu Ile Arg Asp Val 485 490 495Lys Gln Gly Asn Leu Pro Pro Gly Tyr Lys Ile Thr Leu Ile Asp Ile 500 505 510Gly Leu Val Ile Glu Tyr Leu Met Gly Gly Thr Tyr Arg Cys Thr Tyr 515 520 525Thr Arg Lys Arg Phe Arg Leu Ile Tyr Asn Ser Leu Gly Gly Asn Asn 530 535 540Arg Arg Ser Gly Arg Asn Thr Ser Ser Ser Thr Pro Gln Leu Arg Lys545 550 555 560Ser His Glu Thr Phe Gly Asn Arg Ala Asp Lys Lys Glu Lys Met Arg 565 570 575His Asn His Phe Ile Lys Thr Ala Gln Pro Tyr Arg Pro Lys Met Asp 580 585 590Ala Ser Met Glu Glu Gly Lys Lys Lys Arg Thr Lys Asp Glu Ile Val 595 600 605Asp Ile Asp Asp Pro Glu Thr Lys Arg Phe Pro Tyr Pro Leu Asn Glu 610 615 620Leu Leu Ile Trp Ala Cys Leu Met Lys Arg Gln Val Met Ala Arg Phe625 630 635 640Leu Trp Gln His Gly Glu Glu Ser Met Ala Lys Ala Leu Val Ala Cys 645 650 655Lys Ile Tyr Arg Ser Met Ala Tyr Glu Ala Lys Gln Ser Asp Leu Val 660 665 670Asp Asp Thr Ser Glu Glu Leu Lys Gln Tyr Ser Asn Asp Phe Gly Gln 675 680 685Leu Ala Val Glu Leu Leu Glu Gln Ser Phe Arg Gln Asp Glu Thr Met 690 695 700Ala Met Lys Leu Leu Thr Tyr Glu Leu Lys Asn Trp Ser Asn Ser Thr705 710 715 720Cys Leu Lys Leu Ala Val Ser Ser Arg Leu Arg Pro Phe Val Ala His 725 730 735Thr Cys Thr Gln Met Leu Leu Ser Asp Met Trp Met Gly Arg Leu Asn 740 745 750Met Arg Lys Asn Ser Trp Tyr Lys Val Ile Leu Ser Ile Leu Val Pro 755 760 765Pro Ala Ile Leu Met Leu Glu Tyr Lys Thr Lys Ala Glu Met Ser His 770 775 780Ile Pro Gln Ser Gln Asp Ala His Gln Met Thr Met Glu Asp Ser Glu785 790 795 800Asn Asn Phe His Asn Ile Thr Glu Glu Ile Pro Met Glu Val Phe Lys 805 810 815Glu Val Lys Ile Leu Asp Ser Ser Asp Gly Lys Asn Glu Met Glu Ile 820 825 830His Ile Lys Ser Lys Lys Leu Pro Ile Thr Arg Lys Phe Tyr Ala Phe 835 840 845Tyr His Ala Pro Ile Val Lys Phe Trp Phe Asn Thr Leu Ala Tyr Leu 850 855 860Gly Phe Leu Met Leu Tyr Thr Phe Val Val Leu Val Lys Met Glu Gln865 870 875 880Leu Pro Ser Val Gln Glu Trp Ile Val Ile Ala Tyr Ile Phe Thr Tyr 885 890 895Ala Ile Glu Lys Val Arg Glu Val Phe Met Ser Glu Ala Gly Lys Ile 900 905 910Ser Gln Lys Ile Lys Val Trp Phe Ser Asp Tyr Phe Asn Val Ser Asp 915 920 925Thr Ile Ala Ile Ile Ser Phe Phe Val Gly Phe Gly Leu Arg Phe Gly 930 935 940Ala Lys Trp Asn Tyr Ile Asn Ala Tyr Asp Asn His Val Phe Val Ala945 950 955

960Gly Arg Leu Ile Tyr Cys Leu Asn Ile Ile Phe Trp Tyr Val Arg Leu 965 970 975Leu Asp Phe Leu Ala Val Asn Gln Gln Ala Gly Pro Tyr Val Met Met 980 985 990Ile Gly Lys Met Val Ala Asn Met Phe Tyr Ile Val Val Ile Met Ala 995 1000 1005Leu Val Leu Leu Ser Phe Gly Val Pro Arg Lys Ala Ile Leu Tyr 1010 1015 1020Pro His Glu Glu Pro Ser Trp Ser Leu Ala Lys Asp Ile Val Phe 1025 1030 1035His Pro Tyr Trp Met Ile Phe Gly Glu Val Tyr Ala Tyr Glu Ile 1040 1045 1050Asp Val Cys Ala Asn Asp Ser Thr Leu Pro Thr Ile Cys Gly Pro 1055 1060 1065Gly Thr Trp Leu Thr Pro Phe Leu Gln Ala Val Tyr Leu Phe Val 1070 1075 1080Gln Tyr Ile Ile Met Val Asn Leu Leu Ile Ala Phe Phe Asn Asn 1085 1090 1095Val Tyr Leu Gln Val Lys Ala Ile Ser Asn Ile Val Trp Lys Tyr 1100 1105 1110Gln Arg Tyr His Phe Ile Met Ala Tyr His Glu Lys Pro Val Leu 1115 1120 1125Pro Pro Pro Leu Ile Ile Leu Ser His Ile Val Ser Leu Phe Cys 1130 1135 1140Cys Val Cys Lys Arg Arg Lys Lys Asp Lys Thr Ser Asp Gly Pro 1145 1150 1155Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys Lys Leu His Asp Phe 1160 1165 1170Glu Glu Gln Cys Val Glu Met Tyr Phe Asp Glu Lys Asp Asp Lys 1175 1180 1185Phe Asn Ser Gly Ser Glu Glu Arg Ile Arg Val Thr Phe Glu Arg 1190 1195 1200Val Glu Gln Met Ser Ile Gln Ile Lys Glu Val Gly Asp Arg Val 1205 1210 1215Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser Gln Ile Gly 1220 1225 1230His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu Lys Thr 1235 1240 1245Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn Glu 1250 1255 1260Ile Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu 1265 1270 1275Ile Asp Asp Val Pro Val Arg Pro Leu Trp Lys Lys Pro Ser Ala 1280 1285 1290Val Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Arg Glu Ser 1295 1300 1305Asn Asn Pro Phe Leu Cys Asn Ile Phe Met Lys Asp Glu Lys Asp 1310 1315 1320Pro Gln Tyr Asn Leu Phe Gly Gln Asp Leu Pro Val Ile Pro Gln 1325 1330 1335Arg Lys Glu Phe Asn Ile Pro Glu Ala Gly Ser Ser Cys Gly Ala 1340 1345 1350Leu Phe Pro Ser Ala Val Ser Pro Pro Glu Leu Arg Gln Arg Arg 1355 1360 1365His Gly Val Glu Met Leu Lys Ile Phe Asn Lys Asn Gln Lys Leu 1370 1375 1380Gly Ser Ser Pro Asn Ser Ser Pro His Met Ser Ser Pro Pro Thr 1385 1390 1395Lys Phe Ser Val Ser Thr Pro Ser Gln Pro Ser Cys Lys Ser His 1400 1405 1410Leu Glu Ser Thr Thr Lys Asp Gln Glu Pro Ile Phe Tyr Lys Ala 1415 1420 1425Ala Glu Gly Asp Asn Ile Glu Phe Gly Ala Phe Val Gly His Arg 1430 1435 1440Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser Asn Lys Ile 1445 1450 1455Arg Glu Leu Leu Ser Asn Asp Thr Pro Glu Asn Thr Leu Lys His 1460 1465 1470Val Gly Ala Ala Gly Tyr Ser Glu Cys Cys Lys Thr Ser Thr Ser 1475 1480 1485Leu His Ser Val Gln Ala Glu Ser Cys Ser Arg Arg Ala Ser Thr 1490 1495 1500Glu Asp Ser Pro Glu Val Asp Ser Lys Ala Ala Leu Leu Pro Asp 1505 1510 1515Trp Leu Arg Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Gly 1520 1525 1530Gly Thr Leu Asn Gly Leu Ala Ser Pro Phe Lys Pro Val Leu Asp 1535 1540 1545Thr Asn Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg 1550 1555 1560Leu Ser Gln Ser Ile Pro Phe Val Pro Val Pro Pro Arg Gly Glu 1565 1570 1575Pro Val Thr Val Tyr Arg Leu Glu Glu Ser Ser Pro Ser Ile Leu 1580 1585 1590Asn Asn Ser Met Ser Ser Trp Ser Gln Leu Gly Leu Cys Ala Lys 1595 1600 1605Ile Glu Phe Leu Ser Lys Glu Glu Met Gly Gly Gly Leu Arg Arg 1610 1615 1620Ala Val Lys Val Leu Cys Thr Trp Ser Glu His Asp Ile Leu Lys 1625 1630 1635Ser Gly His Leu Tyr Ile Ile Lys Ser Phe Leu Pro Glu Val Ile 1640 1645 1650Asn Thr Trp Ser Ser Ile Tyr Lys Glu Asp Thr Val Leu His Leu 1655 1660 1665Cys Leu Arg Glu Ile Gln Gln Gln Arg Ala Ala Gln Lys Leu Thr 1670 1675 1680Phe Ala Phe Asn Gln Met Lys Pro Lys Ser Ile Pro Tyr Ser Pro 1685 1690 1695Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser Ala Gly Gln 1700 1705 1710Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg Lys Tyr 1715 1720 1725Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu Glu 1730 1735 1740Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg 1745 1750 1755Gly Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu 1760 1765 1770Thr Asp Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys Asp 1775 1780 1785Met Val Phe Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys Asn 1790 1795 1800Phe Arg Ala Lys His His Cys Asn Ser Cys Cys Arg Lys Leu Lys 1805 1810 1815Leu Pro Asp Leu Lys Arg Asn Asp Tyr Thr Pro Asp Lys Ile Ile 1820 1825 1830Phe Pro Gln Asp Glu Ser Ser Asp Leu Asn Leu Gln Ser Gly Asn 1835 1840 1845Ser Thr Lys Glu Ser Glu Ala Thr Asn Ser Val Arg Leu Met Leu 1850 1855 1860308158DNAHomo sapiens 30atgtcccaga aatcctggat taaaggagta tttgacaaga gagaatgtag cacaatcata 60cccagctcaa aaaatcctca cagatgtact ccagtatgcc aagtctgcca gaatttaatc 120aggtgttact gtggccgact gattggagac catgctggga tagattattc ctggaccatc 180tcagctgcca agggtaaaga aagtgaacaa tggtctgttg aaaagcacac aacgaaaagc 240ccaacagata cttttggcac gattaatttc caagatggag agcacaccca tcatgccaag 300tatattagaa cttcttatga tacaaaactg gatcatctgt tacatttaat gttgaaagag 360tggaaaatgg aactgcccaa gcttgtgatc tcagtccatg ggggcatcca gaactttact 420atgccctcta aatttaaaga gattttcagc caaggtttgg ttaaagctgc agagacaaca 480ggagcgtgga taataactga aggcatcaat acagtgtcca agcatgttgg ggatgccttg 540aaatcccatt cctctcattc cttgagaaaa atctggacag ttggaatccc tccttggggt 600gtcattgaga accagagaga ccttattgga aaagatgtgg tgtgcctgta ccagactctg 660gataaccccc tcagcaagct cacaacactc aacagcatgc actcgcactt catcctgtct 720gatgatggga ccgtgggcaa gtatggaaat gaaatgaagc tcagaaggaa cctggagaag 780tacctctctc tgcagaaaat acactgccgc tcaagacaag gcgtgccggt cgtggggctg 840gtggtggaag gcggtcccaa cgtcatcctg tcagtgtggg agactgtcaa ggacaaggac 900ccagtggtgg tgtgtgaggg cacaggtagg gcggctgacc tcctggcctt cacacacaaa 960cacctggcag atgaagggat gctgcgacct caggtgaaag aggagatcat ctgcatgatt 1020cagaacactt tcaactttag tcttaaacag tccaagcacc ttttccaaat tctaatggag 1080tgtatggttc acagggattg tattaccata tttgatgctg actctgaaga gcagcaagac 1140ctggacttag caatcctaac agctttgctg aagggcacaa atttatcagc gtcagagcaa 1200ttaaatctgg caatggcttg ggacagggtg gacattgcca agaaacatat cctaatttat 1260gaacaacact ggaagcctga tgccctggaa caagcaatgt cagatgcttt agtgatggat 1320cgggtggatt ttgtgaagct cttaatagaa tatggagtga acctccatcg ctttcttacc 1380atccctcgac tggaagagct ctacaataca aaacaaggac ctactaatac actcttgcat 1440catctcgtcc aagatgtgaa acagcatacc cttctttcag gctaccgaat aaccttgatt 1500gacattggat tagtagtaga atacctcatt ggtagagcat atcgcagcaa ctacactaga 1560aaacatttca gagccctcta caacaacctc tacagaaaat acaagcacca gagacactcc 1620tcaggaaata gaaatgagtc tgcagaaagt acgctgcact cccagttcat tagaactgca 1680cagccataca aattcaagga aaagtctata gtccttcata aatcaaggaa gaagtcaaaa 1740gaacaaaatg tatcagatga ccctgagtct actggctttc tttaccctta caatgacctg 1800ctggtttggg ctgtgctgat gaaaaggcag aagatggcta tgttcttctg gcagcatgga 1860gaggaggcca cggttaaagc cgtgattgcg tgtatcctct accgggcaat ggcccatgaa 1920gctaaggaga gtcacatggt ggatgatgcc tcagaagagt tgaagaatta ctcaaaacag 1980tttggccagc tggctctgga cttgttggag aaggcattca agcagaatga gcgcatggcc 2040atgacgctgt tgacgtatga actcaggaac tggagcaatt cgacctgcct taaactggcc 2100gtgtcgggag gattacgacc ctttgtttca catacttgta cccagatgct actgacagac 2160atgtggatgg ggaggctgaa aatgaggaaa aactcttggt taaagattat tataagcatt 2220attttaccac ccaccatttt gacactggaa tttaaaagca aagctgagat gtcacatgtt 2280ccccagtccc aggacttcca atttatgtgg tattacagtg accagaacgc cagcagttcc 2340aaagaaagtg cttctgtgaa agagtatgat ttggaaaggg gccatgatga gaaactggat 2400gaaaatcagc attttggttt ggaaagtggg caccaacacc ttccgtggac caggaaagtc 2460tatgagttct acagtgctcc aattgtcaag ttttggtttt atacgatggc gtatttggca 2520ttcctcatgc tgttcactta caccgtgttg gtggagatgc agccccagcc cagcgtgcag 2580gagtggcttg ttagcattta catcttcacc aatgctattg aggtggtcag ggaggtgagt 2640atttcagaac ctgggaagtt tacccaaaag gtgaaggtat ggattagtga gtactggaac 2700ttaacagaaa ctgtggccat tggcctgttt tcagctggct tcgtccttcg atggggtgac 2760cctccttttc acacagcggg aagactgatc tactgcatag acatcatatt ctggttctca 2820cggctcctgg acttctttgc tgtgaatcaa catgcaggtc catatgtgac catgattgca 2880aaaatgacag caaacatgtt ctatattgtg atcatcatgg ccatagtcct gctgagcttt 2940ggagtggcac gcaaggccat cctttcgcca aaagagccac catcttggag tctagctcga 3000gatattgtat ttgagccata ctggatgata tacggagaag tctatgctgg agaaatagat 3060gtttgttcaa gccagccatc ctgccctcct ggttcttttc ttactccatt cttgcaagct 3120gtctacctct tcgtgcaata tatcatcatg gtgaacctgt tgattgcttt cttcaacaac 3180gtttacttag atatggaatc catttcaaat aacctgtgga aatacaaccg ctatcgctac 3240atcatgacct accacgagaa gccctggctg cccccacctc tcatcctgct gagccacgtg 3300ggccttctcc tccgccgcct gtgctgtcat cgagctcctc acgaccaaga agagggtgac 3360gttggattaa aactctacct cagtaaggag gatctgaaaa aacttcatga ttttgaggag 3420cagtgcgtgg aaaaatactt ccatgagaag atggaagatg tgaattgtag ttgtgaggaa 3480cgaatccgag tgacatcaga aagggttaca gagatgtact tccagctgaa agaaatgaat 3540gaaaaggtgt cttttataaa ggactcctta ctgtctttgg acagccaggt gggacacctg 3600caggatctct ctgccctgac tgtggatacc ctgaaagtcc tttctgctgt tgacactttg 3660caagaggatg aggctctcct ggccaagaga aagcattcta cttgcaaaaa acttccccac 3720agctggagca atgtcatctg tgcagaggtt ctaggcagca tggagatcgc tggagagaag 3780aaataccagt attatagcat gccctcttct ttgctgagga gcctggctgg aggccggcat 3840cccccaagag tgcagagggg ggcacttctt gagattacaa acagtaaaag agaggctaca 3900aatgtaagaa atgaccagga aaggcaagaa acacaaagta gtatagtggt ttctggggtg 3960tctcctaaca ggcaagcaca ctcaaagtat ggccagtttc ttctggtccc ctctaatcta 4020aagcgagttc ctttttcagc agaaactgtc ttgcctctgt ccagaccctc tgtgccagat 4080gtgctggcaa ctgaacagga catccagact gaggttcttg ttcatctgac tgggcagacc 4140ccagttgtct ctgactgggc atcagtggat gaacccaagg aaaagcacga gcctattgct 4200cacttactgg atggacaaga caaggcagag caagtgctac ccactttgag ttgcacacct 4260gaacccatga caatgagctc ccctctttcc caagccaaga tcatgcaaac tggaggtgga 4320tatgtaaact gggcattttc agaaggtgat gaaactggtg tgtttagcat caagaaaaag 4380tggcaaacct gcttgccctc cacttgtgac agtgattcct ctcggagtga acagcaccag 4440aagcaggccc aggacagctc cctatctgat aactcaacaa gatcggccca gagtagtgaa 4500tgctcagagg tgggaccatg gcttcagcca aacacatcct tttggatcaa tcctctccgc 4560agatacaggc ccttcgctag gagtcatagt tttagattcc ataaggagga gaaattgatg 4620aagatctgta agattaaaaa tctttcaggc tcttcagaaa tagggcaggg agcatgggtc 4680aaagcgaaaa tgctaaccaa agacaggaga ctgtcaaaga aaaagaagaa tactcaagga 4740ctccaggtgc caatcataac agtcaatgcc tgctctcaga gtgaccagtt gaatccagag 4800ccaggagaaa acagcatctc tgaagaggag tacagcaaga actggttcac agtgtccaaa 4860tttagtcaca caggtgtaga accttacata catcagaaaa tgaaaactaa agaaattgga 4920caatgtgcta tacaaatcag tgattaccta aagcagtctc aagaggatct cagcaaaaac 4980tctttgtgga attccaggag caccaacctc aataggaact ccctgctgaa aagttcaatt 5040ggagttgaca agatctcagc ctccttaaaa agccctcaag agcctcacca tcattattca 5100gccattgaaa ggaataattt aatgaggctt tctcagacca taccatttac accagtccaa 5160ctgtttgcag gagaagaaat aactgtctac aggttggagg agagttcccc tttaaacctt 5220gataaaagca tgtcctcttg gtctcagcgt gggagagcgg caatgatcca ggtattgtcc 5280cgagaggaga tggatggggg cctccgtaaa gctatgagag tcgtcagcac ttggtctgag 5340gatgacattc tcaagccggg acaagttttc attgtcaagt cctttcttcc tgaggttgtg 5400cggacatggc ataaaatctt ccaggagagc actgtgcttc atctttgcct cagggaaatt 5460caacaacaaa gagctgctca aaaattgatc tataccttca accaagtgaa accacaaacc 5520ataccctaca caccaaggtt cctggaagtt ttcttaatct actgccattc agccaaccag 5580tggttgacca ttgagaagta tatgacaggg gagttccgga agtataacaa caacaatggt 5640gatgaaatca cccccaccaa caccctggag gagctgatgt tggctttctc tcactggacc 5700tatgagtaca ctcggggaga gctgctggtt ttagatttgc aaggtgttgg agaaaatttg 5760acagatccat ctgttataaa acctgaagtc aaacaatcaa gaggaatggt gtttggaccg 5820gccaatttgg gggaagatgc aattagaaac ttcattgcaa aacatcattg taactcctgc 5880tgccggaagc tcaaactccc ggatttaaaa agaaatgact attcccctga aaggataaat 5940tccacctttg gacttgagat aaaaatagaa tcagctgagg agcctccagc aagggagacg 6000ggtagaaatt ccccagaaga tgatatgcaa ctataaaaag ggaggagcaa gaagatccca 6060gtgcttgccc tgcctgccag gaactctgtg ataacataga ttgatcaacg tgatgttgat 6120tacatcagcg tctccttggg acacgccttc tgagcctcac atctccttct gttcaaaggc 6180ctcattggta tatgatcaat gggttctcct agacactgac ctctgtccag ggcactttgc 6240agctccatcc tcaagttcca cacgaagatg cttggatgag tcagctggga atattgttct 6300tgtgtacctc attgctttag ctggtcactt ggaactttgg agcagaatcc tgcacattaa 6360aggatggggt tgggggggat acatttattt tattttctca ctatgtatgc agactggacc 6420ccctactact atttgtcacc tcacccacag attgtattta tgtctatata tatgttcata 6480aaaagttatg tgatttcctc ctctgtcttt tccacaacat aggactttga atagcaatga 6540taggaaaaac aatggaacaa gggtgggttt gcacagattg gagcacattc ctgcacaaac 6600taccaagtat actggtgaaa tctcgatggg tttcagatat tgtcagtgaa tcatatgatg 6660cctggatatt tcaggtttct gtaaaagaaa gggaaaccta aaacaaatac ccttccatat 6720ataatatata tggaatatgt atattatata tatttttata tatataatat atatggaata 6780tatatattat atatataaaa tacatatgga atatatatat tttatatata tatatatatt 6840tttatttttg agatggagtt tcactctttt tacccaggct ggagtgcaat gatgcgatct 6900cactgcaacc tctgcctccc gggcttgagc gattcttgtg tctcagtctt ccgggtagct 6960gggactacag gtgtgcacca ctatgcctgg ctaattttgt atttttagta gagatggggt 7020ttcaccatgt tggccaggct ggtctcaaac tcctgacctc agatgatcca cctgccttgg 7080cttcccaaag tgctgggatt acaggcgtga gccactgcgc ctggcctttt tttttttttt 7140tttaaacgag aacaagaata tgaagaactg gaaatcatta agaaagggtt tcccttcctt 7200aaagctcagg ggtactatta gttaggagtt gactaactca acctgtaaaa caccactcct 7260ccttccaaag ttgtatatat aatattgcag gttaaattac tttatgtcag gtcctatgaa 7320gaaagatacg gtttcagact gaaaacatgt ttcacaggtg tttgcttcct tccagagcag 7380agttccctat tcccctggca taaagaatgt atatatattt tgaaatatgg ctgagaacat 7440gtcattggtt tgtgaggcct aaggtgaagc actcctggca gccacactgt gtagtgtatt 7500tgagggatca gtcatccctc ttgtatgctg ggcctggttg ccctacctcg aacaagcacc 7560agcttttcac acaaggagag atgtggggct gggagtcctc tccccatcct attgcatctc 7620ctttcttatt ataagctgtt ccagttcaca ggcagcaaac ctcctgggtt tgaaaaattc 7680caacttattt ttatctttaa tcctgacatt agctgacttg ctagtgagct tgctttaaaa 7740atctacactc ttgcattctt aggcatacag gggaaatgtt gaaaaggaag gtggaaaacc 7800aagaatttag tttgccaatg attgcctctg attcttgtaa gtttgagttc cacaagggct 7860aatttattcc ccttttactt gggttttggg gtggtggaaa gcgggaaatt tgggtgattt 7920gttgattggc aatgaggata aaatgttaat acttttttgg ggacttaaca actttatcct 7980attctacaag tcagtaaagg aacaattggt actcacctca gtgctgcact caactatgga 8040aagaggcaga gtttgcttgc ccaattgcca aactaaagac atcagttcat tggtcaaata 8100tttgttacct ggaatggaac ttgaaagcaa atacatttgg atttcaaatt tcaaaaaa 8158312011PRTHomo sapiens 31Met Ser Gln Lys Ser Trp Ile Lys Gly Val Phe Asp Lys Arg Glu Cys1 5 10 15Ser Thr Ile Ile Pro Ser Ser Lys Asn Pro His Arg Cys Thr Pro Val 20 25 30Cys Gln Val Cys Gln Asn Leu Ile Arg Cys Tyr Cys Gly Arg Leu Ile 35 40 45Gly Asp His Ala Gly Ile Asp Tyr Ser Trp Thr Ile Ser Ala Ala Lys 50 55 60Gly Lys Glu Ser Glu Gln Trp Ser Val Glu Lys His Thr Thr Lys Ser65 70 75 80Pro Thr Asp Thr Phe Gly Thr Ile Asn Phe Gln Asp Gly Glu His Thr 85 90 95His His Ala Lys Tyr Ile Arg Thr Ser Tyr Asp Thr Lys Leu Asp His 100 105 110Leu Leu His Leu Met Leu Lys Glu Trp Lys Met Glu Leu Pro Lys Leu 115 120 125Val Ile Ser Val His Gly Gly Ile Gln Asn Phe Thr Met Pro Ser Lys 130 135 140Phe Lys Glu Ile Phe Ser Gln Gly Leu Val Lys Ala Ala Glu Thr Thr145 150 155 160Gly Ala Trp Ile Ile Thr Glu Gly Ile Asn Thr Val Ser Lys His Val 165 170 175Gly Asp Ala Leu Lys Ser His Ser Ser His Ser Leu Arg Lys Ile Trp 180 185 190Thr Val Gly Ile Pro Pro Trp Gly Val Ile Glu Asn Gln Arg Asp Leu 195 200 205Ile Gly

Lys Asp Val Val Cys Leu Tyr Gln Thr Leu Asp Asn Pro Leu 210 215 220Ser Lys Leu Thr Thr Leu Asn Ser Met His Ser His Phe Ile Leu Ser225 230 235 240Asp Asp Gly Thr Val Gly Lys Tyr Gly Asn Glu Met Lys Leu Arg Arg 245 250 255Asn Leu Glu Lys Tyr Leu Ser Leu Gln Lys Ile His Cys Arg Ser Arg 260 265 270Gln Gly Val Pro Val Val Gly Leu Val Val Glu Gly Gly Pro Asn Val 275 280 285Ile Leu Ser Val Trp Glu Thr Val Lys Asp Lys Asp Pro Val Val Val 290 295 300Cys Glu Gly Thr Gly Arg Ala Ala Asp Leu Leu Ala Phe Thr His Lys305 310 315 320His Leu Ala Asp Glu Gly Met Leu Arg Pro Gln Val Lys Glu Glu Ile 325 330 335Ile Cys Met Ile Gln Asn Thr Phe Asn Phe Ser Leu Lys Gln Ser Lys 340 345 350His Leu Phe Gln Ile Leu Met Glu Cys Met Val His Arg Asp Cys Ile 355 360 365Thr Ile Phe Asp Ala Asp Ser Glu Glu Gln Gln Asp Leu Asp Leu Ala 370 375 380Ile Leu Thr Ala Leu Leu Lys Gly Thr Asn Leu Ser Ala Ser Glu Gln385 390 395 400Leu Asn Leu Ala Met Ala Trp Asp Arg Val Asp Ile Ala Lys Lys His 405 410 415Ile Leu Ile Tyr Glu Gln His Trp Lys Pro Asp Ala Leu Glu Gln Ala 420 425 430Met Ser Asp Ala Leu Val Met Asp Arg Val Asp Phe Val Lys Leu Leu 435 440 445Ile Glu Tyr Gly Val Asn Leu His Arg Phe Leu Thr Ile Pro Arg Leu 450 455 460Glu Glu Leu Tyr Asn Thr Lys Gln Gly Pro Thr Asn Thr Leu Leu His465 470 475 480His Leu Val Gln Asp Val Lys Gln His Thr Leu Leu Ser Gly Tyr Arg 485 490 495Ile Thr Leu Ile Asp Ile Gly Leu Val Val Glu Tyr Leu Ile Gly Arg 500 505 510Ala Tyr Arg Ser Asn Tyr Thr Arg Lys His Phe Arg Ala Leu Tyr Asn 515 520 525Asn Leu Tyr Arg Lys Tyr Lys His Gln Arg His Ser Ser Gly Asn Arg 530 535 540Asn Glu Ser Ala Glu Ser Thr Leu His Ser Gln Phe Ile Arg Thr Ala545 550 555 560Gln Pro Tyr Lys Phe Lys Glu Lys Ser Ile Val Leu His Lys Ser Arg 565 570 575Lys Lys Ser Lys Glu Gln Asn Val Ser Asp Asp Pro Glu Ser Thr Gly 580 585 590Phe Leu Tyr Pro Tyr Asn Asp Leu Leu Val Trp Ala Val Leu Met Lys 595 600 605Arg Gln Lys Met Ala Met Phe Phe Trp Gln His Gly Glu Glu Ala Thr 610 615 620Val Lys Ala Val Ile Ala Cys Ile Leu Tyr Arg Ala Met Ala His Glu625 630 635 640Ala Lys Glu Ser His Met Val Asp Asp Ala Ser Glu Glu Leu Lys Asn 645 650 655Tyr Ser Lys Gln Phe Gly Gln Leu Ala Leu Asp Leu Leu Glu Lys Ala 660 665 670Phe Lys Gln Asn Glu Arg Met Ala Met Thr Leu Leu Thr Tyr Glu Leu 675 680 685Arg Asn Trp Ser Asn Ser Thr Cys Leu Lys Leu Ala Val Ser Gly Gly 690 695 700Leu Arg Pro Phe Val Ser His Thr Cys Thr Gln Met Leu Leu Thr Asp705 710 715 720Met Trp Met Gly Arg Leu Lys Met Arg Lys Asn Ser Trp Leu Lys Ile 725 730 735Ile Ile Ser Ile Ile Leu Pro Pro Thr Ile Leu Thr Leu Glu Phe Lys 740 745 750Ser Lys Ala Glu Met Ser His Val Pro Gln Ser Gln Asp Phe Gln Phe 755 760 765Met Trp Tyr Tyr Ser Asp Gln Asn Ala Ser Ser Ser Lys Glu Ser Ala 770 775 780Ser Val Lys Glu Tyr Asp Leu Glu Arg Gly His Asp Glu Lys Leu Asp785 790 795 800Glu Asn Gln His Phe Gly Leu Glu Ser Gly His Gln His Leu Pro Trp 805 810 815Thr Arg Lys Val Tyr Glu Phe Tyr Ser Ala Pro Ile Val Lys Phe Trp 820 825 830Phe Tyr Thr Met Ala Tyr Leu Ala Phe Leu Met Leu Phe Thr Tyr Thr 835 840 845Val Leu Val Glu Met Gln Pro Gln Pro Ser Val Gln Glu Trp Leu Val 850 855 860Ser Ile Tyr Ile Phe Thr Asn Ala Ile Glu Val Val Arg Glu Val Ser865 870 875 880Ile Ser Glu Pro Gly Lys Phe Thr Gln Lys Val Lys Val Trp Ile Ser 885 890 895Glu Tyr Trp Asn Leu Thr Glu Thr Val Ala Ile Gly Leu Phe Ser Ala 900 905 910Gly Phe Val Leu Arg Trp Gly Asp Pro Pro Phe His Thr Ala Gly Arg 915 920 925Leu Ile Tyr Cys Ile Asp Ile Ile Phe Trp Phe Ser Arg Leu Leu Asp 930 935 940Phe Phe Ala Val Asn Gln His Ala Gly Pro Tyr Val Thr Met Ile Ala945 950 955 960Lys Met Thr Ala Asn Met Phe Tyr Ile Val Ile Ile Met Ala Ile Val 965 970 975Leu Leu Ser Phe Gly Val Ala Arg Lys Ala Ile Leu Ser Pro Lys Glu 980 985 990Pro Pro Ser Trp Ser Leu Ala Arg Asp Ile Val Phe Glu Pro Tyr Trp 995 1000 1005Met Ile Tyr Gly Glu Val Tyr Ala Gly Glu Ile Asp Val Cys Ser 1010 1015 1020Ser Gln Pro Ser Cys Pro Pro Gly Ser Phe Leu Thr Pro Phe Leu 1025 1030 1035Gln Ala Val Tyr Leu Phe Val Gln Tyr Ile Ile Met Val Asn Leu 1040 1045 1050Leu Ile Ala Phe Phe Asn Asn Val Tyr Leu Asp Met Glu Ser Ile 1055 1060 1065Ser Asn Asn Leu Trp Lys Tyr Asn Arg Tyr Arg Tyr Ile Met Thr 1070 1075 1080Tyr His Glu Lys Pro Trp Leu Pro Pro Pro Leu Ile Leu Leu Ser 1085 1090 1095His Val Gly Leu Leu Leu Arg Arg Leu Cys Cys His Arg Ala Pro 1100 1105 1110His Asp Gln Glu Glu Gly Asp Val Gly Leu Lys Leu Tyr Leu Ser 1115 1120 1125Lys Glu Asp Leu Lys Lys Leu His Asp Phe Glu Glu Gln Cys Val 1130 1135 1140Glu Lys Tyr Phe His Glu Lys Met Glu Asp Val Asn Cys Ser Cys 1145 1150 1155Glu Glu Arg Ile Arg Val Thr Ser Glu Arg Val Thr Glu Met Tyr 1160 1165 1170Phe Gln Leu Lys Glu Met Asn Glu Lys Val Ser Phe Ile Lys Asp 1175 1180 1185Ser Leu Leu Ser Leu Asp Ser Gln Val Gly His Leu Gln Asp Leu 1190 1195 1200Ser Ala Leu Thr Val Asp Thr Leu Lys Val Leu Ser Ala Val Asp 1205 1210 1215Thr Leu Gln Glu Asp Glu Ala Leu Leu Ala Lys Arg Lys His Ser 1220 1225 1230Thr Cys Lys Lys Leu Pro His Ser Trp Ser Asn Val Ile Cys Ala 1235 1240 1245Glu Val Leu Gly Ser Met Glu Ile Ala Gly Glu Lys Lys Tyr Gln 1250 1255 1260Tyr Tyr Ser Met Pro Ser Ser Leu Leu Arg Ser Leu Ala Gly Gly 1265 1270 1275Arg His Pro Pro Arg Val Gln Arg Gly Ala Leu Leu Glu Ile Thr 1280 1285 1290Asn Ser Lys Arg Glu Ala Thr Asn Val Arg Asn Asp Gln Glu Arg 1295 1300 1305Gln Glu Thr Gln Ser Ser Ile Val Val Ser Gly Val Ser Pro Asn 1310 1315 1320Arg Gln Ala His Ser Lys Tyr Gly Gln Phe Leu Leu Val Pro Ser 1325 1330 1335Asn Leu Lys Arg Val Pro Phe Ser Ala Glu Thr Val Leu Pro Leu 1340 1345 1350Ser Arg Pro Ser Val Pro Asp Val Leu Ala Thr Glu Gln Asp Ile 1355 1360 1365Gln Thr Glu Val Leu Val His Leu Thr Gly Gln Thr Pro Val Val 1370 1375 1380Ser Asp Trp Ala Ser Val Asp Glu Pro Lys Glu Lys His Glu Pro 1385 1390 1395Ile Ala His Leu Leu Asp Gly Gln Asp Lys Ala Glu Gln Val Leu 1400 1405 1410Pro Thr Leu Ser Cys Thr Pro Glu Pro Met Thr Met Ser Ser Pro 1415 1420 1425Leu Ser Gln Ala Lys Ile Met Gln Thr Gly Gly Gly Tyr Val Asn 1430 1435 1440Trp Ala Phe Ser Glu Gly Asp Glu Thr Gly Val Phe Ser Ile Lys 1445 1450 1455Lys Lys Trp Gln Thr Cys Leu Pro Ser Thr Cys Asp Ser Asp Ser 1460 1465 1470Ser Arg Ser Glu Gln His Gln Lys Gln Ala Gln Asp Ser Ser Leu 1475 1480 1485Ser Asp Asn Ser Thr Arg Ser Ala Gln Ser Ser Glu Cys Ser Glu 1490 1495 1500Val Gly Pro Trp Leu Gln Pro Asn Thr Ser Phe Trp Ile Asn Pro 1505 1510 1515Leu Arg Arg Tyr Arg Pro Phe Ala Arg Ser His Ser Phe Arg Phe 1520 1525 1530His Lys Glu Glu Lys Leu Met Lys Ile Cys Lys Ile Lys Asn Leu 1535 1540 1545Ser Gly Ser Ser Glu Ile Gly Gln Gly Ala Trp Val Lys Ala Lys 1550 1555 1560Met Leu Thr Lys Asp Arg Arg Leu Ser Lys Lys Lys Lys Asn Thr 1565 1570 1575Gln Gly Leu Gln Val Pro Ile Ile Thr Val Asn Ala Cys Ser Gln 1580 1585 1590Ser Asp Gln Leu Asn Pro Glu Pro Gly Glu Asn Ser Ile Ser Glu 1595 1600 1605Glu Glu Tyr Ser Lys Asn Trp Phe Thr Val Ser Lys Phe Ser His 1610 1615 1620Thr Gly Val Glu Pro Tyr Ile His Gln Lys Met Lys Thr Lys Glu 1625 1630 1635Ile Gly Gln Cys Ala Ile Gln Ile Ser Asp Tyr Leu Lys Gln Ser 1640 1645 1650Gln Glu Asp Leu Ser Lys Asn Ser Leu Trp Asn Ser Arg Ser Thr 1655 1660 1665Asn Leu Asn Arg Asn Ser Leu Leu Lys Ser Ser Ile Gly Val Asp 1670 1675 1680Lys Ile Ser Ala Ser Leu Lys Ser Pro Gln Glu Pro His His His 1685 1690 1695Tyr Ser Ala Ile Glu Arg Asn Asn Leu Met Arg Leu Ser Gln Thr 1700 1705 1710Ile Pro Phe Thr Pro Val Gln Leu Phe Ala Gly Glu Glu Ile Thr 1715 1720 1725Val Tyr Arg Leu Glu Glu Ser Ser Pro Leu Asn Leu Asp Lys Ser 1730 1735 1740Met Ser Ser Trp Ser Gln Arg Gly Arg Ala Ala Met Ile Gln Val 1745 1750 1755Leu Ser Arg Glu Glu Met Asp Gly Gly Leu Arg Lys Ala Met Arg 1760 1765 1770Val Val Ser Thr Trp Ser Glu Asp Asp Ile Leu Lys Pro Gly Gln 1775 1780 1785Val Phe Ile Val Lys Ser Phe Leu Pro Glu Val Val Arg Thr Trp 1790 1795 1800His Lys Ile Phe Gln Glu Ser Thr Val Leu His Leu Cys Leu Arg 1805 1810 1815Glu Ile Gln Gln Gln Arg Ala Ala Gln Lys Leu Ile Tyr Thr Phe 1820 1825 1830Asn Gln Val Lys Pro Gln Thr Ile Pro Tyr Thr Pro Arg Phe Leu 1835 1840 1845Glu Val Phe Leu Ile Tyr Cys His Ser Ala Asn Gln Trp Leu Thr 1850 1855 1860Ile Glu Lys Tyr Met Thr Gly Glu Phe Arg Lys Tyr Asn Asn Asn 1865 1870 1875Asn Gly Asp Glu Ile Thr Pro Thr Asn Thr Leu Glu Glu Leu Met 1880 1885 1890Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg Gly Glu Leu 1895 1900 1905Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu Thr Asp Pro 1910 1915 1920Ser Val Ile Lys Pro Glu Val Lys Gln Ser Arg Gly Met Val Phe 1925 1930 1935Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Arg Asn Phe Ile Ala 1940 1945 1950Lys His His Cys Asn Ser Cys Cys Arg Lys Leu Lys Leu Pro Asp 1955 1960 1965Leu Lys Arg Asn Asp Tyr Ser Pro Glu Arg Ile Asn Ser Thr Phe 1970 1975 1980Gly Leu Glu Ile Lys Ile Glu Ser Ala Glu Glu Pro Pro Ala Arg 1985 1990 1995Glu Thr Gly Arg Asn Ser Pro Glu Asp Asp Met Gln Leu 2000 2005 2010321655DNAMus musculus 32aaagtgccca gttggatgca gagccaggag aaactaacac caccgaagag ttcagcaaga 60aatggctctc tgtatccaac ttcggccaga tgggtttaga gccttacata taccagaaaa 120tgaaaatgaa ggaaatcaag cgacatacta cacaagccag tgaccaccta aggcagccac 180aagagaaccg agataaaacc cccatatgga attccgggag caccagcctc agcaggagtt 240ttctaacaag aagtccaaat gaagttcaca agatctcaac ctccttaaaa agccctcaag 300agcctcacca ccattattca gccattgaaa ggaataattt aatgagactg tctcagacca 360taccgtttac accaatccag ctgttcacag gagaggaagt gaccatctac aagcttgaag 420aaagttctcc tctgaccctg gataagagca tgtcctcttg gtcgcagcat ggcagagctg 480ccatgattca ggtgctgtca caagaggaaa tggatggggg tctccgcaaa gccatgcgag 540ttatcagcac ctggtctgag gatgatgttc tcaagcctgg gcaggttttc attgtgaagt 600cttttctccc cgaggttgtg cagacgtggt ataaaatctt ccaggagagc actgtgcttc 660atctttgcct tagggaaatt caacagcaaa gagctgccca aaaactcatc tataccttta 720accaagtaaa accacaaacc attccctata caccaaggtt tctcgaggtt tccttggtct 780actgccattc agccaaccaa tggttaacca ttgagaagta catgacaggg gagttccgga 840aatacaataa caacaatggt gatgaaatag ctcccaccaa taccctggaa gaactgatgt 900tggctttctc tcactggacc tatgaatata cccggggaga gctgctggtt ttagatttgc 960aaggtgttgg agaaaatttg acagatccga aaccggaaga caaacaatca agagggatgg 1020tgtttggacc ggccaattta ggggaagatg caattagaag cttcattgca aaacatcgct 1080gcaactcctg ctgtgggaag ctcagactgc cggatttaaa aaggaatgat tactcccttt 1140caagaacaca ctgcaacttg ggatttgggc aaaccattga accaactgag gagcttccag 1200aaagagacaa aaatagaagt tccctggaag atcacacacg cctttaaaaa gatgatgaag 1260gaagacggtg gtcctttagc tccttctgcc atgacttcta tagtgatgga catagactgg 1320catgatcctg actatgtcag aatctccatc accatgactt tacaatgtgg acctccctgg 1380aagtgccctg tgagcctcat ctccccctgc actagagggc acagtgcata atggaggggt 1440tctcctgggt attgacttct aaaaagaatg tgtggcatgc gtttctcatc tcgccggttc 1500tgcatgaaga tgctagatcg agtcagttgg gaattctttc ctcctatacc tcattgcttc 1560agctggccac ttggagtaga attctgtgca ctaacgaact agggaattaa ttaatttatt 1620ttctccctgc gtttggaaaa aaaaaaaaaa aaaaa 165533414PRTMus musculus 33Ser Ala Gln Leu Asp Ala Glu Pro Gly Glu Thr Asn Thr Thr Glu Glu1 5 10 15Phe Ser Lys Lys Trp Leu Ser Val Ser Asn Phe Gly Gln Met Gly Leu 20 25 30Glu Pro Tyr Ile Tyr Gln Lys Asn Lys Met Lys Glu Ile Lys Arg His 35 40 45Thr Thr Gln Ala Ser Asp His Leu Arg Gln Pro Gln Glu Asn Arg Asp 50 55 60Lys Thr Pro Ile Trp Asn Ser Gly Ser Thr Ser Leu Ser Arg Ser Phe65 70 75 80Leu Thr Arg Ser Pro Asn Glu Val His Lys Ile Ser Thr Ser Leu Lys 85 90 95Ser Pro Gln Glu Pro His His His Tyr Ser Ala Ile Glu Arg Asn Asn 100 105 110Leu Met Arg Leu Ser Gln Thr Ile Pro Phe Thr Pro Ile Gln Leu Phe 115 120 125Thr Gly Glu Glu Val Thr Ile Tyr Lys Leu Glu Glu Ser Ser Pro Leu 130 135 140Thr Leu Asp Lys Ser Met Ser Ser Trp Ser Gln His Gly Arg Ala Ala145 150 155 160Met Ile Gln Val Leu Ser Gln Glu Glu Met Asp Gly Gly Leu Arg Lys 165 170 175Ala Met Arg Val Ile Ser Thr Trp Ser Glu Asp Asp Val Leu Lys Pro 180 185 190Gly Gln Val Phe Ile Val Lys Ser Phe Leu Pro Glu Val Val Gln Thr 195 200 205Trp Tyr Lys Ile Phe Gln Glu Ser Thr Val Leu His Leu Cys Leu Arg 210 215 220Glu Ile Gln Gln Gln Arg Ala Ala Gln Lys Leu Ile Tyr Thr Phe Asn225 230 235 240Gln Val Lys Pro Gln Thr Ile Pro Tyr Thr Pro Arg Phe Leu Glu Val 245 250 255Ser Leu Val Tyr Cys His Ser Ala Asn Gln Trp Leu Thr Ile Glu Lys 260 265 270Tyr Met Thr Gly Glu Phe Arg Lys Tyr Asn Asn Asn Asn Gly Asp Glu 275 280 285Ile Ala Pro Thr Asn Thr Leu Glu Glu Leu Met Leu Ala Phe Ser His 290 295 300Trp Thr Tyr Glu Tyr Thr Arg Gly Glu Leu Leu Val Leu Asp Leu Gln305 310 315 320Gly Val Gly Glu Asn Leu Thr Asp Pro Lys Pro Glu Asp Lys Gln Ser 325 330 335Arg Gly Met Val Phe Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Arg 340 345 350Ser Phe Ile Ala Lys His Arg Cys Asn Ser Cys Cys Gly Lys Leu Arg 355 360 365Leu Pro Asp Leu Lys Arg Asn Asp Tyr

Ser Leu Ser Arg Thr His Cys 370 375 380Asn Leu Gly Phe Gly Gln Thr Ile Glu Pro Thr Glu Glu Leu Pro Glu385 390 395 400Arg Asp Lys Asn Arg Ser Ser Leu Glu Asp His Thr Arg Leu 405 410345375DNAHomo sapiens 34gaatctgctg agcccccact aacccagagt gataaaagag agacttctca caccacagca 60gcagcgactg gtcggagttc ccatgctgat gcaagagaat gtgctatttc aacccaggca 120gagcaagaag caaaaaccct tcaaacttca acagactcag tctccaaaga aggcaacaca 180aattgcaagg gagaaggcat gcaagttaat actctatttg aaacaagcca ggttccagac 240tggagtgatc ctcctcaggt acaagttcag gaaacagtca gagagacaat ctcttgcagc 300cagatgccag ctttctcaga gcctgctggg gaggagtccc cattcactgg gaccacaaca 360atttccttct caaacttagg aggggtccac aaggaaaatg catcattagc tcaacactcg 420gaggtcaaac cctgtacctg tggtccacag caggaagaaa aacaagacag agatggcaac 480atacctgaca atttcaggga agacctaaaa tatgagcaga gcatctcaga agccaatgat 540gagactatgt ccccaggtgt gttctcaagg catctcccca aggatgctcg tgctgacttc 600agggagcctg tggctgtctc tgttgcttcc cctgaaccca cagatactgc cctcaccctg 660gaaaatgtgt gtgatgagcc aagggacaga gaagcagtgt gtgcaatgga gtgttttgag 720gctagtgacc aaggaacatg ttttgatacc atagattctc ttgttgggac accagttgat 780aactattcgc ctcaagaaat ttgctctgta gatacggaac tggcagaagg tcaaaacaaa 840gtatctgatt tatgttcttc taatgacaag acactggaag tcttttttca gacacaagtg 900tctgagactt cagtgtctac gtgcaaaagc agcaaggacg gcaactcagt catgtcccct 960ctttttatca gtactttcac cttgaacatt tcacacacag ctagtgaagg tgccacagga 1020gaaaatctag ccaaggtgga gaaatccacc tacccactgg cctccacagt acatgctggc 1080caggagcagc caagccccag caactcagga gggcttgatg aaacacagct cctttcttct 1140gagaacaatc ctttagtgca atttaaagaa ggaggtgaca agagccccag tcctagtgcc 1200gcagacacca cagccacacc agccagttat agttcaattg tgagttttcc ttgggagaag 1260ccaacaacat taactgctaa taatgagtgc tttcaagcga ccagagagac tgttaccatt 1320gccaccgaag tccacccagc caaatacctt gctgtgtcaa ttcctgagga caagcatgca 1380ggtggcactg aggagaggtt ccctcgtgca tcccatgaaa aggtttccca atttccttcc 1440caagtgcagg tggatcatat tttaagtggt gctaccatca aatctacaaa agagctactt 1500tgcagggcac ccagtgtgcc aggagtccca caccatgtcc tgcagctccc agagggagag 1560ggtttctgca gtaattcccc tcttcaggtt gataacctgt ctggagataa gagccagact 1620gtggacagag cagactttag gagctatgaa gagaatttcc aagaaagagg aagtgaaaca 1680aagcaggggg tccagcagca gagcctgtcc cagcagggtt ctctttctgc acctgatttc 1740caacaaagtt tgcctacgac atctgctgca caagaggaaa gaaacttggt gcccacggcc 1800ccctcaccag caagctctag ggaaggagca gggcagcgct caggttgggg gacgagggtc 1860tccgtggtgg ctgaaactgc tggggaagaa gacagtcagg ctctgagcaa cgttccatct 1920ctctctgata tccttttgga agagtctaaa gaatatagac ctggaaattg ggaggcaggc 1980aacaagctga agattataac tctagaggct tccgcttctg aaatctggcc accacgacaa 2040ctgacaaatt ctgagagcaa ggcatcagac ggtggtctca taattcctga caaggtctgg 2100gctgtacctg atagtctaaa ggcagatgct gttgtgcctg aattggcccc ctctgaaata 2160gcagcattgg ctcacagtcc agaggatgct gagtcagccc ttgctgatag cagagaaagc 2220cataaaggcg aagagcccac catcagtgta cactggagaa gtctttcttc ccggggtttc 2280agccaaccga gactcctgga gtcatccgtg gaccctgtag atgaaaagga gttatctgtc 2340acagattcac tgtcagcggc ttctgaaact ggagggaagg aaaatgttaa caatgtgagt 2400caagaccagg aggaaaaaca actcaagatg gatcacactg ccttctttaa aaagtttctg 2460acctgcccta aaatcctaga gtcctctgta gatcccattg atgagataag tgtgatagag 2520tacaccaggg ctggaaaacc agagccctct gaaaccacac cacagggcgc cagagaagga 2580ggtcaatcaa atgacggaaa catgggccac gaagcggaaa tccagtcggc cattttgcaa 2640gttccatgtc tccagggaac cattctgagt gaaaatagaa tcagcagaag ccaagaaggc 2700agtatgaagc aggaggcaga acaaattcaa cctgaggagg caaaaactgc catttggcaa 2760gtcctgcaac ccagcgaagg cggtgaaaga attccaagtg gatgtagcat aggccaaata 2820caagaaagca gtgatgggag cttaggggag gctgagcaaa gcaaaaagga caaagcagaa 2880ttgatttccc ccacttcacc tctttctagt tgtcttccaa taatgactca ctcttctctt 2940ggggttgaca cgcacaactc cacaggccaa attcatgacg tccctgaaaa tgacatagtt 3000gagcccagaa agcgtcagta tgtgtttcct gtttcacaga aaaggggaac tattgagaat 3060gagcgtggga aacctttgcc ctcttctcct gatcttacca ggttcccttg tacttcatct 3120cctgaaggaa atgtcacaga ctttttgata agccacaaaa tggaggaacc taaaatagag 3180gtgcttcaaa ttggggaaac caaaccccca agctcatcta gctcctcagc gaagaccttg 3240gcatttattt caggagaacg tgagttagag aaagccccta agttactgca ggatccatgt 3300caaaagggca ccctgggctg tgcgaaaaag tccagggaga gagagaagtc cctggaagcc 3360cgagcaggca aatcgccagg gaccctcaca gcagtgacgg ggtcagagga ggtcaagagg 3420aagccagaag ccccaggcag tggacattta gctgagggag taaagaagaa aattttgtcc 3480agggtggcag cactgaggct gaaactggaa gaaaaggaaa atatcagaaa gaactcagcc 3540tttcttaaaa agatgcccaa actcgaaaca tcattatcac acacagaaga gaaacaagac 3600ccaaaaaagc catcttgcaa aagagaagga agagctccag tattactgaa aaaaatccaa 3660gctgagatgt tccctgaaca ctctggaaat gtaaaattaa gctgccaatt tgcagaaatt 3720catgaagatt ctactatctg ctggacaaaa gattcaaagt ccatagccca agtgcagaga 3780agtgcagggg acaactccac tgtttccttt gccatcgtgc aagccagtcc gaaggaccag 3840ggactctatt actgctgcat caagaacagc tacggaaaag tgactgctga atttaacctc 3900acagctgaag ttctcaaaca gctgtcaagt cgccaggata ctaaaggatg tgaagagatt 3960gaattcagcc aactcatctt caaagaagac ttcctccatg acagctactt tgggggccgc 4020ctgcgtggtc agatcgccac ggaggagctg cactttggag aaggggttca ccgcaaagcc 4080ttccgcagca cagtgatgca cggcctcatg cctgtcttca aacctggcca tgcctgtgtg 4140cttaaggtgc acaatgccat tgcctatggg accagaaata atgatgagct catccaaagg 4200aactacaaac tcgctgccca ggaatgctat gttcaaaata ctgccaggta ttatgccaag 4260atctacgctg ctgaagcaca gcctctggaa ggctttggag aagtacctga gatcattcct 4320atttttctta tccatcggcc tgagaacaat atcccgtatg ctacagtgga ggaggagctg 4380attggagaat ttgtgaagta ttccatcagg gatgggaaag aaataaactt cttgagaaga 4440gaatcagaag ctggtcagaa atgttgcacc ttccagcact gggtgtacca gaaaacaagt 4500ggctgcctcc tggtgacgga catgcaaggt gtaggaatga agctaactga cgttggcata 4560gcaacgctgg ctaaagggta caagggattt aaaggcaact gttccatgac cttcattgat 4620cagtttaaag cactacacca gtgtaacaag tattgcaaaa tgctgggact gaaatccctt 4680caaaacaaca accagaaaca gaagcagccg agcattggga aaagcaaagt tcaaacaaac 4740tctatgacag taaagaaggc agggcctgag accccaggcg aaaagaaaac ctaacgtccc 4800tgggtaacct aatggccact ggctagcagc acacaatctc gccagggaaa atctgaggcc 4860acacaggaga gaatatacag cctgcagaga gtgcgtggca atccttaccc ccagccgact 4920gtgcgccaag atgcttctaa acccatcacc tgctgtcttc actcaaatga tttcagaaca 4980ggatttgcga ccaggtttat ggggagattg aatcaacgat tggtctcaaa gacaggccat 5040tctttatata cacgtttagc atttttacca acctcacatc atgtgtatat ttgtgtattt 5100gcacatggtt gtgctgtcga ggacctggtg ctgagaagag tctgttcaca gccaaaattc 5160ttcccactgt cattcctaac ctgggatttc tagacacatc ctgctgtgat gtaaacagaa 5220atcacgaatt cgctcactgg atcaagttgt tccactggtg tctaatacgc tattgttgcc 5280ggaggtgggt tctgtgacgt gaagccattt cccatcattc aacagccagt tacaattttc 5340tgtttaatta aattcatatt taaacaaaaa aaaaa 5375351597PRTHomo sapiens 35Glu Ser Ala Glu Pro Pro Leu Thr Gln Ser Asp Lys Arg Glu Thr Ser1 5 10 15His Thr Thr Ala Ala Ala Thr Gly Arg Ser Ser His Ala Asp Ala Arg 20 25 30Glu Cys Ala Ile Ser Thr Gln Ala Glu Gln Glu Ala Lys Thr Leu Gln 35 40 45Thr Ser Thr Asp Ser Val Ser Lys Glu Gly Asn Thr Asn Cys Lys Gly 50 55 60Glu Gly Met Gln Val Asn Thr Leu Phe Glu Thr Ser Gln Val Pro Asp65 70 75 80Trp Ser Asp Pro Pro Gln Val Gln Val Gln Glu Thr Val Arg Glu Thr 85 90 95Ile Ser Cys Ser Gln Met Pro Ala Phe Ser Glu Pro Ala Gly Glu Glu 100 105 110Ser Pro Phe Thr Gly Thr Thr Thr Ile Ser Phe Ser Asn Leu Gly Gly 115 120 125Val His Lys Glu Asn Ala Ser Leu Ala Gln His Ser Glu Val Lys Pro 130 135 140Cys Thr Cys Gly Pro Gln Gln Glu Glu Lys Gln Asp Arg Asp Gly Asn145 150 155 160Ile Pro Asp Asn Phe Arg Glu Asp Leu Lys Tyr Glu Gln Ser Ile Ser 165 170 175Glu Ala Asn Asp Glu Thr Met Ser Pro Gly Val Phe Ser Arg His Leu 180 185 190Pro Lys Asp Ala Arg Ala Asp Phe Arg Glu Pro Val Ala Val Ser Val 195 200 205Ala Ser Pro Glu Pro Thr Asp Thr Ala Leu Thr Leu Glu Asn Val Cys 210 215 220Asp Glu Pro Arg Asp Arg Glu Ala Val Cys Ala Met Glu Cys Phe Glu225 230 235 240Ala Ser Asp Gln Gly Thr Cys Phe Asp Thr Ile Asp Ser Leu Val Gly 245 250 255Thr Pro Val Asp Asn Tyr Ser Pro Gln Glu Ile Cys Ser Val Asp Thr 260 265 270Glu Leu Ala Glu Gly Gln Asn Lys Val Ser Asp Leu Cys Ser Ser Asn 275 280 285Asp Lys Thr Leu Glu Val Phe Phe Gln Thr Gln Val Ser Glu Thr Ser 290 295 300Val Ser Thr Cys Lys Ser Ser Lys Asp Gly Asn Ser Val Met Ser Pro305 310 315 320Leu Phe Ile Ser Thr Phe Thr Leu Asn Ile Ser His Thr Ala Ser Glu 325 330 335Gly Ala Thr Gly Glu Asn Leu Ala Lys Val Glu Lys Ser Thr Tyr Pro 340 345 350Leu Ala Ser Thr Val His Ala Gly Gln Glu Gln Pro Ser Pro Ser Asn 355 360 365Ser Gly Gly Leu Asp Glu Thr Gln Leu Leu Ser Ser Glu Asn Asn Pro 370 375 380Leu Val Gln Phe Lys Glu Gly Gly Asp Lys Ser Pro Ser Pro Ser Ala385 390 395 400Ala Asp Thr Thr Ala Thr Pro Ala Ser Tyr Ser Ser Ile Val Ser Phe 405 410 415Pro Trp Glu Lys Pro Thr Thr Leu Thr Ala Asn Asn Glu Cys Phe Gln 420 425 430Ala Thr Arg Glu Thr Val Thr Ile Ala Thr Glu Val His Pro Ala Lys 435 440 445Tyr Leu Ala Val Ser Ile Pro Glu Asp Lys His Ala Gly Gly Thr Glu 450 455 460Glu Arg Phe Pro Arg Ala Ser His Glu Lys Val Ser Gln Phe Pro Ser465 470 475 480Gln Val Gln Val Asp His Ile Leu Ser Gly Ala Thr Ile Lys Ser Thr 485 490 495Lys Glu Leu Leu Cys Arg Ala Pro Ser Val Pro Gly Val Pro His His 500 505 510Val Leu Gln Leu Pro Glu Gly Glu Gly Phe Cys Ser Asn Ser Pro Leu 515 520 525Gln Val Asp Asn Leu Ser Gly Asp Lys Ser Gln Thr Val Asp Arg Ala 530 535 540Asp Phe Arg Ser Tyr Glu Glu Asn Phe Gln Glu Arg Gly Ser Glu Thr545 550 555 560Lys Gln Gly Val Gln Gln Gln Ser Leu Ser Gln Gln Gly Ser Leu Ser 565 570 575Ala Pro Asp Phe Gln Gln Ser Leu Pro Thr Thr Ser Ala Ala Gln Glu 580 585 590Glu Arg Asn Leu Val Pro Thr Ala Pro Ser Pro Ala Ser Ser Arg Glu 595 600 605Gly Ala Gly Gln Arg Ser Gly Trp Gly Thr Arg Val Ser Val Val Ala 610 615 620Glu Thr Ala Gly Glu Glu Asp Ser Gln Ala Leu Ser Asn Val Pro Ser625 630 635 640Leu Ser Asp Ile Leu Leu Glu Glu Ser Lys Glu Tyr Arg Pro Gly Asn 645 650 655Trp Glu Ala Gly Asn Lys Leu Lys Ile Ile Thr Leu Glu Ala Ser Ala 660 665 670Ser Glu Ile Trp Pro Pro Arg Gln Leu Thr Asn Ser Glu Ser Lys Ala 675 680 685Ser Asp Gly Gly Leu Ile Ile Pro Asp Lys Val Trp Ala Val Pro Asp 690 695 700Ser Leu Lys Ala Asp Ala Val Val Pro Glu Leu Ala Pro Ser Glu Ile705 710 715 720Ala Ala Leu Ala His Ser Pro Glu Asp Ala Glu Ser Ala Leu Ala Asp 725 730 735Ser Arg Glu Ser His Lys Gly Glu Glu Pro Thr Ile Ser Val His Trp 740 745 750Arg Ser Leu Ser Ser Arg Gly Phe Ser Gln Pro Arg Leu Leu Glu Ser 755 760 765Ser Val Asp Pro Val Asp Glu Lys Glu Leu Ser Val Thr Asp Ser Leu 770 775 780Ser Ala Ala Ser Glu Thr Gly Gly Lys Glu Asn Val Asn Asn Val Ser785 790 795 800Gln Asp Gln Glu Glu Lys Gln Leu Lys Met Asp His Thr Ala Phe Phe 805 810 815Lys Lys Phe Leu Thr Cys Pro Lys Ile Leu Glu Ser Ser Val Asp Pro 820 825 830Ile Asp Glu Ile Ser Val Ile Glu Tyr Thr Arg Ala Gly Lys Pro Glu 835 840 845Pro Ser Glu Thr Thr Pro Gln Gly Ala Arg Glu Gly Gly Gln Ser Asn 850 855 860Asp Gly Asn Met Gly His Glu Ala Glu Ile Gln Ser Ala Ile Leu Gln865 870 875 880Val Pro Cys Leu Gln Gly Thr Ile Leu Ser Glu Asn Arg Ile Ser Arg 885 890 895Ser Gln Glu Gly Ser Met Lys Gln Glu Ala Glu Gln Ile Gln Pro Glu 900 905 910Glu Ala Lys Thr Ala Ile Trp Gln Val Leu Gln Pro Ser Glu Gly Gly 915 920 925Glu Arg Ile Pro Ser Gly Cys Ser Ile Gly Gln Ile Gln Glu Ser Ser 930 935 940Asp Gly Ser Leu Gly Glu Ala Glu Gln Ser Lys Lys Asp Lys Ala Glu945 950 955 960Leu Ile Ser Pro Thr Ser Pro Leu Ser Ser Cys Leu Pro Ile Met Thr 965 970 975His Ser Ser Leu Gly Val Asp Thr His Asn Ser Thr Gly Gln Ile His 980 985 990Asp Val Pro Glu Asn Asp Ile Val Glu Pro Arg Lys Arg Gln Tyr Val 995 1000 1005Phe Pro Val Ser Gln Lys Arg Gly Thr Ile Glu Asn Glu Arg Gly 1010 1015 1020Lys Pro Leu Pro Ser Ser Pro Asp Leu Thr Arg Phe Pro Cys Thr 1025 1030 1035Ser Ser Pro Glu Gly Asn Val Thr Asp Phe Leu Ile Ser His Lys 1040 1045 1050Met Glu Glu Pro Lys Ile Glu Val Leu Gln Ile Gly Glu Thr Lys 1055 1060 1065Pro Pro Ser Ser Ser Ser Ser Ser Ala Lys Thr Leu Ala Phe Ile 1070 1075 1080Ser Gly Glu Arg Glu Leu Glu Lys Ala Pro Lys Leu Leu Gln Asp 1085 1090 1095Pro Cys Gln Lys Gly Thr Leu Gly Cys Ala Lys Lys Ser Arg Glu 1100 1105 1110Arg Glu Lys Ser Leu Glu Ala Arg Ala Gly Lys Ser Pro Gly Thr 1115 1120 1125Leu Thr Ala Val Thr Gly Ser Glu Glu Val Lys Arg Lys Pro Glu 1130 1135 1140Ala Pro Gly Ser Gly His Leu Ala Glu Gly Val Lys Lys Lys Ile 1145 1150 1155Leu Ser Arg Val Ala Ala Leu Arg Leu Lys Leu Glu Glu Lys Glu 1160 1165 1170Asn Ile Arg Lys Asn Ser Ala Phe Leu Lys Lys Met Pro Lys Leu 1175 1180 1185Glu Thr Ser Leu Ser His Thr Glu Glu Lys Gln Asp Pro Lys Lys 1190 1195 1200Pro Ser Cys Lys Arg Glu Gly Arg Ala Pro Val Leu Leu Lys Lys 1205 1210 1215Ile Gln Ala Glu Met Phe Pro Glu His Ser Gly Asn Val Lys Leu 1220 1225 1230Ser Cys Gln Phe Ala Glu Ile His Glu Asp Ser Thr Ile Cys Trp 1235 1240 1245Thr Lys Asp Ser Lys Ser Ile Ala Gln Val Gln Arg Ser Ala Gly 1250 1255 1260Asp Asn Ser Thr Val Ser Phe Ala Ile Val Gln Ala Ser Pro Lys 1265 1270 1275Asp Gln Gly Leu Tyr Tyr Cys Cys Ile Lys Asn Ser Tyr Gly Lys 1280 1285 1290Val Thr Ala Glu Phe Asn Leu Thr Ala Glu Val Leu Lys Gln Leu 1295 1300 1305Ser Ser Arg Gln Asp Thr Lys Gly Cys Glu Glu Ile Glu Phe Ser 1310 1315 1320Gln Leu Ile Phe Lys Glu Asp Phe Leu His Asp Ser Tyr Phe Gly 1325 1330 1335Gly Arg Leu Arg Gly Gln Ile Ala Thr Glu Glu Leu His Phe Gly 1340 1345 1350Glu Gly Val His Arg Lys Ala Phe Arg Ser Thr Val Met His Gly 1355 1360 1365Leu Met Pro Val Phe Lys Pro Gly His Ala Cys Val Leu Lys Val 1370 1375 1380His Asn Ala Ile Ala Tyr Gly Thr Arg Asn Asn Asp Glu Leu Ile 1385 1390 1395Gln Arg Asn Tyr Lys Leu Ala Ala Gln Glu Cys Tyr Val Gln Asn 1400 1405 1410Thr Ala Arg Tyr Tyr Ala Lys Ile Tyr Ala Ala Glu Ala Gln Pro 1415 1420 1425Leu Glu Gly Phe Gly Glu Val Pro Glu Ile Ile Pro Ile Phe Leu 1430 1435 1440Ile His Arg Pro Glu Asn Asn Ile Pro Tyr Ala Thr Val Glu Glu 1445 1450 1455Glu Leu Ile Gly Glu Phe Val Lys Tyr Ser Ile Arg Asp Gly Lys 1460 1465 1470Glu Ile Asn Phe Leu Arg Arg Glu Ser Glu Ala Gly Gln Lys Cys 1475 1480 1485Cys Thr Phe Gln His Trp Val Tyr Gln Lys Thr Ser Gly Cys Leu 1490 1495 1500Leu Val Thr Asp Met Gln Gly Val Gly Met Lys Leu Thr Asp Val 1505 1510 1515Gly Ile Ala Thr Leu Ala Lys Gly Tyr Lys Gly Phe Lys Gly Asn 1520 1525

1530Cys Ser Met Thr Phe Ile Asp Gln Phe Lys Ala Leu His Gln Cys 1535 1540 1545Asn Lys Tyr Cys Lys Met Leu Gly Leu Lys Ser Leu Gln Asn Asn 1550 1555 1560Asn Gln Lys Gln Lys Gln Pro Ser Ile Gly Lys Ser Lys Val Gln 1565 1570 1575Thr Asn Ser Met Thr Val Lys Lys Ala Gly Pro Glu Thr Pro Gly 1580 1585 1590Glu Lys Lys Thr 1595364846DNAMus musculus 36gcgtcgactc tgtctccaac ttgagtgaga tcaacaggga aaatctgtca ttggcccaat 60acccaggact ggaaagctgt cctcaaagcc tccagcagga aggcagacca aacagagaca 120gagacttgcc tggtgctctc tgggcagaat cagcctgtga actgagtctc ctagaagaca 180atgaggaaga agagtcgcag cctccagcct cagtggctct ccctcagggt gatggtgtcc 240cctgcaggga gccagagggt ctctctgatt ctttccccca gcccactgct ccctccctcc 300ccctggaaaa tgtgggcagt gggtcaaggg tcagagaagc tgcaggtggg gtggggtgtt 360ttgaagccgg tgaccaagaa acatgttatg ctaccatgga tctccttgtt ggagcaccag 420ttgataaata tttgcctcaa gaaatttgcc ccgaggactt ggagctgaca gaaggtcaaa 480gcgaagtgtg tgatttatgt tctcctgaca agatactggc tgttctacag acacaaggtt 540atgagcctcc acggtccaca gacaagcgca gccaggatgg caagtcagcc gagggccttc 600tttttaacag taccttcacc tgggacacgg caaaggaggc cagtgaagat gctgtgggag 660agacagcagc tgatgtggag aatcctccct ccaccttctc ttctacgcta ccctacagtg 720aaagagggtt tggggagaca caaccccttt gttctgagac tatctccttt gtaaaggata 780gtgaagggag ctacagaagt tccagtctca gcatcccagc tgccatagac acacttgcca 840gctacagttc tgacagggag tgctcaaaag agcagtcagc cgaatcaact gctaatgtcg 900actgtcatca ggtgaccagg gagatggagg gcatatcaac taatgccgct gaggtccacg 960aaatcaaatg ccactccgtt tctgtccccc aggacaatga ctttgatgtt ggtgctgacc 1020aggtctcgtg tgaggcacga gatgaagata attcccaatc tcttccagac gacgactcac 1080agtcaggtcg ttcattaagt agctccacag gtgaagcaac cggggagact ctggtgccag 1140cacccagcag tgcaggagat catggccact tctccatgcc cgagggacag ggtttgtgta 1200gcagggctct tcagatggat aaccagcctg tgtgtcagag ccaggctatg gagggagccc 1260acagcagagg ccttgaggag cacttccaag aaaagggaag tggaatgaag catggcatcc 1320ggccacagag cacatcccac caggtttctc tttctgcaaa tgacttccaa gaaattttgc 1380cctccatacc caccatgcaa caggagacca atgtggaacc cttggagcac tccctagcag 1440attccaggga agaaattgag tgtagctcag acccgaggac cagtgacttg gtggtggctg 1500agaagactgt gggagaagac agtcatttgg tagtcagtgt cccagctctc cctgacatcc 1560tccttggaga gaaagatgac gttgggctag gaagttgggc tgtgggcggc aaagtgaaga 1620tcataactct agaagctccc gtctttgaaa tctggccacc agaactagtg aggcaccctg 1680ggtacaagga ggcagaagct ggtctcacca tgcctggtag gagctgggct ctgtctgaca 1740tcctcagagc aggtgccacc agatctgagc caggtgcctt gggaggagca gcatgggttc 1800ccagccccca ggctgatgct ctcatggccc ttggagcgaa cagggacacc tggctaggtg 1860ctgcaccaga cagacaagca aactgcaatt gtctgtcttc ccagtgtctg agtcaacccc 1920gattcctgga gtcatctgta gaccctgttg aggacaagga gttagaggtc acggactctc 1980catcagaggt ttccaaaact ggagagatgg aaatgcctga gactctgaat gaggaacagg 2040aggaaaccgt ggaccccatt gacgacaggg gtgagctgga gggtgtctgg cccgagaagc 2100cagagccctc tgactccagc gtagaaggaa acgaattcat tgttggaaac acgtgtcaga 2160gggtagacat ccaacctgct agcctacagc tcccacatcc ccaggacagc ggggaaatca 2220ttccatatga acacacaacc aaccaaaatc gcgtagacgg agagagagca gaagccaaaa 2280ccagtctgcc ggataaagcc aaagcggaag cagaagctgt tgtttggcag gcccaggggc 2340ctggtgaaga gggacaagga attccaagtg tatgcagcat gagccaaaca caagatggtg 2400gtgacagaag cctaggagaa gctgggcaaa ggggaacgga tgagaccgag gtcatttccc 2460ccctgtctcc tctttctagc tgtctcacag gagtgacaca tacatgtgtc aaggctgaaa 2520ccaacaactc cacaggccac atttatggcg gatctgagcc cagaacccgt caaagtgtaa 2580ttcctatgaa gacagaaaag ggaactatcg agagcaagtg tgggaaccat gtgcgctctt 2640cagatgatct cacaaacaca ccttgtactt catctcccaa aggaaatgtc acacgcttgt 2700caataagcca tggcctggag gaactgaaat cagagaagct gcagattgcg gaaaccaaac 2760ccctaaactc atctgactcc ccaacaatga ccttagctct catttcagga gaatgtgagt 2820cagagaaaga ccccaaaagc ttgttacgta gggacccatg tccaaagggc tccaccctgg 2880atagcgggaa gaagtccaga gaccaacagc agaagcctgt ggcagcccag gtcagcaagg 2940cacctgggga ccaatcagca atggctgggt cagaggaggg caagaagaag caagaggctt 3000cggggagtgg acacttgact gcagggataa agaagaaaat tctatccagg gtcgtagccc 3060tgagactgag gctggaggaa aaggaaaatt cgaggaagaa ctccatcgtg aagaagacac 3120ctaagtttga aaggtcctta tcccgcactg atgagaaaag agaccccaaa agggcccctt 3180gcaaagctga agggaaagct ccagtattgc tgaagaggat ccaggccgag atggctcccg 3240agcactccgg aaatataaag ttgagctgcc agttttcaga aatccatgaa gactctaccg 3300tctgctggac aaaagattcc aagtcgatag cccaggccaa gaaaagcgca ggggacaact 3360ccagtgtttc cttggccatc gtccaagctg gtcagaagga ccagggcctg tattactgct 3420gcctcaagaa cagttatgga aaagtcactg ctgagtttaa cctcacagct gaagttctca 3480aacagctttc aagtcacaca gaatatagag gatgtgaaga gattgaattc agccagctca 3540tcttcaaaga agatgttttc aatgacagct acttcgggga ccacctacgt ggccagatct 3600ccacggagga gcttcacttt ggcgaagggg tgcaccgcaa agctttccgg agcaaggtga 3660tgcagggcct catgccggtc ttccagcccg gccacgcatg cgtactcaag gtgcacaatg 3720ccgtcgccca tgggaccaga aacaatgacg aacttgtgca gaggaactac aaactggctg 3780cccaggaatg ctacgtccag aatactgcca gatactacgc caagatctac gccgctgaag 3840cacagcctct ggaaggcttc ggagaggtgc cggagatcat tcctattttc cttatccatc 3900ggcccgagaa caatatccca tatgccacag tggaagaaga gctgattgga gaattcgtga 3960agtattccat ccgggacggg aaggaaatca acttccttag acgagattca gaggctggcc 4020agaaatgttg caccttccag cactgggtat accagaaaac aagtggctgt ctcctggtca 4080cggacatgca gggtgtttcc atgaccttca ttgatcagtt cagagcgctg catcagtgta 4140acaagtactg taaaatgctg gggctgaaat cccttcaaaa caacagccag aagcccagga 4200agcccatcgt cgggaaaggc agggttccga caaacgccac gcaggtgaag acgcctgagt 4260ctgagacgcc gcccgcagaa agaaaaacct agcctccctc ctcccttcat caccagtgac 4320caccaagcca gcatcgcgca ggcttgcgcg tggacatctg caagcacaca agggacacga 4380gcctgcagcc tgcagccgag tgccagtcct ctcagctcct atcactggct gtctgctgaa 4440atgacaatgg catggctctt ccagactagc cttgtagaga gacttagcag ttctgttgat 4500gctctcaaag gcagcccact gtttgtgtac acagctagcc tttctacaca caccctcccc 4560tcccaccgca tcgtctatct atctgtgtgt cgcgcgtggt ttgttgacaa gagttccccc 4620gctgccttgg cgactggcca ctgtcaaaat ccttcccacc tcgaccccct cacctcagga 4680tgttcctgca gtcatgaatg tcaagttgtt gttatcagtg tcaccgacgc tattgttgct 4740ggaggcggct tcccagatgc gagcccattt cccgccacta cccacgcagc ctggcacagt 4800gttctgtttc attaaattca tatttaagca aaaaaaaaaa aaaaaa 4846371475PRTMus musculus 37Val Ala Ser Val Ser Asn Leu Ser Glu Ile Asn Arg Glu Asn Leu Ser1 5 10 15Leu Ala Gln Tyr Pro Gly Leu Glu Ser Cys Pro Gln Ser Leu Gln Gln 20 25 30Glu Gly Arg Pro Asn Arg Asp Arg Asp Leu Pro Gly Ala Leu Trp Ala 35 40 45Glu Ser Ala Cys Glu Leu Ser Leu Leu Glu Asp Asn Glu Glu Glu Glu 50 55 60Ser Gln Pro Pro Ala Ser Val Ala Leu Pro Gln Gly Asp Gly Val Pro65 70 75 80Cys Arg Glu Pro Glu Gly Leu Ser Asp Ser Phe Pro Gln Pro Thr Ala 85 90 95Pro Ser Leu Pro Leu Glu Asn Val Gly Ser Gly Ser Arg Val Arg Glu 100 105 110Ala Ala Gly Gly Val Gly Cys Phe Glu Ala Gly Asp Gln Glu Thr Cys 115 120 125Tyr Ala Thr Met Asp Leu Leu Val Gly Ala Pro Val Asp Lys Tyr Leu 130 135 140Pro Gln Glu Ile Cys Pro Glu Asp Leu Glu Leu Thr Glu Gly Gln Ser145 150 155 160Glu Val Cys Asp Leu Cys Ser Pro Asp Lys Ile Leu Ala Val Leu Gln 165 170 175Thr Gln Gly Tyr Glu Pro Pro Arg Ser Thr Asp Lys Arg Ser Gln Asp 180 185 190Gly Lys Ser Ala Glu Gly Leu Leu Phe Asn Ser Thr Phe Thr Trp Asp 195 200 205Thr Ala Lys Glu Ala Ser Glu Asp Ala Val Gly Glu Thr Ala Ala Asp 210 215 220Val Glu Asn Pro Pro Ser Thr Phe Ser Ser Thr Leu Pro Tyr Ser Glu225 230 235 240Arg Gly Phe Gly Glu Thr Gln Pro Leu Cys Ser Glu Thr Ile Ser Phe 245 250 255Val Lys Asp Ser Glu Gly Ser Tyr Arg Ser Ser Ser Leu Ser Ile Pro 260 265 270Ala Ala Ile Asp Thr Leu Ala Ser Tyr Ser Ser Asp Arg Glu Cys Ser 275 280 285Lys Glu Gln Ser Ala Glu Ser Thr Ala Asn Val Asp Cys His Gln Val 290 295 300Thr Arg Glu Met Glu Gly Ile Ser Thr Asn Ala Ala Glu Val His Glu305 310 315 320Ile Lys Cys His Ser Val Ser Val Pro Gln Asp Asn Asp Phe Asp Val 325 330 335Gly Ala Asp Gln Val Ser Cys Glu Ala Arg Asp Glu Asp Asn Ser Gln 340 345 350Ser Leu Pro Asp Asp Asp Ser Gln Ser Gly Arg Ser Leu Ser Ser Ser 355 360 365Thr Gly Glu Ala Thr Gly Glu Thr Leu Val Pro Ala Pro Ser Ser Ala 370 375 380Gly Asp His Gly His Phe Ser Met Pro Glu Gly Gln Gly Leu Cys Ser385 390 395 400Arg Ala Leu Gln Met Asp Asn Gln Pro Val Cys Gln Ser Gln Ala Met 405 410 415Glu Gly Ala His Ser Arg Gly Leu Glu Glu His Phe Gln Glu Lys Gly 420 425 430Ser Gly Met Lys His Gly Ile Arg Pro Gln Ser Thr Ser His Gln Val 435 440 445Ser Leu Ser Ala Asn Asp Phe Gln Glu Ile Leu Pro Ser Ile Pro Thr 450 455 460Met Gln Gln Glu Thr Asn Val Glu Pro Leu Glu His Ser Leu Ala Asp465 470 475 480Ser Arg Glu Glu Ile Glu Cys Ser Ser Asp Pro Arg Thr Ser Asp Leu 485 490 495Val Val Ala Glu Lys Thr Val Gly Glu Asp Ser His Leu Val Val Ser 500 505 510Val Pro Ala Leu Pro Asp Ile Leu Leu Gly Glu Lys Asp Asp Val Gly 515 520 525Leu Gly Ser Trp Ala Val Gly Gly Lys Val Lys Ile Ile Thr Leu Glu 530 535 540Ala Pro Val Phe Glu Ile Trp Pro Pro Glu Leu Val Arg His Pro Gly545 550 555 560Tyr Lys Glu Ala Glu Ala Gly Leu Thr Met Pro Gly Arg Ser Trp Ala 565 570 575Leu Ser Asp Ile Leu Arg Ala Gly Ala Thr Arg Ser Glu Pro Gly Ala 580 585 590Leu Gly Gly Ala Ala Trp Val Pro Ser Pro Gln Ala Asp Ala Leu Met 595 600 605Ala Leu Gly Ala Asn Arg Asp Thr Trp Leu Gly Ala Ala Pro Asp Arg 610 615 620Gln Ala Asn Cys Asn Cys Leu Ser Ser Gln Cys Leu Ser Gln Pro Arg625 630 635 640Phe Leu Glu Ser Ser Val Asp Pro Val Glu Asp Lys Glu Leu Glu Val 645 650 655Thr Asp Ser Pro Ser Glu Val Ser Lys Thr Gly Glu Met Glu Met Pro 660 665 670Glu Thr Leu Asn Glu Glu Gln Glu Glu Thr Gln Gln Met Leu Arg His 675 680 685Pro Ala Val Val Asn Gln Ser Val Asn Phe Pro Arg Ile Leu Glu Ser 690 695 700Ser Val Asp Pro Ile Asp Asp Arg Gly Glu Leu Glu Gly Val Trp Pro705 710 715 720Glu Lys Pro Glu Pro Ser Asp Ser Ser Val Glu Gly Asn Glu Pro Ile 725 730 735Val Gly Asn Thr Cys Gln Arg Val Asp Ile Gln Pro Ala Ser Leu Gln 740 745 750Leu Pro His Pro Gln Asp Ser Gly Glu Ile Ile Pro Tyr Glu His Thr 755 760 765Thr Asn Gln Asn Arg Val Asp Gly Glu Arg Ala Glu Ala Lys Thr Ser 770 775 780Leu Pro Asp Lys Ala Lys Ala Glu Ala Glu Ala Val Val Trp Gln Ala785 790 795 800Gln Gly Pro Gly Glu Glu Gly Gln Gly Ile Pro Ser Val Cys Ser Met 805 810 815Ser Gln Thr Ser Asp Gly Gly Asp Arg Ser Leu Gly Glu Ala Gly Gln 820 825 830Arg Gly Thr Asp Glu Thr Glu Val Ile Ser Pro Leu Ser Pro Leu Ser 835 840 845Ser Cys Leu Thr Gly Val Thr His Thr Cys Val Lys Ala Glu Thr Asn 850 855 860Asn Ser Thr Gly His Ile Tyr Gly Gly Ser Glu Pro Arg Thr Arg Gln865 870 875 880Ser Val Ile Pro Met Lys Thr Glu Lys Gly Thr Ile Glu Ser Lys Cys 885 890 895Gly Asn His Val Arg Ser Ser Asp Asp Leu Thr Asn Thr Pro Cys Thr 900 905 910Ser Ser Pro Lys Gly Asn Val Thr Arg Leu Ser Ile Ser His Gly Leu 915 920 925Glu Glu Leu Lys Ser Glu Lys Leu Gln Ile Ala Glu Thr Lys Pro Leu 930 935 940Asn Ser Ser Asp Ser Pro Thr Met Thr Leu Ala Leu Ile Ser Gly Glu945 950 955 960Cys Glu Ser Glu Lys Asp Pro Lys Ser Leu Leu Arg Arg Asp Pro Cys 965 970 975Pro Lys Gly Ser Thr Leu Asp Ser Gly Lys Lys Ser Arg Asp Gln Gln 980 985 990Gln Lys Pro Val Ala Ala Gln Val Ser Lys Ala Pro Gly Asp Gln Ser 995 1000 1005Ala Met Ala Gly Ser Glu Glu Gly Lys Lys Lys Gln Glu Ala Ser 1010 1015 1020Gly Ser Gly His Leu Thr Ala Gly Ile Lys Lys Lys Ile Leu Ser 1025 1030 1035Arg Val Val Ala Leu Arg Leu Arg Leu Glu Glu Lys Glu Asn Ser 1040 1045 1050Arg Lys Asn Ser Ile Val Lys Lys Thr Pro Lys Phe Glu Arg Ser 1055 1060 1065Leu Ser Arg Thr Asp Glu Lys Arg Asp Pro Lys Arg Ala Pro Cys 1070 1075 1080Lys Ala Glu Gly Lys Ala Pro Val Leu Leu Lys Arg Ile Gln Ala 1085 1090 1095Glu Met Ala Pro Glu His Ser Gly Asn Ile Lys Leu Ser Cys Gln 1100 1105 1110Phe Ser Glu Ile His Glu Asp Ser Thr Val Cys Trp Thr Lys Asp 1115 1120 1125Ser Lys Ser Ile Ala Gln Ala Lys Lys Ser Ala Gly Asp Asn Ser 1130 1135 1140Ser Val Ser Leu Ala Ile Val Gln Ala Gly Gln Lys Asp Gln Gly 1145 1150 1155Leu Tyr Tyr Cys Cys Leu Lys Asn Ser Tyr Gly Lys Val Thr Ala 1160 1165 1170Glu Phe Asn Leu Thr Ala Glu Val Leu Lys Lys Gln Leu Ser Ser 1175 1180 1185His Thr Glu Tyr Arg Gly Cys Glu Glu Ile Glu Phe Ser Gln Leu 1190 1195 1200Ile Phe Lys Glu Asp Val Phe Asn Asp Ser Tyr Phe Gly Asp His 1205 1210 1215Leu Arg Gly Gln Ile Ser Thr Glu Glu Leu His Phe Gly Glu Gly 1220 1225 1230Val His Arg Lys Ala Phe Arg Ser Lys Val Met Gln Gly Leu Met 1235 1240 1245Pro Val Phe Gln Pro Gly His Ala Cys Val Leu Lys Val His Asn 1250 1255 1260Ala Val Ala His Gly Thr Arg Asn Asn Asp Glu Leu Val Gln Arg 1265 1270 1275Asn Tyr Lys Leu Ala Ala Gln Glu Cys Tyr Val Gln Asn Thr Ala 1280 1285 1290Arg Tyr Tyr Ala Lys Ile Tyr Ala Ala Glu Ala Gln Pro Leu Glu 1295 1300 1305Gly Phe Gly Glu Val Pro Glu Ile Ile Pro Ile Phe Leu Ile His 1310 1315 1320Arg Pro Glu Asn Asn Ile Pro Tyr Ala Thr Val Glu Glu Glu Leu 1325 1330 1335Ile Gly Glu Val Lys Tyr Ser Ile Arg Asp Gly Lys Glu Ile Asn 1340 1345 1350Phe Leu Arg Arg Asp Ser Glu Ala Gly Gln Lys Cys Cys Thr Phe 1355 1360 1365Gln His Trp Val Tyr Gln Lys Thr Ser Gly Cys Leu Leu Val Thr 1370 1375 1380Asp Met Gln Gly Val Gly Met Lys Leu Thr Asp Val Gly Ile Ala 1385 1390 1395Thr Leu Ala Arg Gly Tyr Lys Gly Phe Lys Gly Asn Cys Ser Met 1400 1405 1410Thr Phe Ile Asp Gln Phe Arg Ala Leu His Gln Cys Asn Lys Tyr 1415 1420 1425Cys Lys Met Leu Gly Leu Lys Ser Leu Gln Asn Asn Ser Gln Lys 1430 1435 1440Pro Arg Lys Pro Ile Val Gly Lys Gly Arg Val Pro Thr Asn Ala 1445 1450 1455Thr Gln Val Lys Thr Pro Glu Ser Glu Thr Pro Pro Ala Glu Arg 1460 1465 1470Lys Thr 1475387771DNAHomo sapiens 38gtatcaggac tcagcccatt tccccctctg gtgctgagaa atggaggccg aaggagtgat 60ctagaagtgt taattgagcc cctaatctat gctagttact gggggtgttg ggggagacag 120gagagagatc ccacggggtt ccggcctccc agggactcag gtcactaatg gaggtggctt 180ggcttgtcta tgtgctgggc caacagccac tggcgaggca aggcgagggt cagtcacggc 240tggtgccagg aagagggctg gttctttggc tccctggtct cccgcggtct agcccaagct 300ggccagcggt tgacctggct cccctggccc cggccaggcc tcgtggaccc ctcatatgcc 360acacgggaca tgagcaggcc ggccgggagc cgggtcccgg gagctccacg aaggggcctg 420tcctccatga ccaggacacc cgctgcgcct tcctcccgag gcctcccggg cctctccaga 480cgcggcgcta ctgcagacac cagggccgcc aagggagcgg actcggagcc ggccctgggg 540cgggcacatg ggccccggcg ccccccggcg tctccaagcc gcgctgcccg ggtcgggcca 600ggccagggga gggacagcag caggtgacga cggcccggcc accggctata aataggggcg 660cgcgtcagcc gcgggcggga gcggcggcgg cgggcagggg cccgggggcc ggggcctgga

720ggacaggcga ggcagcggcg agtgcggggc cggcggtcgg ggagggcggt gccatggggt 780cgcggagggc ccccacccgg ggctggggcg cgggtgggcg gtcgggggcg gggggcgacg 840gtgaggacga cggccccgtg tggatcccca gcccagccag ccggagctac ctgctcagcg 900tgcggcccga gaccagctta tcaagcaacc ggttgtctca ccccagctct ggaaggagca 960ccttctgctc catcattgct cagctcacag aggagaccca gccgctattt gagaccacgc 1020tcaagtcccg gtctgtgtcc gaggacagcg acgtcaggtt cacctgcatc gtcacaggat 1080acccagagcc agaggtgacc tggtacaagg atgatacgga gctggaccgc tactgtggct 1140tgccaaaata tgagatcact catcagggca accgccacac actgcagctg tacaggtgtc 1200gagaagaaga tgccgccatc taccaggcct ctgcccagaa cagcaagggc attgtgtcct 1260gctcaggggt cctggaggtg ggcaccatga ctgagtacaa gatccaccag cgctggttcg 1320ccaagttgaa gcgcaaggct gcggcaaagc tgcgcgagat cgagcagagc tggaagcacg 1380agaaggcggt gcctggggag gtcgacactc tgcgcaagct cagccccgac cgcttccagc 1440gaaagcggcg attgagcggg gctcaagcgc cgggcccctc ggtccctacc agggagcctg 1500agggtgggac cctggcggct tggcaggagg gagagactga gactgctcag cactcaggtt 1560tgggcctgat caacagtttt gcttctggag aagtgaccac caacggggag gctgcccccg 1620agaatggaga ggacggagag catggcttgc tgacatacat ctgtgacgcc atggagctgg 1680ggcctcagag agccctcaaa gaggagagtg gggccaagaa gaaaaagaaa gatgaggaat 1740ccaagcaagg cctgcggaag ccagagttag agaaggcagc ccaaagccgc cgttcttcag 1800aaaactgcat ccccagctca gacgagcctg actcctgtgg gactcagggg cccgtgggcg 1860tggagcaggt tcagacccag cccagaggca gggctgcacg ggggcctggg tcctctggca 1920cagatagtac caggaagcca gcctctgctg tgggcactcc agacaaggcc cagaaggccc 1980ctggcccagg cccaggccag gaagtgtatt tctccttgaa ggacatgtac ctggagaaca 2040cccaggcagt caggcctctt ggggaagagg gaccccagac cctgagtgtc cgggcgcctg 2100gggagagtcc caaggggaag gcacccctca gggctagaag cgagggggtg cctggcgctc 2160ctggccagcc cacacactcc ttgacccccc agccgactag gcctttcaac agaaagagat 2220ttgcccctcc aaagcccaaa ggagaggcca ccactgacag caagcccatt tcttctctga 2280gtcaagctcc agaatgcggg gcccagagct taggaaaggc cccacctcag gcctctgtgc 2340aggtgccgac gccccctgcc cggcggagac atggcacccg ggacagcacg ttgcaggggc 2400aagcaggcca caggactcca ggagaggtcc tggaatgcca gacaaccacg gctcctacca 2460tgtcggccag cagcagctct gatgtagcct ccattggggt tagcacttcc ggaagtcaag 2520gtatcattga acccatggat atggaaaccc aggaggatgg gagaacatct gctaaccaga 2580gaactggaag caagaagaat gtgcaggcag atgggaagat acaagtggat ggaaggacca 2640ggggagatgg aacacagaca gcccagagga cacgtgcaga taggaagacg caggtggatg 2700ctgggacaca agaaagcaag aggccacagt cagacaggag tgcacagaag ggcatgatga 2760cacagggaag ggcagagaca cagctagaaa caacacaggc aggtgagaag atacaggaag 2820acaggaaggc ccaggcagat aagggcacac aggaagacag aaggatgcag ggagagaagg 2880ggatgcaggg agagaagggg acgcagtcag aggggagcgc gcccacagcc atggaaggtc 2940agtctgagca agaggtggca accagcctcg gcccaccatc cagaaccccc aaactcccac 3000ctacagcggg tcctagagct cctctgaata ttgaatgttt tgtacagacc ccagaagggt 3060cttgtttccc aaaaaaacct ggttgcctgc ccagatctga ggaggcagta gtaacagcct 3120ccaggaacca tgagcaaact gtgctgggtc ccctgtcagg gaacctcatg ctcccagcac 3180agccgcccca tgaggggagt gtggagcagg tgggaggaga gagatgccga gggccacagt 3240catcaggccc agtcgaggcc aagcaggagg acagcccgtt ccagtgcccc aaggaggagc 3300ggccaggggg agtgccgtgt atggatcagg gtggctgtcc tctagctggc ctgagccagg 3360aggtacccac gatgccttct cttcctggaa ctgggctgac agctagccca aaggcggggc 3420cgtgtagcac cccgacttct cagcacggga gcacagccac cttcctgccc tctgaggatc 3480aggtcctgat gagttctgcc ccaacactgc acctggggct ggggaccccc actcagagtc 3540acccaccaga aaccatggcc accagcagtg agggggcctg cgcccaggta ccagatgtgg 3600aggggcggac cccaggtccc cggagctgtg accctggcct catagattcc ctgaagaact 3660acctgcttct gctgctgaag ctgtccagca cagagacaag tggagcaggg ggagagtccc 3720aggtgggggc agccaccgga ggtctggtgc cctcagccac tctgacaccc actgtggaag 3780tggctgggct tagtccccgg acatcgaggc gcatcctgga gcgtgtggag aacaaccacc 3840tggtgcagag tgcacagacc ctgctgctga gcccctgtac ctcccgccgc ctcaccggcc 3900tcctggaccg tgaggtgcag gctggccgcc aggcccttgc tgctgcccga ggctcctggg 3960gtcctggtcc cagctccctc actgtccctg ccattgtggt agacgaggag gaccctgggc 4020tggcctcaga aggagccagt gagggtgaag gagaggtttc ccttgagggg cctggcctcc 4080tgggggcctc tcaggagagc agcatggctg gtcgactggg ggaggcgggt gggcaggcag 4140cccctggaca ggggccctca gcagagagca tagcccagga gccctcccaa gaggagaagt 4200tcccagggga ggctctgaca ggcctcccgg cagctacacc tgaggaactg gctctagggg 4260cccggaggaa gagatttctc cctaaggtca gagcagcagg agacggggag gcaaccacac 4320ctgaagaaag ggagagcccc acggtttccc cccgggggcc caggaaaagc ctggtgcctg 4380ggtccccagg gactccaggg cgggagagac gctcccctac gcagggcaga aaggcgagca 4440tgctggaggt gcctcgggca gaggaggagc tggcggcagg agacctgggc cccagcccca 4500aggccggcgg tctggacaca gaggtggccc tggatgaagg caagcaggag acactggcca 4560agcccaggaa agccaaagac ctgctgaaag ccccacaggt gatccggaag attcgggtgg 4620agcagtttcc tgatgcctcc ggtagcctga agctgtggtg ccagtttttc aacattctta 4680gtgactcagt cttgacatgg gccaaggatc agcgcccagt gggcgaggtg ggcaggagcg 4740caggggatga ggggccggcg gccttggcca tcgtgcaggc ctcccccgta gactgcggtg 4800tgtatcggtg caccatccac aatgagcacg gctcggcctc caccgacttc tgcctcagcc 4860ctgaggtgtt gtcaggattc atctccagag aagaaggtga agttggagaa gagattgaga 4920tgacccctat ggtgtttgct aagggtctgg ctgactctgg ctgctggggg gacaagctct 4980ttgggcgact ggtaagcgag gagctccgag ggggtggata tgggtgtggc cttcggaagg 5040cctcccaggc caaggtcatc tacgggctgg aacccatctt cgagtcgggc cgcacgtgca 5100tcatcaaggt gtccagcctg cttgtgtttg ggcccagcag tgagacttct cttgtgggca 5160gaaactacga cgtcaccatc caggggtgca agatccagaa catgagtcgg gagtactgca 5220aaatcttcgc agcagaagcc cgggccgcgc ctggctttgg ggaggtgcct gagatcatcc 5280cactgtatct gatctaccgg cctgcaaaca atatcccata tgctaccctg gaggaagacc 5340tgggcaagcc cctggagtct tactgttctc gggaatgggg ctgtgctgag gctccgacag 5400catctggcag ctctgaggcc atgcagaaat gccagacctt ccaacactgg ctgtatcagt 5460ggacaaatgg cagcttcctt gtcacagact tggcaggggt tgactggaag atgactgatg 5520tgcagattgc taccaaactc cgaggatacc agggcctcaa ggaaagctgc ttccctgccc 5580tgctggaccg gttcgcctcc tcccaccagt gcaatgccta ctgtgagctg ctggggctga 5640cacctctcaa gggcccggag gcggcccacc cccaagccaa agccaaaggc tctaagagtc 5700catctgctgg caggaaaggc tcccagctga gtcctcagcc ccagaagaaa ggcctcccta 5760gtcctcaggg cacccggaag agtgctccaa gttccaaggc cacccctcag gcctcagagc 5820cagtcaccac tcagttgttg ggacagcctc ccacccaaga ggagggctcc aaggcccagg 5880gcatgcggta gcctctgcag aggctggggg cctccaccca gcagcagacc aaccaggaag 5940cagcttgaac tggatggaga ctttccaaat atggaactaa ctggagaagg tgcacgaagg 6000agacaccact tggggacctc tctgagcagg ctctcgtgaa tcagctcgtc atcagatggc 6060tttggtgcat ggcacatagc ccactggcct cttctggtgc cactgtcacc cagggctccc 6120gggcctcaag cagtccccac ctccgagtgc ctggcaacct aggccctcct tgaagtttac 6180actttgccac tgctggaggc tcccctgagt cctctgcatg agttctgcac cccaagccct 6240tgccccagcc cagtccagca gcagatgtta caatctgagt gaggacatgc aggccaactt 6300ttaccctcct gcatttgcct ggccctgatc tcgcctgtcc tcagggatcc agacttcctc 6360tgctggtctg gcctggtgac tctcagggta tcttctcctt ccagctactt tcgctcactg 6420atctcagctt atcctgcaac taaccatcct tgagcccaga tggggctcag ggcccttcca 6480gagcctgtca tgtccttgtg cagtggcctt tgatgtgtgt tcacgctctt cccccttcac 6540tcactcgcct gcttcccatg ctcccttgta ccccctcgcc acatccctgt cttggggccc 6600agctgcagcc tgctgcctgc ccttcatggc tctgcacatg gccctttgct tgagggctcc 6660ccactccctg cccaccaata cccaggtgag gaacagaccc tctggcctct caccccactt 6720cagtgctctc ttccccaact tctctcgggc tctttgctca tgaggtgaga gctggtgtga 6780gggttgtgtc agcagctgta gccagagaga ggtgttgact ctgagagacc ttgcactcca 6840tactgaaagg aggtggggtc acagtgaatt tcacatcccc tctcaaccag gagtggaggg 6900ctaggtccct tccccatggg gagtacactt gggtgttcta ggagggatgc agtctatcca 6960tgcacttggg tggaggggag tctctgtgcc tgggaattag gacccctgct ccaaccatcg 7020ctcttgatcc tggggcccca gctctgggtc ctcatgtatg ggctcccaag gacccagcag 7080cctggatcct tccagagcat ccctcctgga ggcctgggat ggggtaggtc tgcagctagc 7140ctactccctt tggaatgcaa taaaggcagc attgtgtgcc ctgcttgccc tcatctggtg 7200tggttggagg tctgtggagt caaggtcccc ctctcccagg caggctctct gagggcattc 7260tgtagtccca ggcccactgg aaaaatgaat ctatattttg gttcctggac cgaagttcag 7320tcgcagcctt ctgtggccac agaaagacag cttgtgctgc ttgcacaact gagctgctgg 7380tgtgtacccc ttagcagggt gtctggggac ttacgccttt ggaattgctc ttcattcaga 7440agaggaacac aaaggaagcc acccaggaag gaagcacaga gctgggggct ctggaaacgc 7500cctgtgtctc tggctacagc aagaccagcc caggagccca ccagcacctg cctctcagct 7560acttgctgac catttcctgc ttctcaagct gcagagaagc ttttcattcc cacccccacc 7620cggaacctcc ccttgcctaa catttcccct ctatggtaac atctctgact tctctacctc 7680ctctgtgctc aggtgactcc acatcttctg ccccagtgtg tccccacctc tcccagcctg 7740tatacccaga ttactttggt gaactgaaaa a 7771391907PRTHomo sapiens 39Met Glu Val Ala Trp Leu Val Tyr Val Leu Gly Gln Gln Pro Leu Ala1 5 10 15Arg Gln Gly Glu Gly Gln Ser Arg Leu Val Pro Gly Arg Gly Leu Val 20 25 30Leu Trp Leu Pro Gly Leu Pro Arg Ser Ser Pro Ser Trp Pro Ala Val 35 40 45Asp Leu Ala Pro Leu Ala Pro Ala Arg Pro Arg Gly Pro Leu Ile Cys 50 55 60His Thr Gly His Glu Gln Ala Gly Arg Glu Pro Gly Pro Gly Ser Ser65 70 75 80Thr Lys Gly Pro Val Leu His Asp Gln Asp Thr Arg Cys Ala Phe Leu 85 90 95Pro Arg Pro Pro Gly Pro Leu Gln Thr Arg Arg Tyr Cys Arg His Gln 100 105 110Gly Arg Gln Gly Ser Gly Leu Gly Ala Gly Pro Gly Ala Gly Thr Trp 115 120 125Ala Pro Ala Pro Pro Gly Val Ser Lys Pro Arg Cys Pro Gly Arg Ala 130 135 140Arg Pro Gly Glu Gly Gln Gln Gln Val Thr Thr Ala Arg Pro Pro Ala145 150 155 160Ile Asn Arg Gly Ala Arg Gln Pro Arg Ala Gly Ala Ala Ala Ala Gly 165 170 175Arg Gly Pro Gly Ala Gly Ala Trp Arg Thr Gly Glu Ala Ala Ala Ser 180 185 190Ala Gly Pro Ala Val Gly Glu Gly Gly Ala Met Gly Ser Arg Arg Ala 195 200 205Pro Thr Arg Gly Trp Gly Ala Gly Gly Arg Ser Gly Ala Gly Gly Asp 210 215 220Gly Glu Asp Asp Gly Pro Val Trp Ile Pro Ser Pro Ala Ser Arg Ser225 230 235 240Tyr Leu Leu Ser Val Arg Pro Glu Thr Ser Leu Ser Ser Asn Arg Leu 245 250 255Ser His Pro Ser Ser Gly Arg Ser Thr Phe Cys Ser Ile Ile Ala Gln 260 265 270Leu Thr Glu Glu Thr Gln Pro Leu Phe Glu Thr Thr Leu Lys Ser Arg 275 280 285Ser Val Ser Glu Asp Ser Asp Val Arg Phe Thr Cys Ile Val Thr Gly 290 295 300Tyr Pro Glu Pro Glu Val Thr Trp Tyr Lys Asp Asp Thr Glu Leu Asp305 310 315 320Arg Tyr Cys Gly Leu Pro Lys Tyr Glu Ile Thr His Gln Gly Asn Arg 325 330 335His Thr Leu Gln Leu Tyr Arg Cys Arg Glu Glu Asp Ala Ala Ile Tyr 340 345 350Gln Ala Ser Ala Gln Asn Ser Lys Gly Ile Val Ser Cys Ser Gly Val 355 360 365Leu Glu Val Gly Thr Met Thr Glu Tyr Lys Ile His Gln Arg Trp Phe 370 375 380Ala Lys Leu Lys Arg Lys Ala Ala Ala Lys Leu Arg Glu Ile Glu Gln385 390 395 400Ser Trp Lys His Glu Lys Ala Val Pro Gly Glu Val Asp Thr Leu Arg 405 410 415Lys Leu Ser Pro Asp Arg Phe Gln Arg Lys Arg Arg Leu Ser Gly Ala 420 425 430Gln Ala Pro Gly Pro Ser Val Pro Thr Arg Glu Pro Glu Gly Gly Thr 435 440 445Leu Ala Ala Trp Gln Glu Gly Glu Thr Glu Thr Ala Gln His Ser Gly 450 455 460Leu Gly Leu Ile Asn Ser Phe Ala Ser Gly Glu Val Thr Thr Asn Gly465 470 475 480Glu Ala Ala Pro Glu Asn Gly Glu Asp Gly Glu His Gly Leu Leu Thr 485 490 495Tyr Ile Cys Asp Ala Met Glu Leu Gly Pro Gln Arg Ala Leu Lys Glu 500 505 510Glu Ser Gly Ala Lys Lys Lys Lys Lys Asp Glu Glu Ser Lys Gln Gly 515 520 525Leu Arg Lys Pro Glu Leu Glu Lys Ala Ala Gln Ser Arg Arg Ser Ser 530 535 540Glu Asn Cys Ile Pro Ser Ser Asp Glu Pro Asp Ser Cys Gly Thr Gln545 550 555 560Gly Pro Val Gly Val Glu Gln Val Gln Thr Gln Pro Arg Gly Arg Ala 565 570 575Ala Arg Gly Pro Gly Ser Ser Gly Thr Asp Ser Thr Arg Lys Pro Ala 580 585 590Ser Ala Val Gly Thr Pro Asp Lys Ala Gln Lys Ala Pro Gly Pro Gly 595 600 605Pro Gly Gln Glu Val Tyr Phe Ser Leu Lys Asp Met Tyr Leu Glu Asn 610 615 620Thr Gln Ala Val Arg Pro Leu Gly Glu Glu Gly Pro Gln Thr Leu Ser625 630 635 640Val Arg Ala Pro Gly Glu Ser Pro Lys Gly Lys Ala Pro Leu Arg Ala 645 650 655Arg Ser Glu Gly Val Pro Gly Ala Pro Gly Gln Pro Thr His Ser Leu 660 665 670Thr Pro Gln Pro Thr Arg Pro Phe Asn Arg Lys Arg Phe Ala Pro Pro 675 680 685Lys Pro Lys Gly Glu Ala Thr Thr Asp Ser Lys Pro Ile Ser Ser Leu 690 695 700Ser Gln Ala Pro Glu Cys Gly Ala Gln Ser Leu Gly Lys Ala Pro Pro705 710 715 720Gln Ala Ser Val Gln Val Pro Thr Pro Pro Ala Arg Arg Arg His Gly 725 730 735Thr Arg Asp Ser Thr Leu Gln Gly Gln Ala Gly His Arg Thr Pro Gly 740 745 750Glu Val Leu Glu Cys Gln Thr Thr Thr Ala Pro Thr Met Ser Ala Ser 755 760 765Ser Ser Ser Asp Val Ala Ser Ile Gly Val Ser Thr Ser Gly Ser Gln 770 775 780Gly Ile Ile Glu Pro Met Asp Met Glu Thr Gln Glu Asp Gly Arg Thr785 790 795 800Ser Ala Asn Gln Arg Thr Gly Ser Lys Lys Asn Val Gln Ala Asp Gly 805 810 815Lys Ile Gln Val Asp Gly Arg Thr Arg Gly Asp Gly Thr Gln Thr Ala 820 825 830Gln Arg Thr Arg Ala Asp Arg Lys Thr Gln Val Asp Ala Gly Thr Gln 835 840 845Glu Ser Lys Arg Pro Gln Ser Asp Arg Ser Ala Gln Lys Gly Met Met 850 855 860Thr Gln Gly Arg Ala Glu Thr Gln Leu Glu Thr Thr Gln Ala Gly Glu865 870 875 880Lys Ile Gln Glu Asp Arg Lys Ala Gln Ala Asp Lys Gly Thr Gln Glu 885 890 895Asp Arg Arg Met Gln Gly Glu Lys Gly Met Gln Gly Glu Lys Gly Thr 900 905 910Gln Ser Glu Gly Ser Ala Pro Thr Ala Met Glu Gly Gln Ser Glu Gln 915 920 925Glu Val Ala Thr Ser Leu Gly Pro Pro Ser Arg Thr Pro Lys Leu Pro 930 935 940Pro Thr Ala Gly Pro Arg Ala Pro Leu Asn Ile Glu Cys Phe Val Gln945 950 955 960Thr Pro Glu Gly Ser Cys Phe Pro Lys Lys Pro Gly Cys Leu Pro Arg 965 970 975Ser Glu Glu Ala Val Val Thr Ala Ser Arg Asn His Glu Gln Thr Val 980 985 990Leu Gly Pro Leu Ser Gly Asn Leu Met Leu Pro Ala Gln Pro Pro His 995 1000 1005Glu Gly Ser Val Glu Gln Val Gly Gly Glu Arg Cys Arg Gly Pro 1010 1015 1020Gln Ser Ser Gly Pro Val Glu Ala Lys Gln Glu Asp Ser Pro Phe 1025 1030 1035Gln Cys Pro Lys Glu Glu Arg Pro Gly Gly Val Pro Cys Met Asp 1040 1045 1050Gln Gly Gly Cys Pro Leu Ala Gly Leu Ser Gln Glu Val Pro Thr 1055 1060 1065Met Pro Ser Leu Pro Gly Thr Gly Leu Thr Ala Ser Pro Lys Ala 1070 1075 1080Gly Pro Cys Ser Thr Pro Thr Ser Gln His Gly Ser Thr Ala Thr 1085 1090 1095Phe Leu Pro Ser Glu Asp Gln Val Leu Met Ser Ser Ala Pro Thr 1100 1105 1110Leu His Leu Gly Leu Gly Thr Pro Thr Gln Ser His Pro Pro Glu 1115 1120 1125Thr Met Ala Thr Ser Ser Glu Gly Ala Cys Ala Gln Val Pro Asp 1130 1135 1140Val Glu Gly Arg Thr Pro Gly Pro Arg Ser Cys Asp Pro Gly Leu 1145 1150 1155Ile Asp Ser Leu Lys Asn Tyr Leu Leu Leu Leu Leu Lys Leu Ser 1160 1165 1170Ser Thr Glu Thr Ser Gly Ala Gly Gly Glu Ser Gln Val Gly Ala 1175 1180 1185Ala Thr Gly Gly Leu Val Pro Ser Ala Thr Leu Thr Pro Thr Val 1190 1195 1200Glu Val Ala Gly Leu Ser Pro Arg Thr Ser Arg Arg Ile Leu Glu 1205 1210 1215Arg Val Glu Asn Asn His Leu Val Gln Ser Ala Gln Thr Leu Leu 1220 1225 1230Leu Ser Pro Cys Thr Ser Arg Arg Leu Thr Gly Leu Leu Asp Arg 1235 1240 1245Glu Val Gln Ala Gly Arg Gln Ala Leu Ala Ala Ala Arg Gly Ser 1250 1255 1260Trp Gly Pro Gly Pro Ser Ser Leu Thr Val Pro Ala Ile Val Val 1265 1270 1275Asp Glu Glu Asp Pro Gly Leu Ala Ser Glu Gly Ala Ser Glu Gly 1280 1285 1290Glu Gly Glu Val Ser Leu Glu Gly Pro Gly Leu Leu Gly Ala Ser 1295

1300 1305Gln Glu Ser Ser Met Ala Gly Arg Leu Gly Glu Ala Gly Gly Gln 1310 1315 1320Ala Ala Pro Gly Gln Gly Pro Ser Ala Glu Ser Ile Ala Gln Glu 1325 1330 1335Pro Ser Gln Glu Glu Lys Phe Pro Gly Glu Ala Leu Thr Gly Leu 1340 1345 1350Pro Ala Ala Thr Pro Glu Glu Leu Ala Leu Gly Ala Arg Arg Lys 1355 1360 1365Arg Phe Leu Pro Lys Val Arg Ala Ala Gly Asp Gly Glu Ala Thr 1370 1375 1380Thr Pro Glu Glu Arg Glu Ser Pro Thr Val Ser Pro Arg Gly Pro 1385 1390 1395Arg Lys Ser Leu Val Pro Gly Ser Pro Gly Thr Pro Gly Arg Glu 1400 1405 1410Arg Arg Ser Pro Thr Gln Gly Arg Lys Ala Ser Met Leu Glu Val 1415 1420 1425Pro Arg Ala Glu Glu Glu Leu Ala Ala Gly Asp Leu Gly Pro Ser 1430 1435 1440Pro Lys Ala Gly Gly Leu Asp Thr Glu Val Ala Leu Asp Glu Gly 1445 1450 1455Lys Gln Glu Thr Leu Ala Lys Pro Arg Lys Ala Lys Asp Leu Leu 1460 1465 1470Lys Ala Pro Gln Val Ile Arg Lys Ile Arg Val Glu Gln Phe Pro 1475 1480 1485Asp Ala Ser Gly Ser Leu Lys Leu Trp Cys Gln Phe Phe Asn Ile 1490 1495 1500Leu Ser Asp Ser Val Leu Thr Trp Ala Lys Asp Gln Arg Pro Val 1505 1510 1515Gly Glu Val Gly Arg Ser Ala Gly Asp Glu Gly Pro Ala Ala Leu 1520 1525 1530Ala Ile Val Gln Ala Ser Pro Val Asp Cys Gly Val Tyr Arg Cys 1535 1540 1545Thr Ile His Asn Glu His Gly Ser Ala Ser Thr Asp Phe Cys Leu 1550 1555 1560Ser Pro Glu Val Leu Ser Gly Phe Ile Ser Arg Glu Glu Gly Glu 1565 1570 1575Val Gly Glu Glu Ile Glu Met Thr Pro Met Val Phe Ala Lys Gly 1580 1585 1590Leu Ala Asp Ser Gly Cys Trp Gly Asp Lys Leu Phe Gly Arg Leu 1595 1600 1605Val Ser Glu Glu Leu Arg Gly Gly Gly Tyr Gly Cys Gly Leu Arg 1610 1615 1620Lys Ala Ser Gln Ala Lys Val Ile Tyr Gly Leu Glu Pro Ile Phe 1625 1630 1635Glu Ser Gly Arg Thr Cys Ile Ile Lys Val Ser Ser Leu Leu Val 1640 1645 1650Phe Gly Pro Ser Ser Glu Thr Ser Leu Val Gly Arg Asn Tyr Asp 1655 1660 1665Val Thr Ile Gln Gly Cys Lys Ile Gln Asn Met Ser Arg Glu Tyr 1670 1675 1680Cys Lys Ile Phe Ala Ala Glu Ala Arg Ala Ala Pro Gly Phe Gly 1685 1690 1695Glu Val Pro Glu Ile Ile Pro Leu Tyr Leu Ile Tyr Arg Pro Ala 1700 1705 1710Asn Asn Ile Pro Tyr Ala Thr Leu Glu Glu Asp Leu Gly Lys Pro 1715 1720 1725Leu Glu Ser Tyr Cys Ser Arg Glu Trp Gly Cys Ala Glu Ala Pro 1730 1735 1740Thr Ala Ser Gly Ser Ser Glu Ala Met Gln Lys Cys Gln Thr Phe 1745 1750 1755Gln His Trp Leu Tyr Gln Trp Thr Asn Gly Ser Phe Leu Val Thr 1760 1765 1770Asp Leu Ala Gly Val Asp Trp Lys Met Thr Asp Val Gln Ile Ala 1775 1780 1785Thr Lys Leu Arg Gly Tyr Gln Gly Leu Lys Glu Ser Cys Phe Pro 1790 1795 1800Ala Leu Leu Asp Arg Phe Ala Ser Ser His Gln Cys Asn Ala Tyr 1805 1810 1815Cys Glu Leu Leu Gly Leu Thr Pro Leu Lys Gly Pro Glu Ala Ala 1820 1825 1830His Pro Gln Ala Lys Ala Lys Gly Ser Lys Ser Pro Ser Ala Gly 1835 1840 1845Arg Lys Gly Ser Gln Leu Ser Pro Gln Pro Gln Lys Lys Gly Leu 1850 1855 1860Pro Ser Pro Gln Gly Thr Arg Lys Ser Ala Pro Ser Ser Lys Ala 1865 1870 1875Thr Pro Gln Ala Ser Glu Pro Val Thr Thr Gln Leu Leu Gly Gln 1880 1885 1890Pro Pro Thr Gln Glu Glu Gly Ser Lys Ala Gln Gly Met Arg 1895 1900 1905403726DNAHomo sapiens 40atgaataatc aaaaagtggt agctgtgcta ctgcaagagt gcaagcaagt gctggatcag 60ctcttgttgg aagcgccaga tgtgtcggaa gaggacaaga gcgaggacca gcgctgcaga 120gctttactcc ccagcgagtt aaggaccctg atccaggagg caaaggaaat gaagtggccc 180ttcgtgcctg aaaagtggca gtacaaacaa gccgtgggcc cagaggacaa aacaaacctg 240aaggatgtga ttggcgccgg gttgcagcag ttactggcgt ccctgagggc ctccatcctc 300gctcgggact gtgcggctgc ggcggctatt gtgttcttgg tggaccggtt cctgtatggg 360ctcgacgtct ctggaaaact tctgcaggtc gccaaaggtc tccacaagtt gcagccagcc 420acgccaattg ccccgcaggt ggttattcgc caagcccgaa tctccgtgaa ctcaggaaaa 480cttttaaaag cagagtatat tctgagcagt ctaataagca acaatggagc aacgggtacc 540tggctgtaca gaaatgaaag tgacaaggtc ctggtgcagt cggtctgtat acagatcaga 600gggcagattc tgcaaaagct gggtatgtgg tacgaagcag cagagttaat atgggcctcc 660attgtaggat atttggcact tcctcagccg gataaaaagg gcctctccac gtcgctaggt 720atactggcag acatctttgt ttccatgagc aagaacgatt atgaaaagtt taaaaacaat 780ccacaaatta atttgagcct gctgaaggag tttgaccacc atttgctgtc cgctgcagaa 840gcctgcaagc tggcagctgc cttcagtgcc tatacgccgc tcttcgtgct cacagctgtg 900aatatccgtg gcacgtgttt attgtcctac agtagttcaa atgactgtcc tccagaattg 960aaaaacttac atctgtgtga agccaaagag gcctttgaga ttggcctcct caccaagaga 1020gatgatgagc ctgttactgg aaaacaggag cttcacagct ttgtcaaagc tgctttcggt 1080ctcaccacag tgcacagaag gctccatggg gagacaggga cggtccatgc agcaagtcag 1140ctctgtaagg aagcaatggg gaagctgtac aatttcagca cttcctccag aagtcaggac 1200agagaagctc tgtctcaaga agttatgtct gtgattgccc aggtgaagga acatttacaa 1260gttcaaagct tctcaaatgt agatgacaga tcttatgttc ccgagagttt cgagtgcagg 1320ttggataaac ttatcttgca tgggcaaggg gatttccaaa aaatccttga cacctattca 1380cagcaccata cttcggtgtg tgaagtattt gaaagtgatt gtggaaacaa caaaaatgaa 1440cagaaagatg caaaaacagg agtctgcatc actgctctaa aaacagaaat aaaaaacata 1500gatactgtga gtactactca agaaaagcca cattgtcaaa gagacacagg aatatcttcc 1560tccctaatgg gtaagaatgt tcagagggaa ctcagaaggg gaggaaggag aaactggacc 1620cattctgatg catttcgagt ctccttggat caagatgtgg agactgagac tgagccatcg 1680gactacagca atggtgaggg agctgttttc aacaagtctc tgagtggcag ccagacttcc 1740agtgcttgga gcaacttatc agggtttagt tcctctgcaa gctgggagga agtgaattat 1800cacgttgacg acaggtcagc cagaaaagag cctggcaaag aacatctggt ggacactcag 1860tgttccactg ccttgtctga ggagctagag aatgacaggg aaggcagagc tatgcattca 1920ttgcattcac agcttcatga tctctctctt caggaaccca acaatgacaa tttggagcct 1980tctcaaaatc agccacagca acagatgccc ttgacaccct tctcgcctca taatacccca 2040ggcattttct tggcccctgg tgcagggctt ctagaaggag ctccagaagg tatccaggaa 2100gtcagaaata tgggacccag aaatacttct gctcactcca gaccctcata tcgttctgct 2160tcttggtctt ctgattctgg taggcccaag aatatgggca cacatccttc agtccaaaaa 2220gaagaagcct ttgaaataat tgttgagttt ccagaaacca actgcgatgt caaagacagg 2280caggggaaag agcagggaga agaaattagt gaaagaggcg caggccctac atttaaagct 2340agtccctcct gggttgaccc agaaggagaa acagcagaaa gcactgaaga tgcaccctta 2400gactttcaca gggtcctgca caattctctg ggaaacattt ccatgctgcc atgtagctcc 2460ttcaccccta attggcctgt tcaaaatcct gactccagaa aaagtggtgg cccagtcgca 2520gagcagggca tcgaccctga tgcctccaca gtggatgagg aggggcaact gctcgacagc 2580atggatgttc cctgcacaaa tgggcacggc tctcatagac tgtgcattct gagacagccg 2640cctggtcaga gggcggagac ccccaattcc tctgtaagcg gtaacatcct cttccctgtc 2700ctcagcgagg actgcactac cacagaggaa ggaaatcagc ctggaaacat gctaaactgc 2760agccagaact ccagctcatc ctcagtgtgg tggctgaaat cacctgcatt ttccagtggt 2820tcttctgagg gggacagccc ttggtcctat ctgaattcca gtgggagttc ttgggtttca 2880ttgccgggaa agatgaggaa agagatcctt gaggctcgca ccttgcaacc tgatgacttt 2940gaaaagctgt tggcaggagt gaggcatgat tggctgtttc agagactaga gaatacgggg 3000gtttttaagc ccagtcaact ccaccgagca catagtgctc ttttgttaaa atattcaaaa 3060aaatctgaac tgtggacggc ccaggaaact attgtctatt tgggggacta cttgactgtg 3120aagaaaaaag gcagacaaag aaatgctttt tgggttcatc atcttcatca agaagaaatt 3180ctggggaggt atgttgggaa agactataag gagcagaagg ggctctggca ccacttcact 3240gatgtggagc gacagatgac cgcacagcac tatgtgacag aatttaacaa gagactctat 3300gaacaaaaca ttcccaccca gatattctac atcccatcca caatactact gattttagag 3360gacaagacaa taaagggatg tatcagtgtg gagccttaca tactgggaga atttgtaaaa 3420ttgtcaaata acacgaaagt ggtgaaaaca gaatacaaag ccacagaata tggcttggcc 3480tatggccatt tttcttatga gttttctaat catagagatg ttgtggtcga tttacaaggt 3540tgggtaaccg gtaatggaaa aggactcatc tacctcacag atccccagat tcactccgtt 3600gatcagaaag ttttcactac caattttgga aagagaggaa ttttttactt ctttaataac 3660cagcatgtgg aatgtaatga aatctgccat cgtctttctt tgactagacc ttcaatggag 3720aaacca 3726411242PRTHomo sapiens 41Met Asn Asn Gln Lys Val Val Ala Val Leu Leu Gln Glu Cys Lys Gln1 5 10 15Val Leu Asp Gln Leu Leu Leu Glu Ala Pro Asp Val Ser Glu Glu Asp 20 25 30Lys Ser Glu Asp Gln Arg Cys Arg Ala Leu Leu Pro Ser Glu Leu Arg 35 40 45Thr Leu Ile Gln Glu Ala Lys Glu Met Lys Trp Pro Phe Val Pro Glu 50 55 60Lys Trp Gln Tyr Lys Gln Ala Val Gly Pro Glu Asp Lys Thr Asn Leu65 70 75 80Lys Asp Val Ile Gly Ala Gly Leu Gln Gln Leu Leu Ala Ser Leu Arg 85 90 95Ala Ser Ile Leu Ala Arg Asp Cys Ala Ala Ala Ala Ala Ile Val Phe 100 105 110Leu Val Asp Arg Phe Leu Tyr Gly Leu Asp Val Ser Gly Lys Leu Leu 115 120 125Gln Val Ala Lys Gly Leu His Lys Leu Gln Pro Ala Thr Pro Ile Ala 130 135 140Pro Gln Val Val Ile Arg Gln Ala Arg Ile Ser Val Asn Ser Gly Lys145 150 155 160Leu Leu Lys Ala Glu Tyr Ile Leu Ser Ser Leu Ile Ser Asn Asn Gly 165 170 175Ala Thr Gly Thr Trp Leu Tyr Arg Asn Glu Ser Asp Lys Val Leu Val 180 185 190Gln Ser Val Cys Ile Gln Ile Arg Gly Gln Ile Leu Gln Lys Leu Gly 195 200 205Met Trp Tyr Glu Ala Ala Glu Leu Ile Trp Ala Ser Ile Val Gly Tyr 210 215 220Leu Ala Leu Pro Gln Pro Asp Lys Lys Gly Leu Ser Thr Ser Leu Gly225 230 235 240Ile Leu Ala Asp Ile Phe Val Ser Met Ser Lys Asn Asp Tyr Glu Lys 245 250 255Phe Lys Asn Asn Pro Gln Ile Asn Leu Ser Leu Leu Lys Glu Phe Asp 260 265 270His His Leu Leu Ser Ala Ala Glu Ala Cys Lys Leu Ala Ala Ala Phe 275 280 285Ser Ala Tyr Thr Pro Leu Phe Val Leu Thr Ala Val Asn Ile Arg Gly 290 295 300Thr Cys Leu Leu Ser Tyr Ser Ser Ser Asn Asp Cys Pro Pro Glu Leu305 310 315 320Lys Asn Leu His Leu Cys Glu Ala Lys Glu Ala Phe Glu Ile Gly Leu 325 330 335Leu Thr Lys Arg Asp Asp Glu Pro Val Thr Gly Lys Gln Glu Leu His 340 345 350Ser Phe Val Lys Ala Ala Phe Gly Leu Thr Thr Val His Arg Arg Leu 355 360 365His Gly Glu Thr Gly Thr Val His Ala Ala Ser Gln Leu Cys Lys Glu 370 375 380Ala Met Gly Lys Leu Tyr Asn Phe Ser Thr Ser Ser Arg Ser Gln Asp385 390 395 400Arg Glu Ala Leu Ser Gln Glu Val Met Ser Val Ile Ala Gln Val Lys 405 410 415Glu His Leu Gln Val Gln Ser Phe Ser Asn Val Asp Asp Arg Ser Tyr 420 425 430Val Pro Glu Ser Phe Glu Cys Arg Leu Asp Lys Leu Ile Leu His Gly 435 440 445Gln Gly Asp Phe Gln Lys Ile Leu Asp Thr Tyr Ser Gln His His Thr 450 455 460Ser Val Cys Glu Val Phe Glu Ser Asp Cys Gly Asn Asn Lys Asn Glu465 470 475 480Gln Lys Asp Ala Lys Thr Gly Val Cys Ile Thr Ala Leu Lys Thr Glu 485 490 495Ile Lys Asn Ile Asp Thr Val Ser Thr Thr Gln Glu Lys Pro His Cys 500 505 510Gln Arg Asp Thr Gly Ile Ser Ser Ser Leu Met Gly Lys Asn Val Gln 515 520 525Arg Glu Leu Arg Arg Gly Gly Arg Arg Asn Trp Thr His Ser Asp Ala 530 535 540Phe Arg Val Ser Leu Asp Gln Asp Val Glu Thr Glu Thr Glu Pro Ser545 550 555 560Asp Tyr Ser Asn Gly Glu Gly Ala Val Phe Asn Lys Ser Leu Ser Gly 565 570 575Ser Gln Thr Ser Ser Ala Trp Ser Asn Leu Ser Gly Phe Ser Ser Ser 580 585 590Ala Ser Trp Glu Glu Val Asn Tyr His Val Asp Asp Arg Ser Ala Arg 595 600 605Lys Glu Pro Gly Lys Glu His Leu Val Asp Thr Gln Cys Ser Thr Ala 610 615 620Leu Ser Glu Glu Leu Glu Asn Asp Arg Glu Gly Arg Ala Met His Ser625 630 635 640Leu His Ser Gln Leu His Asp Leu Ser Leu Gln Glu Pro Asn Asn Asp 645 650 655Asn Leu Glu Pro Ser Gln Asn Gln Pro Gln Gln Gln Met Pro Leu Thr 660 665 670Pro Phe Ser Pro His Asn Thr Pro Gly Ile Phe Leu Ala Pro Gly Ala 675 680 685Gly Leu Leu Glu Gly Ala Pro Glu Gly Ile Gln Glu Val Arg Asn Met 690 695 700Gly Pro Arg Asn Thr Ser Ala His Ser Arg Pro Ser Tyr Arg Ser Ala705 710 715 720Ser Trp Ser Ser Asp Ser Gly Arg Pro Lys Asn Met Gly Thr His Pro 725 730 735Ser Val Gln Lys Glu Glu Ala Phe Glu Ile Ile Val Glu Phe Pro Glu 740 745 750Thr Asn Cys Asp Val Lys Asp Arg Gln Gly Lys Glu Gln Gly Glu Glu 755 760 765Ile Ser Glu Arg Gly Ala Gly Pro Thr Phe Lys Ala Ser Pro Ser Trp 770 775 780Val Asp Pro Glu Gly Glu Thr Ala Glu Ser Thr Glu Asp Ala Pro Leu785 790 795 800Asp Phe His Arg Val Leu His Asn Ser Leu Gly Asn Ile Ser Met Leu 805 810 815Pro Cys Ser Ser Phe Thr Pro Asn Trp Pro Val Gln Asn Pro Asp Ser 820 825 830Arg Lys Ser Gly Gly Pro Val Ala Glu Gln Gly Ile Asp Pro Asp Ala 835 840 845Ser Thr Val Asp Glu Glu Gly Gln Leu Leu Asp Ser Met Asp Val Pro 850 855 860Cys Thr Asn Gly His Gly Ser His Arg Leu Cys Ile Leu Arg Gln Pro865 870 875 880Pro Gly Gln Arg Ala Glu Thr Pro Asn Ser Ser Val Ser Gly Asn Ile 885 890 895Leu Phe Pro Val Leu Ser Glu Asp Cys Thr Thr Thr Glu Glu Gly Asn 900 905 910Gln Pro Gly Asn Met Leu Asn Cys Ser Gln Asn Ser Ser Ser Ser Ser 915 920 925Val Trp Trp Leu Lys Ser Pro Ala Phe Ser Ser Gly Ser Ser Glu Gly 930 935 940Asp Ser Pro Trp Ser Tyr Leu Asn Ser Ser Gly Ser Ser Trp Val Ser945 950 955 960Leu Pro Gly Lys Met Arg Lys Glu Ile Leu Glu Ala Arg Thr Leu Gln 965 970 975Pro Asp Asp Phe Glu Lys Leu Leu Ala Gly Val Arg His Asp Trp Leu 980 985 990Phe Gln Arg Leu Glu Asn Thr Gly Val Phe Lys Pro Ser Gln Leu His 995 1000 1005Arg Ala His Ser Ala Leu Leu Leu Lys Tyr Ser Lys Lys Ser Glu 1010 1015 1020Leu Trp Thr Ala Gln Glu Thr Ile Val Tyr Leu Gly Asp Tyr Leu 1025 1030 1035Thr Val Lys Lys Lys Gly Arg Gln Arg Asn Ala Phe Trp Val His 1040 1045 1050His Leu His Gln Glu Glu Ile Leu Gly Arg Tyr Val Gly Lys Asp 1055 1060 1065Tyr Lys Glu Gln Lys Gly Leu Trp His His Phe Thr Asp Val Glu 1070 1075 1080Arg Gln Met Thr Ala Gln His Tyr Val Thr Glu Phe Asn Lys Arg 1085 1090 1095Leu Tyr Glu Gln Asn Ile Pro Thr Gln Ile Phe Tyr Ile Pro Ser 1100 1105 1110Thr Ile Leu Leu Ile Leu Glu Asp Lys Thr Ile Lys Gly Cys Ile 1115 1120 1125Ser Val Glu Pro Tyr Ile Leu Gly Glu Phe Val Lys Leu Ser Asn 1130 1135 1140Asn Thr Lys Val Val Lys Thr Glu Tyr Lys Ala Thr Glu Tyr Gly 1145 1150 1155Leu Ala Tyr Gly His Phe Ser Tyr Glu Phe Ser Asn His Arg Asp 1160 1165 1170Val Val Val Asp Leu Gln Gly Trp Val Thr Gly Asn Gly Lys Gly 1175 1180 1185Leu Ile Tyr Leu Thr Asp Pro Gln Ile His Ser Val Asp Gln Lys 1190 1195 1200Val Phe Thr Thr Asn Phe Gly Lys Arg Gly Ile Phe Tyr Phe Phe 1205 1210 1215Asn Asn Gln His Val Glu Cys Asn Glu Ile Cys His Arg Leu Ser 1220 1225

1230Leu Thr Arg Pro Ser Met Glu Lys Pro 1235 12404230DNAArtificial Sequenceprimer 42ctgcgacaga gactacatgg ggtagaactc 304330DNAArtificial Sequenceprimer 43tgagtgtctt cggtagatgg ccttctactg 304421DNAArtificial Sequenceprimer 44atggagattg ctggagagaa g 214521DNAArtificial Sequenceprimer 45attcactact ctgggccgat c 21

Claims

1. An isolated nucleic acid encoding mammalian melanoma alpha kinase, wherein the nucleic acid is selected from the group consisting of: a. the DNA sequence of SEQ ID NO: 28; b. the DNA sequence of SEQ ID NO: 26; c. DNA sequences that hybridize to the sequence of subparts (a) or (b) under standard hybridization conditions; and d. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of subparts (a), (b) or (c).

2. The isolated nucleic acid of claim 1, encoding human melanoma alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 26.

3. The isolated nucleic acid of claim 1, encoding mouse melanoma alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 28.

4.-9. (canceled)

10. An isolated nucleic acid encoding mammalian skeletal muscle alpha kinase, wherein the nucleic acid is selected from the group consisting of: a. the DNA sequence of SEQ ID NO: 38; b. DNA sequences that hybridize to the sequence of subpart (a) under standard hybridization conditions; and c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b).

11. The isolated nucleic acid of claim 10, encoding human skeletal muscle alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 38.

12. An isolated nucleic acid encoding mammalian lymphocyte alpha kinase, wherein the nucleic acid is selected from the group consisting of a. the DNA sequence of SEQ ID NO: 40; b. DNA sequences that hybridize to the sequence of subpart (a) under standard hybridization conditions; and c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b).

13. The isolated nucleic acid of claim 12, encoding human lymphocyte alpha kinase, wherein the nucleic acid comprises the DNA sequence of SEQ ID NO: 40.

14. A recombinant DNA expression vector comprising the nucleic acid of any of claims 1, 10 or 12, wherein the DNA encoding the alpha kinase is operatively associated with an expression control sequence.

15. (canceled)

16. A unicellular host transformed with a recombinant DNA molecule comprising a DNA sequence or degenerate variant thereof, which encodes an alpha kinase, or a fragment thereof, selected from the group consisting of: a. the DNA sequence of (SEQ ID NO: 26); b. the DNA sequence of (SEQ ID NO: 28); c. the DNA sequence of (SEQ ID NO: 32); d. the DNA sequence of (SEQ ID NO: 38); e. the DNA sequence of (SEQ ID NO: 40); f. DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and g. DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences; wherein said DNA sequence is operatively linked to an expression control sequence.

17. The unicellular host of claim 16 wherein the unicellular host is selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeasts, CHO, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, and BMT10 cells, plant cells, insect cells, mouse cells and human cells in tissue culture.

18.-48. (canceled)